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ABSTRACT 
Sexual behavior in male rats is a complex rewarding behavior and many 
neurotransmitters and neuropeptides play an important role in mediation of sexual 
performance, motivation and reward. The hypothalamic neuropeptide orexin has been 
shown play a key role in reward associated with food and drugs of abuse, but the role of 
this neuropeptide in control of sexual performance, motivation and reward is currently 
unclear. First, it was shown that orexin neurons in the hypothalamus are activated during 
sexual performance and reward. Next, using cell specific lesions of orexin neurons it was 
demonstrated that orexin is involved in arousal and anxiety, but is not critical for sexual 
performance or motivation. Moreover, orexin was shown to play a critical role in control 
of sexual reward. Thus, these studies provided novel information regarding a role for 
orexin in this natural reward behavior. Recent studies have shown that sexual behavior in 
male rats causes neuroplasticity in the mesolimbic system and enhanced psychostimulant-
induced locomotor activity and drug craving. The latter of which is dependent on a period 
of abstinence from sexual behavior, suggesting an increased vulnerability for addiction 
following loss of sexual reward. Thus, the next goal of this thesis determined if 
abstinence from sexual behavior also leads increased vulnerability for other disorders 
related to reward processing, specifically depression-like behavior. It was demonstrated 
that a prolonged (28 day) but not short (1 or 7 day) period of abstinence causes 
depression-like behavior in sexually experienced male rats seen as increased passive 
stress coping behaviors and anhedonia. Development of depression-like behavior was 
associated with increased levels of corticotropin releasing factor mRNA in the 
paraventricular nucleus of the hypothalamus and increased hypothalamic-pituitary-
iii 
 
 
 
adrenal axis activity in response to an acute stressor. Thus, these studies provide novel 
information on behavioral and neuroplastic alterations observed following a prolonged 
period of abstinence from mating and suggest that loss of sexual reward in male rats may 
be a paradigm to study depression following loss of social reward in humans.  
 
Keywords: orexin, hypocretin, sexual behavior, neural activation, motivation, reward, 
hypothalamus, conditioned placed preference, anxiety, depression, abstinence, passive 
stress coping, anhedonia, corticotropin releasing factor, hypothalamic-pituitary adrenal 
axis, corticosterone, adrenocorticotropic hormone  
 
iv 
 
 
 
CO-AUTHORSHIP 
Sections 1.2 -1.5 of Chapter 1 entitled “Orexin and Natural Reward: Feeding, Maternal and Male 
Sexual Behavior” was written by Andrea R. Di Sebastiano with inputs by Lique M. 
Coolen. Chapter 2 entitled “Orexin mediates initiation of sexual behavior in sexually 
naive male rats, but is not critical for sexual performance.” was written by Andrea R.    
Di Sebastiano with inputs by Lique M. Coolen, and Michael N. Lehman. Study design 
was by Andrea R. Di Sebastiano and Lique M. Coolen, with intellectual inputs from 
Michael N. Lehman. Experimental procedures and data analysis were performed by 
Andrea R. Di Sebastiano, Sabrina Yong-Yow and Lauren Wagner. Chapter 3 entitled 
“Lesions of orexin neurons block conditioned place preference for sexual behavior in 
male rats” was written by Andrea R. Di Sebastiano with inputs by Dr. Lique M. Coolen 
and Michael N. Lehman. Study design was by Andrea R. Di Sebastiano and Lique M. 
Coolen, with intellectual inputs from Michael N. Lehman. Experimental procedures and 
data analysis were performed was by Andrea R. Di Sebastiano and Hilary E. Wilson-
Perez. Chapter 4 entitled “Loss of sexual reward causes depression-like behavior in male 
rats” was written by Andrea R. Di Sebastiano with inputs by Dr. Lique M. Coolen, 
experimental procedures and data analysis were performed was by Andrea R. Di 
Sebastiano. Drs. Michael N. Lehman, Steven R. Laviolette, and Lique Coolen provided 
intellectual input. Chapter 5 entitled “Loss of Sexual Reward Causes Enhanced Stress 
Reactivity in Male Rats” was written by Andrea R. Di Sebastiano with inputs by Dr. 
Lique M. Coolen, experimental procedures and data analysis were performed was by 
Andrea R. Di Sebastiano. Drs. Michael N. Lehman, Steven R. Laviolette, James P. 
Herman and Lique M. Coolen provided intellectual input. 
v 
 
 
 
ACKNOWLEDGEMENTS 
I would first like thank to my supervisor, friend, and mentor, Dr. Lique Coolen. Thank 
you for your endless advice and support throughout this exciting, challenging, sometimes 
overwhelming, but ultimately very rewarding journey that has been my PhD thesis. I know I 
would not have made it through this process without your guidance. Thank you for constantly 
challenging me to be a better scientist, and I hope to one day become the kind of scientist and 
mentor that you are. I would also like to thanks members of my advisory committee, Drs. 
Michael Lehman, Steven Laviolette and Vania Prado for their continued advice and support 
throughout my degree. 
I would also like to thank all of the members of the Coolen/Lehman lab that have been 
such an integral part of my life during this process. It has been a pleasure working with all of you 
and I am thankful for your friendships. I especially would like to thank Karla Frohmader, Kyle 
Pitchers, Cleusa De Oliveira and Xu Wang for all of their help with conducting my experiments. I 
can’t imagine working with a better group of people! 
On a personal level I would like to thank my family, my mom, dad and sister for their 
love and endless support during this process. I truly couldn’t make it through this without you! 
Finally, I would like to thank my husband-to-be, Michael Staudt. You have been by my 
side throughout this entire process and have supported me unconditionally. I look forward to 
sharing our future successes together. 
 
 
 
 
vi 
 
 
 
TABLE OF CONTENTS 
 
TITLE i
ABSTRACT iii
CO-AUTHORSHIP v
ACKNOWLEDGEMENTS vi
TABLE OF CONTENTS vii
LIST OF TABLES xii
LIST OF FIGURES xiii
LIST OF APPENDICES xv
LIST OF ABBREVIATIONS xvi
 
CHAPTER 1: INTRODUCTION 
1.1 Introduction – Part 1 2
          1.1.1 Natural Reward Behaviors 2
          1.1.2 Male Rat Sexual Behavior 2
          1.1.3 Sexual Motivation and Performance 3
          1.1.4 Sexual Reward 4
          1.1.5 Neuropeptides in Sexual Motivation, Performance and Reward 5
1.2 Orexin and Natural Reward: Feeding, Maternal and Male Sexual Behavior 10
1.3 Orexin, Feeding and Energy Homeostasis 11
1.4 Orexin and Food Motivation and Reward 13
1.5 Orexin and other naturally rewarding behaviors 16
          1.5.1 Orexin and maternal behavior 16
          1.5.2 Orexin and sexual performance and motivation 17
1.6 Rationale and Objectives: Part 1 19
          1.6.1 Objectives 19
1.7 Introduction: Part 2 20
          1.7.1 Drug Induced Neuroplasticity in the Mesolimbic System 20
1.8 Sexual Reward and Neuroplasticity 21
1.9 Drug Addiction and Depression 22
1.10 Depression 23
          1.10.1 Animal Models of Depression           23
1.11 Neural Circuitry of Depression 25
          1.11.1 Drug Addiction, Withdrawal and HPA Axis Alterations 26
          1.11.2 Alterations in Stress Responses Following Sexual Behavior 27
1.12 Rationale and Objectives: Part 2 29
          1.12.1 Hypothesis 29
          1.12.2 Objectives 30
1.13 References 31
vii 
 
 
 
CHAPTER 2: Orexin mediates initiation of sexual behavior in sexually naive male 
rats, but is not critical for sexual performance. 
2.1 INTRODUCTION 47
 
2.2 MATERIALS AND METHODS 49
2.2.1 Animals 49
2.2.2 cFos expression studies 49
            2.2.2A Perfusions: cFos expression 51
            2.2.2B Immunohistochemistry 51
            2.2.2C cFos/orexin 52
                      2.2.2D Data Analysis 52
2.2.3 Orexin Lesion Studies 53
            2.2.3A Surgery 53
                      2.2.3B Sexual Behavior  55
                      2.2.3C Sexual Motivation: Runway Test 56
                      2.2.3D Anxiety-like Behavior: Elevated Plus Maze 56
            2.2.3E Perfusions and mating induced cFos 57
            2.2.3F Immunohistochemistry 57
            2.2.3G Lesion Verification 58
                      2.2.3H Lesion Specificity 58
                      2.2.3I Mating induced cFos in lesion animals 62
 
2.3 RESULTS 62
2.3.1 Orexin neuron activation by sexual behavior 62
2.3.2 Effects of orexin lesions  63
            2.3.2A Sexual Behavior 63
            2.3.2B Runway Test 66
            2.3.2C Anxiety-like Behavior 66
            2.3.2D cFos Expression 69
 
2.4 DISCUSSION 69
 
2.5 REFERENCES 76
 
CHAPTER 3: Lesions of orexin neurons block conditioned place preference for 
sexual behavior in male rats. 
 
3.1 INTRODUCTION 82
 
3.2 MATERIALS AND METHODS 84
3.2.1 Animals 84
3.2.2 Experiment1: cFos expression studies 84
            3.2.2A Apparatus 84
viii 
 
 
 
                      3.2.2B Experimental Design 85
                      3.2.2C Tissue Processing 86
                      3.2.2D Immunohistochemistry: cFos/orexin 86
                      3.2.2E Data Analysis 88
3.2.3 Experiment 2: Orexin Cell Specific Lesion Studies 88
                      3.2.3A Lesion Surgery 88
                      3.2.3B Conditioned Place Preference (CPP) 91
                      3.2.3C Conditioned Place Aversion (CPA) 91
                      3.2.3D Tissue Processing 92
            3.2.3E Immunohistochemistry 92
            3.2.3F Lesion Verification 92
            3.2.3G Lesion Specificity 93
 
3.3 RESULTS 95
          3.4.1 Orexin neuron activation by sexual reward 95
          3.4.2 Mating induced conditioned place preference (CPP) 97
          3.4.3 Conditioned place aversion (CPA) 100
           
3.4 DISCUSSION 103
 
3.5 REFERENCES 108
 
CHAPTER 4: Loss of Sexual Reward Causes Depression-like Behavior in Male Rats 
 
4.1 INTRODUCTION 114
 
4.2 MATERIALS AND METHODS 115
          4.2.1 Animals 115
          4.2.2 Sexual Behavior 116
          4.2.3 Forced Swim Test 117
          4.2.4 Tail Suspension Test 118
          4.2.5 Social Interaction Test 119
          4.2.6 Sucrose Preference Test 120
          4.2.7 Conditioned Place Preference 121
          4.2.8 Antidepressant Administration 122
          4.2.9 Rescue of depression-like behavior by sexual experience 122
          4.2.10 Anxiety-like Behavior: Elevated plus maze 123
 
4.3 RESULTS 124
          4.3.1 Forced Swim Test and Tail Suspension Test 124
          4.3.2 Antidepressant Treatment 124
          4.3.3 Rescue of depression-like behavior by sexual experience 126
          4.3.4 Anhedonia: Social Interaction 127
          4.3.5 Anhedonia: Sucrose Preference 127
          4.3.6 Mating Induced Conditioned Place Preference 127
ix 
 
 
 
          4.3.7 Anxiety-like Behavior: Elevated Plus Maze 129
 
4.4 DISCUSSION 129
 
4.5 REFERENCES 139
 
CHAPTER 5: Loss of Sexual Reward Causes Enhanced Stress Reactivity in Male 
Rats 
 
5.1 INTRODUCTION 145
 
5.2 MATERIALS AND METHODS 147
5.2.1 Animals 147
5.2.2 Sexual Behavior 148
5.2.3 Activation of CRF neurons by sexual behavior 148
5.2.3A Tissue Collection 148
5.2.3B Immunohistochemistry 149
5.2.3C Analysis 150
5.2.4 Changes in CRF mRNA following mating abstinence 151
              5.2.4A Tissue Collection 151
5.2.4B mRNA isolation and real-time polymerase chain reactions 151
          5.2.5 Acute restraint stress and blood collection 152
          5.2.6 Chronic ICV CRF receptor antagonist administration via osmotic          153
 minipumps 153
           5.2.6A Surgery 153
 5.2.6B Forced swim test 154
 5.2.6C Tissue collection and real-time qPCR 156
          5.2.7 Acute ICV CRF receptor antagonist administration 156
          5.2.8 Local manipulations of CRFR1 in nucleus accumbens or prefrontal  157
                   cortex 
 
5.3 RESULTS 158
          5.3.1 Activation of CRF neurons by sexual behavior 158
          5.3.2 Activation of CRF mRNA by abstinence from sexual behavior 158
          5.3.3 Acute stress responses 162
          5.3.4 Effects of chronic ICV treatment with CRF receptor antagonists 164
          5.3.5 Effects of acute ICV treatment with CRFR1 antagonist 164
          5.3.6 Effects of local manipulations of CRFR1 nucleus accumbens and 165
                   prefrontal cortex 
 
5.4 DISCUSSION 168
 
5.5 REFERENCES 176
 
 
x 
 
 
 
CHAPTER 6: GENERAL DISCUSSION 
6.1 Orexin and Sexual Reward 185
          6.1.1 Future Directions: Orexin 185
6.2 Development of animal model for depression following loss of sexual reward 187
6.2.1 Future Directions: Interactions with vulnerability to addiction 187
6.2.2 Future Directions: Glutamate 188
6.2.3 Future Directions: BDNF 190
6.3 Orexin interactions with CRF and the stress system 191
6.4 Overall Conclusions 192
6.6 REFERENCES 193
 
APPENDICES 
APPENDIX A 197
 
APPENDIX B 199
 
APPENDIX C 202
 
CURRICULUM VITA 206
xi 
 
 
 
LIST OF TABLES 
 
Table 2.1: Verification of orexin lesion specificity              61
 
Table 2.2: Mating induced cFos in sham, partial and lesion groups compared to non-  
mating controls of the same lesion status               
70
 
Table 3.1: Quantitative data for orexin lesion verification 96
 
Table 3.2:  Sexual behavior during the CPP conditioning trial 99
 
 
 
 
 
 
 
 
xii 
 
 
 
LIST OF FIGURES 
xiii 
 
Figure 2.1: Location of orexin neurons in the hypothalamus and orexin neurons in 
the PFA-DMH expressing cFos following mating
54
 
Figure 2.2: Lesion Verification  59
 
Figure 2.3: Orexin neurons in PFA-DMH and LHA express cFos following all 
parameters of mating behavior in naïve and experienced animals 
64
 
Figure 2.4: Orexin lesions shortened latencies to mount and intromission in sexually 
naive males 
65
 
Figure 2.5: Orexin lesions did not affect sexual motivation in sexually experienced 
males 
67
 
Figure 2.6:  Orexin lesions decreased anxiety-like behavior on the elevated plus maze. 68
 
Figure 3.1: Orexin and cFos immunoreactivity in PFA-DMH and LHA 89
 
Figure 3.2: Representative images showing orexin neurons in the hypothalamus of a 
sham animal injected with BLANK-saporin and loss of orexin neurons in the 
hypothalamus of a lesion animal injected with orexin-B-saporin 
94
 
Figure 3.3:  Percentages of orexin neurons expressing cFos in the PFA-DMH and LHA 
                     following exposure to the CPP apparatus.                            
98
                    
Figure 3.4: Orexin lesions prevent mating-induced CPP 101
 
Figure 3.4: Orexin lesions do not prevent CPA for an aversive stimulus 102
 
Figure 4.1: Percentage of time spent immobile in forced swim test and tail 
suspension test of sexually naïve and experienced males at 28, 7, or 1 
days following last handling or mating session. 
125
 
Figure 4.2: Effects of antidepressant treatment or mating during the period of 
abstinence on development of depression-like behavior in the forced 
swim test 
128
 
Figure 4.3: Effects of 28 days of abstinence on anhedonia in the social interaction 
and sucrose preference tests   
130
 
Figure 4.4: Effects of mating or a period of abstinence on anxiety-like behavior 
on the elevated plus maze   
131
 
 
 
  
 
 
 
 
 
Figure 5.1: Representative images of neurons in the PVN, CeA and BnST 
expressing CRF and cFos 
 159 
 
Figure 5.2: Mean numbers of CRF neurons in naïve and experienced males that 
mated 1 hour before or 24 hours prior to tissue collection in the PVN 
CeA and BnST. 
160
 
Figure 5.3  CRF mRNA expression in the PVN, CeA and BnST of sexually naïve 
and experienced males 1 and 28 days following last handling or 
mating 
161
 
Figure 5.4 Plasma corticosterone and ACTH levels in response to acute restraint 
stress in sexually naïve and experienced males 28 days following last 
handling or mating. 
163
 
Figure 5.5 Effects of chronic or acute ICV infusions of CRF receptor antagonist, 
and chronic intra-NAc or intra-mPFC infusions of CRFR1 antagonist 
on development of depression-like behavior in naïve and experienced 
males 28 days following last handling or mating 
167
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
 
 
LIST OF APPENDICES 
 
APPENDIX A:  UWO Council of Animal Care – Animal Protocol Approval 
 
 
APPENDIX B:  The University of Michigan University Committee on Use and  
                            Care of Animals – Animal Protocol Approval 
 
APPENDIX C:  Copyright License Agreements 
xv 
 
 
 
LIST OF ABBREVIATIONS 
5HT, serotonin 
8-OH-DPAT, 8-Hydroxy-N,N-dipropyl-2-aminotetralin 
ABC, avidin-biotin–horseradish peroxidase complex              
ACTH, adrenocorticotropic hormone      
AD, antidepressant   
AF, anestrous female 
AMPA, 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid 
BDNF, brain derived neurotrophic factor 
BLA, basolateral amygdala 
BnST, bed nucleus of the stria terminalis 
CeA, central amygdala 
CPA, conditioned place aversion 
CPP, conditioned place preference 
CRF, corticotropin releasing factor 
CRFR1, corticotropin releasing factor receptor 1 
CRFR2, corticotropin releasing factor receptor 2 
cort, corticosterone 
DAB, diaminobenzidene 
DAMGO, D-Ala2, N-MePhe4,Gly-ol-enkephalin 
DPX, dibutyl phthalate xylene 
E, Ejaculation 
EPM, elevated plus maze 
EF, estrous female 
Exp, experienced 
GABA, gamma-aminobutyric acid 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase 
GR, glucocorticoid receptor 
HPA, hypothalamic-pituitary-adrenal 
ICV, Intracerebroventricular 
IP, intraperitoneal 
xvi 
 
 
 
xvii 
 
IM, intromission 
IP, intraperitoneal 
LiCl, lithium chloride 
LHA, lateral hypothalamic area 
MEA medial amygdala 
MCH, melanocyte concentrating hormone 
MDMA, 3,4-methylenedioxy-methamphetamine 
MOR, mu-opioid receptor  
M, mount 
MeA, medial amygdala 
mPFC, medial prefrontal cortex 
mPOA, medial preoptic are 
NAc, nucleus Accumbens 
NMDA, N-methyl-D-aspartate 
OxR1, orexin receptor 1 
OxR2, orexin receptor 2 
PB, phosphate buffer 
PBS, phosphate buffered saline  
PEI, post ejaculatory interval 
PFA, paraformaldehyde 
PFA-DMH , perifornical dorsomedial hypothalamus 
PVN, paraventricular nucleus of the hypothamalus 
qRT-PCR, quantitative real time polymerase chain reaction 
SON, supraoptic nucleus 
SPFp, subparafascicular thalamic nucleus 
SSRI, selective serotonin reuptake inhibitor 
TNF-alpha, tumor necrosis factor alpha 
VTA, ventral tegmental area 
 
 
 
 
 
 
 
CHAPTER 1: GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sections 1.2-1.5 were published in Progress in Brain Research 198: 64-77 (2012) 
1.1 Introduction – Part 1 
1.1.1 Natural Reward Behaviors 
An individual’s behavior is altered by experience (Schultz, 2006). If a behavior is 
followed by reward, this will increase frequency of the behavior (i.e. reinforcement), 
however if a behavior is followed by punishment, frequency of the behavior will be 
decreased (Schultz, 2006). The brain system that is critical for mediation of reward 
behaviors is the mesolimbic system, which consists of interconnected brain regions 
including the ventral tegmental area (VTA), nucleus accumbens (NAc) and medial 
prefrontal cortex (mPFC) (Morgane et al., 2005). The mesolimbic system is important for 
mediation of natural rewards including feeding (Hernandez and Hoebel, 1988, Martel and 
Fantino, 1996, Avena et al., 2008, Vucetic and Reyes, 2010), drinking (Yoshida et al., 
1992), maternal behavior (Numan, 2007), social bonding (Young et al., 2001, Young et 
al., 2011) and sexual behavior (Pfaus et al., 1990a, Balfour et al., 2004, Frohmader et al., 
2010, Pitchers et al., 2010).   
There is great interest in understanding the neurobiology of natural reward 
behaviors and how these behaviors change the brain to alter subsequent behavior. As 
such, studies in this thesis will examine the neurobiology of sexual behavior and 
neuroplasticity related to sexual behavior, an extremely motivated and rewarding 
behavior in mammals (Paredes, 2009). 
 
1.1.2. Male Rat Sexual Behavior 
 The model animal for studies in this thesis is the male rat. In male rats, sexual 
behavior is a complex interaction which involves pursuit and investigation of the female, 
2 
 
mounts, intromissions, culminating in ejaculation (Hull et al., 2002 ). Following 
investigation the male will mount the female and perform rapid pelvic thrusts, without 
penetration (Agmo, 1997). An intromission begins with a mount and continues until the 
male performs a deeper pelvic thrust that results in vaginal penetration (Agmo, 1997). 
Culmination of this sexual activity is ejaculation, which in turn is followed by a 4-7 
minute period of sexual inactivity, the post-ejaculatory interval, after which the male 
reinitiates sexual behavior. Male rats will perform numerous copulatory series prior to 
reaching sexual satiety (Agmo, 1997).  
 
1.1.3 Sexual Motivation and Performance 
In male rats, approach and investigation of the receptive female is indicative of 
sexual motivation. Latencies to first mount and intromission are also considered to be 
measures of sexual motivation. Sexual behavior is highly motivating in male rats, as 
males spend increased time investigating a receptive female presented behind a barrier 
vs. a nonreceptive female, show increased speeds to reach a sexually receptive female in 
a straight runway test (Lopez et al., 1999) and change levels more frequently in the 
bilevel chamber test in search of a sexually receptive female (Mendelson and Pfaus, 
1989). Males also show decreased latencies to mount and intromission with repeated 
sexual experience, indicating increased sexual motivation (Pfaus et al., 1990b, Agmo, 
1997). Sexual performance in male rats is indicated by the frequency of mounts and 
intromissions an animal performs in a copulatory series, and also by latencies to 
ejaculation (Agmo, 1997). Sexual performance is enhanced by sexual experience, as 
copulation efficiency is increased (increased numbers of intromissions relative to number 
3 
 
of mounts) (Agmo, 1997), and latencies to ejaculation are shortened (Pitchers et al., 
2012). The neural systems mediating sexual motivation and performance begin with 
chemosensory input from the olfactory bulb that project to the medial amygdala (MeA), 
which sends these signals to the medial preoptic area (mPOA), both directly and 
indirectly, via the bed nucleus of the stria terminalis (BnST). Genitosensory inputs are 
relayed through the spinal cord to the subparafascicular thalamic nucleus (SPFp) which 
projects to the MeA and mPOA. Furthermore the mPOA, MeA, BnST and SPFp all show 
cFos activation following display of sexual behavior (Coolen et al., 1996, 1997b), 
indicating neural activation by mating. The mPOA is a major integrative site for control 
of sexual behavior and lesions of this brain region cause impairments in both sexual 
motivation (Paredes et al., 1993, Edwards et al., 1996) and performance (Larsson and 
Heimer, 1964, Arendash and Gorski, 1983).  
 
1.1.4 Sexual Reward 
  In humans, ejaculation is associated with the pleasurable feeling of orgasm. 
Similarly in rats, ejaculation is associated with reward and is the most rewarding 
component of sexual behavior (Tenk et al., 2009). Sexual behavior in male rats has been 
shown to be a rewarding and reinforcing behavior as males will perform operant tasks, 
(Everitt et al., 1987, Everitt and Stacey, 1987) climb barriers (Sheffield et al., 1951) or 
cross electrified grids (Moss, 1924) to gain access to a sexually receptive female. 
Moreover, male rats facilitate their sexual performance with repeated sexual experience 
(Pitchers et al., 2012) and form a conditioned place preference for sexual behavior 
(Agmo and Berenfeld, 1990, Tenk et al., 2009). The mesolimbic system, which is critical 
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for mediation of reward, is activated during sexual behavior. It has been shown that both 
sexual behavior and exposure to cues associated with sexual reward lead to cFos 
activation in the NAc and increased cFos activation of dopamine neurons in the VTA 
(Balfour et al., 2004), suggesting an important role of these brain regions in mediation of 
sexual reward. 
 
1.1.5. Neuropeptides in Sexual Motivation, Performance and Reward 
As mentioned above, sexual behavior is a complex behavior that involves 
integration of many different brain regions. As such, there are also many 
neurotransmitters and neuropeptides involved in mediation of this behavior that will be 
discussed below. 
 
Glutamate 
Glutamate is the main excitatory neurotransmitter in the central nervous system 
and is released in the mPOA during sexual behavior (Dominguez et al., 2006). NMDA 
receptors also become activated in the mPOA following copulation (Dominguez et al., 
2007). Both systemic (Powell et al., 2003) and intra-mPOA (Dominguez et al., 2007) 
administration of glutamate antagonists also have been shown to lead to impairments in 
sexual performance. Thus, glutamate appears to play a facilitatory role in sexual 
performance. Moreover, blockade of N-methyl-D-aspartate (NMDA) receptors decreased 
mating induced cFos as well as mating induced phosphorylation of the NR1 subunit of 
the NMDA receptor in the mPOA (Dominguez et al., 2007), suggesting that facilitatory 
effects of glutamate on sexual performance may be via NMDA receptors in the mPOA. 
5 
 
Dopamine 
Dopamine has also been shown to play a role in sexual behavior. Systemically 
administered dopamine agonists facilitate male sexual performance (Ahlenius and 
Larsson, 1990, Pfaus and Phillips, 1991, Melis and Argiolas, 1995, Olivier et al., 2007), 
while systemic administration of dopamine antagonists impair sexual performance 
(Ahlenius and Larsson, 1990). Dopamine is released into the mPOA with presentation of 
a receptive female and remains elevated throughout display of sexual behavior (Hull et 
al., 1995), indicating a role for mPOA dopamine in sexual motivation and performance. 
Additionally, intra-mPOA administration of dopamine receptor antagonists has been 
shown to lead to impairments in both sexual motivation and performance (Pfaus and 
Phillips, 1991). During sexual behavior dopamine is also released into the NAc with 
presentation of a receptive female, and remains elevated during the entire display of 
copulation (Pfaus et al., 1990a, Pfaus and Phillips, 1991, Damsma et al., 1992, Wenkstern 
et al., 1993), suggesting dopamine may be important for mediation of sexual reward. 
However, there have been many studies demonstrating that dopamine neurotransmission 
does not appear to be critical for mating-induced conditioned place preference (Agmo 
and Berenfeld, 1990, Garcia Horsman and Paredes, 2004, Paredes and Agmo, 2004, 
Ismail et al., 2009), a well established model for measuring sexual reward (Tzschentke, 
2007). Instead, it has been proposed that dopamine in the NAc may play a role in the 
prediction of reward upon presentation of a reward-associated cue (Schultz, 2006) or be 
important for mediation of incentive motivation for sexual behavior (Robinson and 
Berridge, 1993). 
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Endogenous Opioids 
Opioids have been shown to be inhibitory to sexual performance as infusion of 
morphine, heroin and methadone all lead to impairments in sexual behavior (Pfaus and 
Gorzalka, 1987). Similarly, infusion of opioid peptides such as β-endorphin impairs 
sexual performance (Hughes et al., 1987). Infusion of µ-opioid receptor antagonists such 
as naloxone and natrexone facilitate sexual performance in sexually naïve (Pfaus and 
Wilkins, 1995) and sexually experienced male rats (Myers and Baum, 1979). However, 
there are also studies that have shown that opioids may have facilitative effects on sexual 
behavior. Increasing enkephalin levels ICV using enkephalinase inhibitors that block 
degradation of endogenous enkephalin, facilitated sexual behavior and decreased latency 
to ejaculate in male rats (Agmo et al., 1994), while intra-VTA morphine or dynorphin led 
to improvements in copulatory performance and increased dopamine release in the NAc  
(Mitchell and Stewart, 1990). Furthermore, opioid receptors are activated by sexual 
behavior as mating induces internalization of µ-opioid receptors in the mPOA (Coolen et 
al., 2004b) and VTA (Balfour et al., 2004). Endogenous opioids also appear to be critical 
for mediation of sexual motivation, as infusion of naloxone in the VTA prevented the 
increase in level changes in the bilevel chamber in anticipation of a sexual receptive 
female (van Furth and van Ree, 1996). Endogenous opioids have also been shown to be 
activated by sexual reward, as µ-opioid receptors in the VTA are activated by exposure to 
conditioned contextual cues associated with prior sexual reward (Balfour et al., 2004). 
Furthermore, opioids play a critical role in mediation of sexual reward as both systemic 
and intra-mPOA infusion of naloxone blocks development and expression sexual reward 
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induced conditioned place preference (Agmo and Berenfeld, 1990, Mehrara and Baum, 
1990, Agmo and Gomez, 1993, Paredes and Martinez, 2001, Ismail et al., 2009).  
 
Serotonin 
 Serotonin (5HT) is generally regarded as being inhibitory to sexual behavior (Hull 
et al., 2004) as a common side effect of selective serotonin reuptake inhibitor (SSRI) 
antidepressants, which increase extracellular 5HT release, is impaired sexual behavior in 
both humans (Rosen et al., 1999) and rats (Mos et al., 1999). There are fourteen known 
G-protein-coupled receptors for serotonin that are divided into seven classes; however 
only a few thus far have been shown to be related to sexual behavior. The inhibitory 
actions of 5HT appear to be mediated by the 5HT1B and the 5HT2 receptors. Systemic or 
intracranial administration of a 5HT1B (Fernandez-Guasti et al., 1989a, Fernandez-Guasti 
et al., 1992) or 5HT2 (Foreman et al., 1989, Watson and Gorzalka, 1991) agonists impair 
copulatory performance, while 5HT2 antagonists facilitate sexual behavior (Gonzalez et 
al., 1994). Furthermore, the mPOA and NAc appear to be brain regions important for 
5HT’s inhibitory effect on sexual behavior, as 5HT injected into these brain regions 
impairs copulatory performance (Verma et al., 1989, Fernandez-Guasti et al., 1992). 
Serotonin has also been shown to have facilitatory effects on sexual behavior and these 
effects have been shown to be mediated by the 5HT1A receptor, as systemic (Ahlenius and 
Larsson, 1990, Haensel et al., 1991, Fernandez-Guasti et al., 1992, Coolen et al., 1997a), 
intra-mPOA (Fernandez-Guasti et al., 1992), intra-NAc (Matuszewich et al., 1999), and 
intra-MeA (de Castilhos et al., 2006) administration of the 5HT1A agonist, 8-OH-DPAT 
facilitates sexual performance. There have been fewer studies on the role of 5HT in 
8 
 
sexual reward, however it has been shown that systemic administration of 3,4-
methylenedioxy-methamphetamine (MDMA,“ecstasy”) that leads to a 40-55% depletion 
of 5HT in brain regions such as the striatum, hypothalamus, cortex, hippocampus and 
NAc blocks formation of conditioned place preference for sexual behavior (Straiko et al., 
2007), suggesting that serotonin may also play an important role in mediation of sexual 
reward. 
 
Oxytocin 
 Oxytocin is a hypothalamic neuropeptide produced in the paraventricular nucleus 
of the hypothalamus (PVN) and supraoptic nucleus (SON) (Bargmann and Scharrer, 
1951). Oxytocin is generally regarded as facilitatory to sexual performance as intra-PVN 
infusion of oxytocin stimulates penile erections (Kita et al., 2006), and systemic, ICV, or 
intra-mPOA administration of oxytocin facilitates sexual performance in male rats 
(Argiolas and Melis, 2005, Gil et al., 2011). Conversely, oxytocin antagonists have been 
shown to impair sexual performance (Argiolas and Melis, 2005). Furthermore, sexual 
interaction has been shown to increase cFos in oxytocin neurons of the PVN that have 
projections to the spinal cord and are involved in control of penile erection (Witt and 
Insel, 1994). Low levels of oxytocin mRNA in the PVN are associated with sexual 
impotence in rats (inability to copulate with a sexually receptive female) (Arletti et al., 
1997), further supporting a role for oxytocin in sexual performance. Oxytocin may also 
play a role in sexual motivation and reward as oxytocin has been shown to facilitate 
sexually conditioned partner preference in male rats (Pfaus, 2009), and interaction with a 
sexually receptive female leads to oxytocin release in male rats (Hillegaart et al., 1998). 
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Furthermore, neutral odors associated with prior sexual reward have been shown to 
activate oxytocin in the PVN (Ménard et al., 2005).  
Therefore, it is evident that many neurotransmitters and neuropeptides play an 
important role in sexual performance, motivation and reward. As such, studies in 
Chapters 2 and 3 of this thesis will focus on a more recently discovered neuropeptide, the 
hypothalamic neuropeptide, orexin. Orexin has been implicated to play a key role in 
reward associated with food and drugs, but the role of this neuropeptide in mediation of 
sexual performance, motivation or reward is currently unclear. 
 
1.2 Orexin and Natural Reward Behavior: Feeding, Maternal and Male Sexual 
Behavior 
Orexin-A and orexin-B, also known as hypocretin-1 and hypocretin-2, are 
hypothalamic neuropeptides produced exclusively in the perifornical dosomedial 
hypothalamus (PFA-DMH) and lateral hypothalamic area (LHA), that arise from the 
precursor peptide prepro-orexin (de Lecea et al., 1998, Sakurai et al., 1998). The orexins 
bind to two G-protein coupled receptors, orexin receptor 1 (OxR1) and orexin receptor 2 
(OxR2), with OxR1 being selective for orexin-A and OxR2 being equally selective for 
both orexin-A and orexin-B (Sakurai et al., 1998). Orexin neurons project their axons 
broadly throughout the brain and spinal cord to regions important for arousal and sleep, 
feeding behavior, and reward and motivation (Peyron et al., 1998). OxR1 and OxR2 are 
also widely distributed throughout the brain and spinal cord (Trivedi et al., 1998, Marcus 
et al., 2001). The discovery of orexins was accompanied with great interest in orexin’s 
role in arousal and sleep (Paredes et al., 1997, Chemelli et al., 1999, Lin et al., 1999, 
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Furlong and Carrive, 2007, Sakurai, 2007) and in feeding behavior (de Lecea et al., 1998, 
Sakurai et al., 1998, Sakurai, 2006). Orexin neuronal dysfunction leads to narcolepsy in 
mice (Chemelli et al., 1999), dogs (Lin et al., 1999) and humans (Siegel, 1999, Nishino et 
al., 2000, Thannickal et al., 2000), suggesting that orexin is critically involved in arousal 
and maintenance of waking state. Orexin neurons indeed project to arousal associate 
brain regions such as the locus coeruleus (Peyron et al., 1998). Furthermore, 
intracerebroventricular (ICV) administration of orexin-A and orexin-B causes increased 
food intake in rats, and fasting leads to upregulation of prepro-orexin mRNA (Sakurai et 
al., 1998). With a role established for orexin in feeding it was next hypothesized that 
these peptides are involved in mediation of reward and motivation. Indeed, there is now 
ample evidence that orexin plays a critical role in reward related to drugs of abuse and 
addiction behaviors. 
 
1.3 Orexin, Feeding and Energy Homeostasis 
 Orexin neurons are localized in brain regions important for regulation of feeding 
behavior and energy homeostasis, the PFA-DMH and LHA (Elmquist et al., 1999). 
Furthermore ICV infusions of orexin-A and orexin-B stimulate food intake in rats and 
mice (Sakurai et al., 1998, Edwards et al., 1999). Thus orexin likely plays a role in 
feeding and energy balance. Indeed, human narcoleptics that have orexin neuron 
deficiency (Peyron et al., 2000, Thannickal et al., 2000) and decreased orexin-A levels in 
CSF (Nishino et al., 2000, Schuld et al., 2002, Scammell, 2003) show decreased food 
intake (Lammers et al., 1996) with an increased body mass index (Nishino et al., 2000, 
Schuld et al., 2000, Nishino et al., 2001), indicating metabolic abnormalities. Mice with 
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genetic ablation of orexin and that display narcoleptic symptoms have significantly 
decreased food intake, and eventually develop late-onset obesity (Hara et al., 2001), 
suggesting that orexin is an important mediator of energy homeostasis and metabolism. 
Additionally, increasing extracellular glucose and leptin levels leads to hyperpolarization 
of orexin neurons, while decreasing extracellular glucose and leptin levels leads to 
depolarization of orexin neurons, indicating that orexin neurons are glucose and leptin 
sensitive (Yamanaka et al., 2003). Orexin neurons are also sensitive to triglycerides, as 
intraperitoneal (IP) injection of lipids increases orexin mRNA levels in the hypothalamus 
(Chang et al., 2004) and are sensitive to dietary amino acids, as oral gavage of 
nutritionally relevant levels of amino acids leads to increased cFos expression in orexin 
neurons (Karnani et al., 2011). Furthermore, orexin has been suggested to act as a sensor 
for nutritional state as prepro-orexin mRNA is upregulated by fasting (Sakurai et al., 
1998) and hypoglycemia (Griffond et al., 1999). The findings that orexin neurons 
respond to glucose, leptin, triglycerides and dietary amino acids further implicate a role 
for orexin in energy homeostasis. Orexin neurons are innervated by both the appetite 
suppressing peptide, proopiomelanocortin and the appetite stimulatory peptide 
neuropeptide-Y (Elias et al., 1998). Furthermore, ICV infusion of agouti related peptide, 
which is co-expressed in the same neurons as neuropeptide-Y and stimulates appetite, 
leads to increased cFos expression in orexin neurons (Zheng et al., 2002). Thus there is 
clear evidence that orexin interacts with the hypothalamic peptides that regulate food 
intake and energy homeostasis. 
 
1.4 Orexin and Food Motivation and Reward 
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In addition to mediating energy homeostasis, orexin is an important mediator of 
motivation and reward associated with feeding. ICV orexin-A and orexin-B infusion 
stimulates feeding (Sakurai et al., 1998) and IP infusion of an OxR1 specific antagonist, 
SB-334867 reduces food intake in both male and female rats (Haynes et al., 2000). 
Moreover, IP pre-treatment with SB-334867 attenuates orexin-A induced feeding 
behavior, indicating the actions of orexin-A on feeding are via OrXR1 (Rodgers et al., 
2001). Mice with a genetic ablation of orexin have decreased intake of food (Hara et al., 
2001) and orexin knockout mice show decreased intake of sucrose (Matsuo et al., 2011). 
These effects of orexin or orexin receptor antagonism appear to be caused by alterations 
in motivation to eat or reward associated with feeding. Orexin-A stimulates feeding when 
infused into the nucleus accumbens shell (Thorpe and Kotz, 2005), an area important for 
goal-directed behaviors and hedonia related to feeding (Berridge, 1996, Zhang et al., 
1998, Pecina and Berridge, 2000, Pecina et al., 2006). In self administration studies 
which assess motivation for food, animals learn to lever press to receive food reward. 
ICV administration of  SB-334867 attenuates lever pressing on a fixed ratio schedule for 
food (Borgland et al., 2009), sucrose pellets (Thorpe et al., 2005) and high fat chocolate 
pellets (Nair et al., 2008). SB-334867 also attenuates the number of sucrose reinforcers 
obtained in a fixed ratio self administration paradigm in both ad libitum fed and food 
restricted rats (Cason et al., 2010). Studies using a progressive ratio self administration 
procedure in which the animal must press a lever progressively more times to obtain the 
same reinforcer are also used to examine the role of orexin in food motivation. 
Motivation in the progressive ratio procedure is determined by the maximum number of 
times an animal will lever press to receive the reinforcer, called the breakpoint 
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(Richardson and Roberts, 1996). The effects of orexin in the progressive ratio schedule 
appears to be dependent on the satiety state of the animal as intra-LHA administration of 
orexin-A increased breakpoint responding for sucrose pellets (Thorpe et al., 2005, Choi et 
al., 2010), and this breakpoint was increased further following 24 hours of food 
deprivation (Thorpe et al., 2005). Further supporting this, IP administration of SB-
334867 decreased breakpoint for sucrose pellets in sated but not food-restricted rats 
(Espana et al., 2010). IP injection of SB-334867 also reduces consumption of high fat, 
palatable food in both a fixed ratio schedule (Nair et al., 2008, Choi et al., 2010) and a 
progressive ratio schedule (Borgland et al., 2009). The latter study also showed that the 
same dose of SB-334867 did not affect intake of normal chow, suggesting orexin-A is 
important for mediation of motivation for positive, highly salient reinforcers (Borgland et 
al., 2009). In mice, pharmacological blockade of OxR1 using SB-334867 or viral vector 
mediated knockdown of prepro-orexin decreases responding for food in a progressive 
ratio schedule (Sharf et al., 2010). In contrast, orexin knockout mice do not show any 
differences in responses for food on a progressive ratio schedule, suggesting 
developmental compensation in orexin knockout mice (Sharf et al., 2010). Another 
method of measuring food motivation is an effort based feeding paradigm in which rats 
are given a choice between exerting a small amount of effort to obtain regular food 
pellets, or jump over a barrier to receive high fat chocolate pellets in a T-maze. Rats will 
willingly jump the barrier to obtain the palatable food pellets (Salamone et al., 1994). 
Systemic or intra-VTA administration of SB-334867 significantly decreases number of 
entries into the high fat-containing arms (Borgland et al., 2009), demonstrating that OxR1 
blockade decreases motivation for palatable food. Orexin is also important for cue-
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induced reinstatement of sucrose seeking, as IP SB-334867 significantly attenuates lever 
pressing in reinstatement trials in food restricted, but not in ad libitum fed rats (Cason et 
al., 2010). Furthermore, SB -334867 pre-treatment also significantly attenuates 
yohimbine-induced reinstatement of sucrose seeking, further implicating a role for 
orexin-A and OxR1 in food seeking and motivation for palatable food (Richards et al., 
2008).  
 Orexin is an important mediator of food motivation and is also important for the 
rewarding aspects of feeding behavior. Orexin neurons in the LHA show significant cFos 
induction following exposure to a conditioned place preference (CPP) apparatus they had 
previously learned to associate with food reward (Harris et al., 2005) and the degree of 
cFos induction is correlated with the degree of preference animals display for the food 
reward paired chamber, thus suggesting that orexin is activated by food reward associated 
conditioned cues (Harris et al., 2005). Orexin is also involved in reward based feeding 
behavior, a paradigm in which sated animals will over-consume a high fat diet. This is 
referred to as non-homeostatic feeding and in humans is thought to be a major contributor 
to the obesity epidemic (Berthoud, 2004). IP administration of SB-334867 in sated rats 
decreased intake of high fat diet (Choi et al., 2010) and IP administration of SB-334867 
attenuates ghrelin enhanced conditioned place preference for high fat diet in ad libitum 
fed rats that were not sated (Perello et al., 2010). Finally, orexin-A expressing neurons 
are significantly activated in animals expecting a daily meal of regular chow or high fat 
chocolate (Choi et al., 2010), suggesting a role for orexin in food anticipation.  
In summary, orexin clearly plays a role in mediating reward and motivation 
related to food intake. Outstanding questions remain regarding the areas in the brain 
15 
 
where orexin may be acting to mediate these effects, and the roles of orexin-B and OxR2 
as studies described above primarily examine the role of orexin-A and OxR1 in food 
motivation and reward. 
 
1.5 Orexin and other naturally rewarding behaviors  
  Even though a role for orexin in feeding behavior, food motivation and reward is 
well documented, a role for orexin in other naturally rewarding behaviors has not been 
extensively studied. Studies that examined orexin’s role in the natural rewarding 
behaviors maternal behavior and male sexual behavior will be discussed below. 
 
1.5.1 Orexin and maternal behavior 
 Orexin receptors are found in brain regions shown to be important for mediation 
of maternal behavior and aggression (Trivedi et al., 1998) including the paraventricular 
nucleus of the hypothalamus (Numan and Corodimas, 1985, Insel and Harbaugh, 1989, 
Giovenardi et al., 1997, 1998), nucleus accumbens (Hansen, 1994, Keer and Stern, 1999), 
medial preoptic area (Numan, 1974, Numan et al., 1977) and bed nucleus of the stria 
terminalis (Terkel et al., 1979). Additionally, it has been shown that lactating female rats 
have significantly higher levels of prepro-orexin and OxR1 mRNA in the lateral 
hypothalamus compared to pregnant females (Wang et al., 2003), suggesting orexin may 
be involved in maternal behavior.  D’Anna and Gammie tested this hypothesis and show 
that an intermediate doses of orexin-A (0.06 – 1 µg) ICV increases licking and grooming 
behavior of the mothers towards the pups, and increases numbers of nursing bouts. In 
addition, this intermediate dose of orexin-A induces cFos  activation in brain areas 
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involved in maternal behavior including the ventral tegmental area, bed nucleus of the 
stria terminalis, central and medial amygdala (D'Anna and Gammie, 2006). In contrast, a 
higher dose of ICV orexin-A (3µg) impairs maternal behavior by delaying latency to 
nurse, decreasing total time nursing and increasing time away from the nest (D'Anna and 
Gammie, 2006). Furthermore, this higher dose of orexin-A also decreases maternal 
aggression in the mothers towards an intruder male. However, IP injection of SB-334867 
(10 or 30 mg/kg), does not significantly affect any aspect of maternal behavior or 
aggression, although there were trends towards impaired maternal care (D'Anna and 
Gammie, 2006). These findings suggest that intermediate levels of orexin-A may be 
important for maintaining proper maternal behavior such as licking and grooming, 
however, when levels of orexin are too high maternal care is impaired. Future studies are 
needed to further elucidate the role of orexin in maternal behavior and aggression, in 
particular to determine where in the brain orexin may be acting to mediate maternal 
behavior and aggression. 
 
1.5.2 Orexin and sexual performance & motivation 
Several studies have demonstrated a role for orexin in sexual performance, reward 
and motivation. It has been long known that electrical stimulation of the lateral 
hypothalamus facilitates sexual behavior in male rats (Vaughan and Fisher, 1962, 
Caggiula and Hoebel, 1966). Since the lateral hypothalamus contains orexin neurons it 
was thus hypothesized that orexin may be important for sexual behavior in male rats. 
Sexual behavior culminating in ejaculation in male rats leads to cFos induction in orexin 
neurons of the PFA-DMH and LHA (Muschamp et al., 2007). These results suggest that 
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orexin may play an important role in the initiation of, or motivation for mating as well as 
sexual performance.  
Several studies have used pharmacological manipulations to test whether orexin is 
critically involved in mediation of sexual motivation and performance. Orexin-A 
administration into the medial preoptic area (mPOA), a brain region that is important for 
sexual performance (Hansen et al., 1982, Coolen et al., 2004a) facilitates sexual 
motivation and performance in male rats. Orexin-A in the mPOA increases sexual 
motivation, by decreasing latencies to mount, intromit, and pursue a receptive female 
(Gulia et al., 2003). Intra-mPOA orexin-A also increases sexual performance, by 
decreasing latency to ejaculate and increasing frequency of mounts and intromissions 
(Gulia et al., 2003). These studies suggest that orexin-A may act in the mPOA to 
facilitate sexual motivation and performance. In contrast to these findings ICV 
administration of orexin-A attenuates sexual motivation, but only in highly sexually 
motivated male rats (Bai et al., 2009b). This discrepancy in findings may suggest that 
orexin-A has opposing effects on sexual behavior by acting in multiple brain regions, 
with facilitatory effects in mPOA, but inhibitory effects in other areas. Studies testing 
effects of antagonists however, have also yielded puzzling results. In one study ICV 
administration of SB-334867 had no effect on sexual motivation or arousal (Bai et al., 
2009b), and in another study systemic injection of SB-334867 caused only a slight 
impairment in sexual performance seen as longer latencies to intromission and decreases 
in ejaculation frequency (Muschamp et al., 2007). Thus, with numerous conflicting 
studies, the role of orexin in mediation of sexual behavior and performance is unclear.  
Moreover, a role for orexin in sexual reward has yet to be tested.  
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 1.6 Rationale and Objectives: Part 1 
 In chapters 2 and 3, I set out to test the hypothesis that orexin is a critical mediator 
of sexual performance, motivation, and reward. 
 
1.6.1 Objectives  
1. Demonstrate that exposure to different parameters of sexual motivation and 
performance cause activation of orexin neurons seen as increased expression of 
the immediate early gene cFos in orexin neurons. Establish that orexin is a critical 
mediator of sexual motivation and performance utilizing cell-specific lesions of 
orexin neurons in the hypothalamus of male rats. 
 
2. Show that orexin is activated by conditioned cues related to sexual reward using 
cFos expression as marker of neural activity. Establish that orexin is critically 
involved in sexual reward by demonstrating that cell-specific lesions of orexin 
neurons block conditioned place preference for sexual reward. 
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1.7 Introduction: Part 2 
 
1.7.1 Drug Induced Neuroplasticity in the Mesolimbic Sytem 
The mesolimbic system, consisting of the interconnected brain regions of the 
ventral tegmental area (VTA), nucleus accumbens (NAc) and medial prefrontal cortex 
(mPFC) is critical for mediation of natural reward behaviors (Hyman et al., 2006). Drugs 
of abuse have been shown to converge upon the mesolimbic system and specifically, 
repeated exposure to drugs of abuse causes neural alterations at the levels of gene 
expression, synaptic strength and neuron morphology within the mesolimbic system 
(Hyman et al., 2006; Kalivas et al., 2009). These alterations subsequently lead to the 
development of drug addiction and cause increased susceptibility for relapse (Kalivas et 
al., 2009). In rodents, repeated exposure to drugs of abuse leads to sensitization of the 
locomotor response to opiates and psychostimulants (Segal and Mandell, 1974, Post and 
Rose, 1976, Kalivas and Stewart, 1991), enhanced conditioned drug reward (Lett, 1989, 
Shippenberg et al., 1996) and increased lever pressing for conditioned cues associated 
with prior drug reward (Crombag et al., 2008). Repeated exposure to drugs of abuse 
causes long lasting alterations in numbers of dendritic spines and spine density within the 
NAc (Robinson and Kolb, 1997, 1999, Robinson et al., 2002, Li et al., 2003, Li et al., 
2004, Robinson and Kolb, 2004) and VTA (Sarti et al., 2007). Moreover, repeated 
exposure to drugs of abuse causes alterations in synaptic strength in VTA dopamine 
neurons (Kauer, 2003, Liu et al., 2005) and neurons in the NAc (Thomas et al., 2000, 
Thomas and Malenka, 2003). Thus, is clear that repeated exposure to drugs of abuse 
leads to neuroplasticity in the mesolimbic system. Until recently, it was unclear as to 
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whether natural rewarding behaviors, such as sexual behavior lead to similar 
neuroplasticity. 
 
1.8 Sexual Reward and Neuroplasticity 
  Studies from our lab have recently shown that repeated exposure to sexual 
behavior also causes neuroplasticity in the mesolimbic system, similar to that seen 
following repeated exposure to drugs of abuse. Repeated sexual experience has been 
shown to cause sensitized responses to sexual behavior, seen as facilitation of sexual 
performance with experience (Pitchers et al., 2012), as well as cross-sensitization to the 
psychostimulant amphetamine (Frohmader et al., 2010, Pitchers et al., 2010). It has also 
been demonstrated that these changes persist following a period of abstinence from 
mating (Pitchers et al., 2012), as facilitation of sexual behavior and sensitization to 
amphetamine are both maintained one week and one month following last sexual 
experience (Pitchers et al., 2012). Repeated sexual experience also causes 
electrophysiological changes observed as long-term depression in the NAc that persists 
after a one week period of abstinence from mating (Pitchers et al., 2012). Furthermore, 
some of the neuroplastic changes seen following repeated sexual experience appear to be 
dependent on this period of abstinence from mating, consistent with findings that some 
neuroplastic alterations seen following repeated exposure to drugs of abuse are dependent 
on a period of abstinence from drug taking (Nestler, 2001, Wolf et al., 2004, Kauer and 
Malenka, 2007). Repeated sexual experience in male rats, followed by a seven-ten day 
period of abstinence from mating causes enhanced drug reward seen as formation of a 
conditioned place preference for subthreshold doses of amphetamine (Pitchers et al., 
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2010). This effect is only seen following a period of mating abstinence, and is not 
observed one day following last sexual experience (Pitchers et al., 2010). Moreover, 
morphological changes in the NAc including increased dendritic branching and increased 
numbers of dendritic spines are observed seven days following last mating, but not at 
earlier timepoints (Pitchers et al., 2010). It is therefore evident that natural reward causes 
neuroplasticity in the mesolimbic system, similar to that caused by repeated exposure to 
drugs of abuse. Neuroplasticity induced by sexual behavior appears to regulate the 
reinforcing components of sexual behavior and may regulate reward behavior in general. 
Yet, abstinence from sexual reward appears to induce a state of increased reward-seeking 
and potential vulnerability to the addictive properties of drugs of abuse, which may 
mimic the effects of abstinence from drugs of abuse on the “incubation of craving” (Lu et 
al., 2004, Lu et al., 2005). Thus, this neuroplasticity following abstinence from sexual 
behavior that causes increased reward seeking and vulnerability for drugs of abuse, may 
also cause increased susceptibility for other disorders related to reward, including mood 
disorders such as depression. 
 
1.9 Drug Addiction and Depression 
Drug addiction is often comorbid with other neuropsychiatric disorders, including 
mood disorders such as depression (Kessler et al., 2003, Volkow, 2004, DuPont, 1995). It 
is estimated that the comorbidity of drug abuse and mood disorders is 19.4%, and drug 
abuse increases risk for depression by a factor of 5 (Regier et al., 1990). Withdrawal and 
subsequent abstinence from drugs of abuse in human addicts leads to feelings of anxiety 
and depressed mood (Koob, 2009). Similarly, studies in rats and mice have shown that 
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withdrawal and abstinence from drugs of abuse cause anxiety and depression-like 
phenotypes (Perrine et al., 2008).  
 
1.10 Depression 
Depression is a mood disorder in which feelings of sadness, loss, anger, or 
frustration interfere with everyday life for a prolonged period of time (Krishnan and 
Nestler, 2008). It is estimated that 16.2% of adults in the United States will experience a 
major depressive episode at some point in their lifetime (Kessler et al., 2003). Depression 
is often triggered by stressful life events such as childhood abuse or neglect, chronic 
stress, chronic abuse or loss of rewarding social interactions such as death of partner, 
friend or relative, or loss of job (Newport et al., 2002, Henn and Vollmayr, 2005, 
Krishnan and Nestler, 2008, Nestler and Hyman, 2010, Krishnan and Nestler, 2011). 
However, some individuals are more susceptible to develop depression due to genetic and 
environmental vulnerability (Krishnan and Nestler, 2008). 
 
1.10.1 Animal Models of Depression 
As depression is such a prevalent problem in the human population, many animal 
models have been developed to attempt to elucidate the underlying neural mechanisms of 
depression. Depression is a multivariate illness with a number of symptoms, including 
depressed mood and irritability, cognitive symptoms such as feelings of guilt and 
suicidality, anhedonia or inability to experience pleasure, homeostatic symptoms such as 
weight loss or gain, insomnia or hypersomnia, appetite and energy abnormalities and 
alterations in psychomotor behavior (Nestler and Hyman, 2010). As such, animal models 
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of depression can only objectively mimic some but not all symptoms of human 
depression. As depression in humans is often triggered by stressful life events, current 
animal models rely on exposing animals to stressful stimuli to induce depression-like 
behavior. Several chronic stress rodent models of depression have been developed in 
attempt to mimic the effects of chronic life stress on development of depression in 
humans. Chronic mild stress or chronic unpredictable stress models of depression rely on 
exposing animals to daily stressors (i.e. foot shock, hot or cold temperature, swim stress, 
restraint) for periods of weeks to months or more (Henn and Vollmayr, 2005, Willner, 
2005). Following chronic stress, animals develop anhedonia that can be blocked by 
administration of antidepressants (Willner, 2005), thus providing pharmacological 
validation of this model. The social defeat model of depression attempts to model 
depression following chronic abuse in humans. Rodents are subjected to daily encounters 
with an aggressor and social subordination. After a period of weeks to months, these 
animals develop depression-like symptoms including anhedonia and social withdrawal 
that can be blocked by chronic administration of antidepressants (Krishnan et al., 2007). 
The social defeat model also mimics some of the homeostatic symptoms of depression 
such as weight gain and insulin resistance (Chuang et al., 2010). The maternal separation 
model of depression mimics childhood abuse and neglect, and relies on separating pups 
from their mothers for  brief period of time during the first few weeks of life. These 
animals develop life-long behavioral and neuroendocrine abnormalitites, some of which 
can be blocked by antidepressants (Meaney, 2001). All of these animal models reliably 
induce depression-like behavior in rodents, and provide valuable insight into 
development of depression in humans following stressful life events. However, as 
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mentioned above, depression in humans can also be triggered by loss of socially 
rewarding stimuli, such as loss of partner, relative or job (Newport et al., 2002, Henn and 
Vollmayr, 2005, Krishnan and Nestler, 2008, Nestler and Hyman, 2010, Krishnan and 
Nestler, 2011). Currently there are no animal models to study effects of loss of social 
reward in humans. Recently, it has been demonstrated that socially monogamous prairie 
voles that establish pair bonds develop depression-like behavior when they are separated 
from their partner (Bosch et al., 2009), however, few mammals establish pair bonds 
(Kleiman, 1977). Thus a reliable animal model for studying effects loss of social reward 
on development of depression is needed. 
 
1.11 Neural Circuitry of Depression 
An initial trigger for development of depression is activation of the stress system 
(Holsboer, 2000). The stress system is controlled by the hypothalamic-pituitary-adrenal 
(HPA) axis. In response to a stressor, corticotropin releasing factor (CRF) is released 
from the paraventricular nucleus of the hypothalamus (PVN) and acts on the pituitary to 
cause release of adrenocorticotropic horme (ACTH) (Koob and Heinrichs, 1999). ACTH 
then acts on the adrenal glands to cause release of cortisol (humans) or corticosterone 
(rodents) (Koob and Heinrichs, 1999). CRF is the main neurotransmitter in the HPA axis 
and is also synthesized in the PVN as well as in extrahypothalamic brain regions 
including the central amygdala (CeA) and bed nucleus of the stria terminalis (BnST) 
(Swanson et al., 1983). Hyperactivity of the HPA axis is a prominent endophenotype of 
human depression (Holsboer, 2000). Depressed humans show increased plasma and 
salivary cortisol, as well as increased size and activity of the adrenal glands (Nemeroff 
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and Vale, 2005). Depressed humans also show increased CRF mRNA in the 
cerebrospinal fluid and hypothalamus (Kling et al., 1991). Rodent models of depression 
including social defeat, maternal separation and chronic stress all lead to hyperactivity of 
the HPA axis seen as corticosterone hypersecretion (Ayensu et al., 1995, Francis et al., 
1999, Francis et al., 2002, Kieran et al., 2010). Increased levels of CRF in the brain are 
also seen in following chronic stress (Stout et al., 2000), social defeat (Keeney et al., 
2006, Marini et al., 2006) and maternal separation (Francis et al., 1999).  Thus, it is clear 
that stress models of depression mimic some of the neural alterations that are present in 
human depression. Moreover, administration of CRF antagonists has been shown to 
block development of depression-like behavior in the chronic stress model of depression 
(Ducottet et al., 2003).  
 
1.11.1 Drug Addiction, Withdrawal and HPA Axis Alterations 
The stress system is connected to the limbic system (Herman et al., 2005). As 
such, exposure to stressful stimuli has been shown to lead to activation of the mesolimbic 
system, and this activation has been shown to lead to relapse in drug taking in humans 
and animal models (Sinha, 2008, 2009). Stress induced activation of the mesolimbic 
system has also been shown to cause sensitization of the locomotor response to 
psychostimulants (Kalivas and Stewart, 1991, Yap et al., 2005, Mathews et al., 2008), 
synaptic adaptations of VTA dopamine neurons (Daftary et al., 2009, Hahn et al., 2009) 
as well as morphological changes in the mPFC (Shansky and Morrison, 2009). Moreover, 
within the HPA axis CRF signaling appears to play a role in the rewarding aspects of 
stress-induced relapse associated with drug withdrawal (Hyman et al., 2006) and CRF 
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antagonists have been shown to reduce effects of stress during drug withdrawal and 
periods of abstinence (George et al., 2007a, George et al., 2007b, Koob, 2009).  Exposure 
to drugs of abuse increases HPA axis activity (Sarnyai, 1998, Sarnyai et al., 2001, 
Goeders, 2002, Goeders and Clampitt, 2002) seen as increased corticosterone and ACTH 
release, as well as activation of CRF neurons in rodents (Sarnyai et al., 2001). 
Furthermore, during drug withdrawal, rodents demonstrate enhanced ACTH and 
corticosterone release, and increased levels of CRF (Koob and Kreek, 2007, Koob, 
2008).Withdrawal and subsequent abstinence from drugs of abuse in human addicts leads 
to feelings of depression and anxiety (Koob, 2009), and rodents display anxiety and 
depression-like behavior following withdrawal from drugs of abuse (Cryan et al., 2003, 
Perrine et al., 2008). Studies in rodents have also shown that administration of CRF 
antagonists prevents development of drug withdrawal induced anxiety and depression-
like behavior (Sarnyai et al., 1995, Rodriguez de Fonseca et al., 1997, Basso et al., 1999, 
Sarnyai et al., 2001). Thus, there is evidence that the HPA axis is activated by drugs of 
abuse and as well as in drug withdrawal. Moreover, CRF signaling appears to be a critical 
mediator of drug withdrawal induced anxiety and depression. 
 
1.11.2 Alterations in Stress Responses Following Sexual Behavior 
Studies have shown that natural reward behaviors such as sexual activity cause 
activation of the HPA axis. Specifically, following mating to ejaculation both sexually 
naïve and experienced male rats demonstrate increased plasma corticosterone release 
(Bonilla-Jaime et al., 2006, Waldherr et al., 2010, Buwalda et al., 2012) and plasma 
ACTH release (Waldherr et al., 2010). Sexual behavior also causes increased cFos 
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immunoreactivity in the PVN (Buwalda et al., 2012). Thus, results of these studies 
indicate that the HPA axis is acutely activated by sexual behavior. When examining 
longer term effects of sexual behavior in male rats, it has been shown that copulation to 
ejaculation reduces anxiety-like behavior (Fernandez-Guasti et al., 1989b, Saldivar et al., 
1991) and this anxiolytic effect persists for up to four hours following mating (Waldherr 
and Neumann, 2007). In addition, male rats housed with a sexually receptive female and 
allowed to mate following contextual fear conditioning, demonstrate decreased fear 
responses when exposed to fear associated cues (Bai et al., 2009a). Moreover, brief 
exposure to estrous female odors leads to increased risk taking behaviors towards a 
predator in male mice (Kavaliers et al., 2001, Kavaliers et al., 2008). In humans sexual 
behavior has also been shown to lead to decreased stress responses which may persist for 
hours (Brody, 2006). Thus, results of these studies suggest that sexual behavior leads to 
decreased stress and anxiety related behaviors in humans and rodents following sexual 
activity. In rats, sexual behavior has also been shown to lead to dampened stress 
responses one day following mating seen as decreased corticosterone release in response 
to acute restraint stress (Ulrich-Lai et al., 2010). Brief exposure to estrous female odors 
also blocks the increase in corticosterone seen following exposure to a predator 
(Kavaliers et al., 2001). Furthermore, CRF and cFos mRNA are decreased in the PVN 
following exposure to forced swim stress in sexually experienced males both 45 minutes 
and 4 hours following mating (Waldherr et al., 2010). Thus it is clear that mating causes 
alterations in HPA axis activity as well as alterations in responses to stressors, however it 
is currently unknown whether there are alterations in stress responses and HPA axis 
reactivity following a prolonged abstinence period from sexual behavior. Abstinence 
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from sexual behavior leads to increased vulnerability for drugs of abuse and enhances 
drug craving, as well as neuroplasticity in the mesolimbic system similar to that seen 
following repeated exposure to drugs of abuse (Pitchers et al., 2010). A depression and 
substance abuse are often comorbid, (Kessler et al., 2003, Volkow, 2004, DuPont, 1995) 
it is hypothesized that abstinence from sexual reward will also lead to depression-like 
behavior, and underlying neuropathology including increased stress responses. 
 
1.12 Rationale and Objectives: Part 2 
Repeated exposure to sexual behavior causes neuroplastic changes in the 
mesolimbic system, some of which are dependent on a period of abstinence from mating, 
that may lead to increased vulnerability for drug addiction (Pitchers et al., 2010, Pitchers 
et al., 2012),. However, it is currently unknown if abstinence from sexual reward leads to 
increased vulnerability for other disorders related to reward processing, such as 
depression-like behavior, or alters other systems that are activated by sexual behavior, 
such as the HPA axis (Buwalda et al., 2012). 
  
1.12.1 Hypothesis 
I hypothesize that an extended abstinence period from sexual reward will lead to 
depression-like behavior, including passive stress coping and anhedonia, as well as 
underlying neural pathology, including hyperactivity of the HPA axis and alterations in 
CRF mRNA expression.  
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 1.12.2 Objectives 
1. Test the hypothesis that a prolonged period of abstinence from sexual 
behavior leads to depression-like behavior in male rats using standard tests for 
depression in rodents, including passive stress coping and anhedonia. 
 
2. Test the hypothesis that abstinence from sexual reward leads to HPA axis 
hyperactivity, including increased corticosterone and ACTH release following 
exposure to an acute stressor, and increased CRF mRNA expression in the 
paraventricular nucleus of the hypothalamus. 
 
3. Determine that CRF is a critical mediator of sexual reward abstinence induced 
depression-like behavior using pharmacological manipulations of CRF 
receptors in the nucleus accumbens and medial prefrontal cortex. 
 
 
 
 
 
 
 
 
 
30 
 
1.13 References 
Agmo A (Male rat sexual behavior. Brain Res Brain Res Protoc 1:203-209.1997). 
Agmo A, Berenfeld R (Reinforcing properties of ejaculation in the male rat: role of 
opioids and dopamine. Behav Neurosci 104:177-182.1990). 
Agmo A, Gomez M (Sexual reinforcement is blocked by infusion of naloxone into the 
medial preoptic area. Behav Neurosci 107:812-818.1993). 
Agmo A, Gomez M, Irazabal Y (Enkephalinase inhibition facilitates sexual behavior in 
the male rat but does not produce conditioned place preference. Pharmacol 
Biochem Behav 47:771-778.1994). 
Ahlenius S, Larsson K (Effects of selective dopamine D1 and D2 antagonists on male rat 
sexual behavior. Experientia 46:1026-1028.1990). 
Arendash GW, Gorski RA (Effects of discrete lesions of the sexually dimorphic nucleus 
of the preoptic area or other medial preoptic regions on the sexual behavior of 
male rats. Brain Res Bull 10:147-154.1983). 
Argiolas A, Melis MR (Central control of penile erection: role of the paraventricular 
nucleus of the hypothalamus. Prog Neurobiol 76:1-21.2005). 
Arletti R, Calza L, Giardino L, Benelli A, Cavazzuti E, Bertolini A (Sexual impotence is 
associated with a reduced production of oxytocin and with an increased 
production of opioid peptides in the paraventricular nucleus of male rats. Neurosci 
Lett 233:65-68.1997). 
Aston-Jones G, Smith RJ, Moorman DE, Richardson KA (Role of lateral hypothalamic 
orexin neurons in reward processing and addiction. Neuropharmacology 56 Suppl 
1:112-121.2009a). 
Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, 
Richardson KA (Lateral hypothalamic orexin/hypocretin neurons: A role in 
reward-seeking and addiction. Brain Res.2009b). 
Avena NM, Rada P, Hoebel BG (Evidence for sugar addiction: behavioral and 
neurochemical effects of intermittent, excessive sugar intake. Neurosci Biobehav 
Rev 32:20-39.2008). 
Ayensu WK, Pucilowski O, Mason GA, Overstreet DH, Rezvani AH, Janowsky DS 
(Effects of chronic mild stress on serum complement activity, saccharin 
preference, and corticosterone levels in Flinders lines of rats. Physiol Behav 
57:165-169.1995). 
Bai HY, Cao J, Liu N, Xu L, Luo JH (Sexual behavior modulates contextual fear memory 
through dopamine D1/D5 receptors. Hippocampus 19:289-298.2009a). 
Bai YJ, Li YH, Zheng XG, Han J, Yang XY, Sui N (Orexin A attenuates unconditioned 
sexual motivation in male rats. Pharmacol Biochem Behav 91:581-589.2009b). 
Balfour ME, Yu L, Coolen LM (Sexual behavior and sex-associated environmental cues 
activate the mesolimbic system in male rats. Neuropsychopharmacology 29:718-
730.2004). 
Bargmann W, Scharrer E (The origin of the posterior pituitary hormones. Am Sci 39:249-
255.1951). 
Basso AM, Spina M, Rivier J, Vale W, Koob GF (Corticotropin-releasing factor 
antagonist attenuates the "anxiogenic-like" effect in the defensive burying 
31 
 
paradigm but not in the elevated plus-maze following chronic cocaine in rats. 
Psychopharmacology (Berl) 145:21-30.1999). 
Berridge KC (Food reward: brain substrates of wanting and liking. Neurosci Biobehav 
Rev 20:1-25.1996). 
Berthoud HR (Neural control of appetite: cross-talk between homeostatic and non-
homeostatic systems. Appetite 43:315-317.2004). 
Bonilla-Jaime H, Vazquez-Palacios G, Arteaga-Silva M, Retana-Marquez S (Hormonal 
responses to different sexually related conditions in male rats. Horm Behav 
49:376-382.2006). 
Borgland SL, Chang SJ, Bowers MS, Thompson JL, Vittoz N, Floresco SB, Chou J, 
Chen BT, Bonci A (Orexin A/hypocretin-1 selectively promotes motivation for 
positive reinforcers. J Neurosci 29:11215-11225.2009). 
Bosch OJ, Nair HP, Ahern TH, Neumann ID, Young LJ (The CRF system mediates 
increased passive stress-coping behavior following the loss of a bonded partner in 
a monogamous rodent. Neuropsychopharmacology 34:1406-1415.2009). 
Brody S (Blood pressure reactivity to stress is better for people who recently had penile-
vaginal intercourse than for people who had other or no sexual activity. Biol 
Psychol 71:214-222.2006). 
Buwalda B, Scholte J, de Boer SF, Coppens CM, Koolhaas JM (The acute glucocorticoid 
stress response does not differentiate between rewarding and aversive social 
stimuli in rats. Horm Behav 61:218-226.2012). 
Caggiula AR, Hoebel BG ("Copulation-reward site" in the posterior hypothalamus. 
Science 153:1284-1285.1966). 
Cason AM, Smith RJ, Tahsili-Fahadan P, Moorman DE, Sartor GC, Aston-Jones G (Role 
of orexin/hypocretin in reward-seeking and addiction: implications for obesity. 
Physiol Behav 100:419-428.2010). 
Chang GQ, Karatayev O, Davydova Z, Leibowitz SF (Circulating triglycerides impact on 
orexigenic peptides and neuronal activity in hypothalamus. Endocrinology 
145:3904-3912.2004). 
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, 
Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper 
CB, Yanagisawa M (Narcolepsy in orexin knockout mice: molecular genetics of 
sleep regulation. Cell 98:437-451.1999). 
Choi DL, Davis JF, Fitzgerald ME, Benoit SC (The role of orexin-A in food motivation, 
reward-based feeding behavior and food-induced neuronal activation in rats. 
Neuroscience 167:11-20.2010). 
Chuang JC, Krishnan V, Yu HG, Mason B, Cui H, Wilkinson MB, Zigman JM, Elmquist 
JK, Nestler EJ, Lutter M (A beta3-adrenergic-leptin-melanocortin circuit regulates 
behavioral and metabolic changes induced by chronic stress. Biol Psychiatry 
67:1075-1082.2010). 
Coolen LM, Allard J, Truitt WA, McKenna KE (Central regulation of ejaculation. 
Physiol Behav 83:203-215.2004a). 
Coolen LM, Fitzgerald ME, Yu L, Lehman MN (Activation of mu opioid receptors in the 
medial preoptic area following copulation in male rats. Neuroscience 124:11-
21.2004b). 
32 
 
Coolen LM, Olivier B, Peters HJ, Veening JG (Demonstration of ejaculation-induced 
neural activity in the male rat brain using 5-HT1A agonist 8-OH-DPAT. Physiol 
Behav 62:881-891.1997a). 
Coolen LM, Peters HJ, Veening JG (Fos immunoreactivity in the rat brain following 
consummatory elements of sexual behavior: a sex comparison. Brain Res 738:67-
82.1996). 
Coolen LM, Peters HJ, Veening JG (Distribution of Fos immunoreactivity following 
mating versus anogenital investigation in the male rat brain. Neuroscience 
77:1151-1161.1997b). 
Crombag HS, Bossert JM, Koya E, Shaham Y (Review. Context-induced relapse to drug 
seeking: a review. Philos Trans R Soc Lond B Biol Sci 363:3233-3243.2008). 
Cryan JF, Hoyer D, Markou A (Withdrawal from chronic amphetamine induces 
depressive-like behavioral effects in rodents. Biol Psychiatry 54:49-58.2003). 
D'Anna KL, Gammie SC (Hypocretin-1 dose-dependently modulates maternal behaviour 
in mice. J Neuroendocrinol 18:553-566.2006). 
Daftary SS, Panksepp J, Dong Y, Saal DB (Stress-induced, glucocorticoid-dependent 
strengthening of glutamatergic synaptic transmission in midbrain dopamine 
neurons. Neurosci Lett 452:273-276.2009). 
Damsma G, Pfaus JG, Wenkstern D, Phillips AG, Fibiger HC (Sexual behavior increases 
dopamine transmission in the nucleus accumbens and striatum of male rats: 
comparison with novelty and locomotion. Behav Neurosci 106:181-191.1992). 
de Castilhos J, Marcuzzo S, Forti CD, Frey RM, Stein D, Achaval M, Rasia-Filho AA 
(Further studies on the rat posterodorsal medial amygdala: dendritic spine density 
and effect of 8-OH-DPAT microinjection on male sexual behavior. Brain Res 
Bull 69:131-139.2006). 
de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, 
Battenberg EL, Gautvik VT, Bartlett FS, 2nd, Frankel WN, van den Pol AN, 
Bloom FE, Gautvik KM, Sutcliffe JG (The hypocretins: hypothalamus-specific 
peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95:322-
327.1998). 
Dominguez JM, Balfour ME, Lee HS, Brown JL, Davis BA, Coolen LM (Mating 
activates NMDA receptors in the medial preoptic area of male rats. Behav 
Neurosci 121:1023-1031.2007). 
Dominguez JM, Gil M, Hull EM (Preoptic glutamate facilitates male sexual behavior. J 
Neurosci 26:1699-1703.2006). 
Ducottet C, Griebel G, Belzung C (Effects of the selective nonpeptide corticotropin-
releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model 
of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 27:625-
631.2003). 
DuPont RL (Anxiety and addiction: a clinical perspective on comorbidity. Bull 
Menninger Clin 59:A53-72.1995). 
Edwards CM, Abusnana S, Sunter D, Murphy KG, Ghatei MA, Bloom SR (The effect of 
the orexins on food intake: comparison with neuropeptide Y, melanin-
concentrating hormone and galanin. J Endocrinol 160:R7-12.1999). 
Edwards DA, Walter B, Liang P (Hypothalamic and olfactory control of sexual behavior 
and partner preference in male rats. Physiol Behav 60:1347-1354.1996). 
33 
 
Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J, Tatro JB, Hoffman GE, 
Ollmann MM, Barsh GS, Sakurai T, Yanagisawa M, Elmquist JK (Chemically 
defined projections linking the mediobasal hypothalamus and the lateral 
hypothalamic area. J Comp Neurol 402:442-459.1998). 
Elmquist JK, Elias CF, Saper CB (From lesions to leptin: hypothalamic control of food 
intake and body weight. Neuron 22:221-232.1999). 
Espana RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR (The 
hypocretin-orexin system regulates cocaine self-administration via actions on the 
mesolimbic dopamine system. Eur J Neurosci 31:336-348.2010). 
Everitt BJ, Fray P, Kostarczyk E, Taylor S, Stacey P (Studies of instrumental behavior 
with sexual reinforcement in male rats (Rattus norvegicus): I. Control by brief 
visual stimuli paired with a receptive female. J Comp Psychol 101:395-406.1987). 
Everitt BJ, Stacey P (Studies of instrumental behavior with sexual reinforcement in male 
rats (Rattus norvegicus): II. Effects of preoptic area lesions, castration, and 
testosterone. J Comp Psychol 101:407-419.1987). 
Fernandez-Guasti A, Escalante A, Agmo A (Inhibitory action of various 5-HT1B 
receptor agonists on rat masculine sexual behaviour. Pharmacol Biochem Behav 
34:811-816.1989a). 
Fernandez-Guasti A, Escalante AL, Ahlenius S, Hillegaart V, Larsson K (Stimulation of 
5-HT1A and 5-HT1B receptors in brain regions and its effects on male rat sexual 
behaviour. Eur J Pharmacol 210:121-129.1992). 
Fernandez-Guasti A, Roldan-Roldan G, Saldivar A (Reduction in anxiety after 
ejaculation in the rat. Behav Brain Res 32:23-29.1989b). 
Foreman MM, Hall JL, Love RL (The role of the 5-HT2 receptor in the regulation of 
sexual performance of male rats. Life Sci 45:1263-1270.1989). 
Francis DD, Champagne FA, Liu D, Meaney MJ (Maternal care, gene expression, and the 
development of individual differences in stress reactivity. Ann N Y Acad Sci 
896:66-84.1999). 
Francis DD, Diorio J, Plotsky PM, Meaney MJ (Environmental enrichment reverses the 
effects of maternal separation on stress reactivity. J Neurosci 22:7840-
7843.2002). 
Frohmader KS, Pitchers KK, Balfour ME, Coolen LM (Mixing pleasures: review of the 
effects of drugs on sex behavior in humans and animal models. Horm Behav 
58:149-162.2010). 
Furlong T, Carrive P (Neurotoxic lesions centered on the perifornical hypothalamus 
abolish the cardiovascular and behavioral responses of conditioned fear to context 
but not of restraint. Brain Res 1128:107-119.2007). 
Garcia Horsman P, Paredes RG (Dopamine antagonists do not block conditioned place 
preference induced by paced mating behavior in female rats. Behav Neurosci 
118:356-364.2004). 
George O, Ghozland S, Azar MR, Cottone P, Zorrilla EP, Parsons LH, O'Dell LE, 
Richardson HN, Koob GF (CRF-CRF1 system activation mediates withdrawal-
induced increases in nicotine self-administration in nicotine-dependent rats. Proc 
Natl Acad Sci U S A 104:17198-17203.2007a). 
34 
 
George S, Venkataraman G, Parida A (Identification of stress-induced genes from the 
drought-tolerant plant Prosopis juliflora (Swartz) DC. through analysis of 
expressed sequence tags. Genome 50:470-478.2007b). 
Gil M, Bhatt R, Picotte KB, Hull EM (Oxytocin in the medial preoptic area facilitates 
male sexual behavior in the rat. Horm Behav 59:435-443.2011). 
Giovenardi M, Padoin MJ, Cadore LP, Lucion AB (Hypothalamic paraventricular 
nucleus, oxytocin, and maternal aggression in rats. Ann N Y Acad Sci 807:606-
609.1997). 
Giovenardi M, Padoin MJ, Cadore LP, Lucion AB (Hypothalamic paraventricular 
nucleus modulates maternal aggression in rats: effects of ibotenic acid lesion and 
oxytocin antisense. Physiol Behav 63:351-359.1998). 
Goeders NE (The HPA axis and cocaine reinforcement. Psychoneuroendocrinology 
27:13-33.2002). 
Goeders NE, Clampitt DM (Potential role for the hypothalamo-pituitary-adrenal axis in 
the conditioned reinforcer-induced reinstatement of extinguished cocaine seeking 
in rats. Psychopharmacology (Berl) 161:222-232.2002). 
Gonzalez MI, Farabollini F, Albonetti E, Wilson CA (Interactions between 5-
hydroxytryptamine (5-HT) and testosterone in the control of sexual and nonsexual 
behaviour in male and female rats. Pharmacol Biochem Behav 47:591-601.1994). 
Griffond B, Risold PY, Jacquemard C, Colard C, Fellmann D (Insulin-induced 
hypoglycemia increases preprohypocretin (orexin) mRNA in the rat lateral 
hypothalamic area. Neurosci Lett 262:77-80.1999). 
Gulia KK, Mallick HN, Kumar VM (Orexin A (hypocretin-1) application at the medial 
preoptic area potentiates male sexual behavior in rats. Neuroscience 116:921-
923.2003). 
Haensel SM, Mos J, Olivier B, Slob AK (Sex behavior of male and female Wistar rats 
affected by the serotonin agonist 8-OH-DPAT. Pharmacol Biochem Behav 
40:221-228.1991). 
Hahn J, Hopf FW, Bonci A (Chronic cocaine enhances corticotropin-releasing factor-
dependent potentiation of excitatory transmission in ventral tegmental area 
dopamine neurons. J Neurosci 29:6535-6544.2009). 
Hansen S (Maternal behavior of female rats with 6-OHDA lesions in the ventral striatum: 
characterization of the pup retrieval deficit. Physiol Behav 55:615-620.1994). 
Hansen S, Kohler C, Goldstein M, Steinbusch HV (Effects of ibotenic acid-induced 
neuronal degeneration in the medial preoptic area and the lateral hypothalamic 
area on sexual behavior in the male rat. Brain Res 239:213-232.1982). 
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, 
Yagami K, Goto K, Yanagisawa M, Sakurai T (Genetic ablation of orexin 
neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345-
354.2001). 
Harris GC, Wimmer M, Aston-Jones G (A role for lateral hypothalamic orexin neurons in 
reward seeking. Nature 437:556-559.2005). 
Haynes AC, Jackson B, Chapman H, Tadayyon M, Johns A, Porter RA, Arch JR (A 
selective orexin-1 receptor antagonist reduces food consumption in male and 
female rats. Regul Pept 96:45-51.2000). 
35 
 
Henn FA, Vollmayr B (Stress models of depression: forming genetically vulnerable 
strains. Neurosci Biobehav Rev 29:799-804.2005). 
Herman JP, Ostrander MM, Mueller NK, Figueiredo H (Limbic system mechanisms of 
stress regulation: hypothalamo-pituitary-adrenocortical axis. Prog 
Neuropsychopharmacol Biol Psychiatry 29:1201-1213.2005). 
Hernandez L, Hoebel BG (Feeding and hypothalamic stimulation increase dopamine 
turnover in the accumbens. Physiol Behav 44:599-606.1988). 
Hillegaart V, Alster P, Uvnas-Moberg K, Ahlenius S (Sexual motivation promotes 
oxytocin secretion in male rats. Peptides 19:39-45.1998). 
Holsboer F (The corticosteroid receptor hypothesis of depression. 
Neuropsychopharmacology 23:477-501.2000). 
Hughes AM, Everitt BJ, Herbert J (Selective effects of beta-endorphin infused into the 
hypothalamus, preoptic area and bed nucleus of the stria terminalis on the sexual 
and ingestive behaviour of male rats. Neuroscience 23:1063-1073.1987). 
Hull EM, Du J, Lorrain DS, Matuszewich L (Extracellular dopamine in the medial 
preoptic area: implications for sexual motivation and hormonal control of 
copulation. J Neurosci 15:7465-7471.1995). 
Hull EM, Meisel RL, Sachs BD (2002) Male Sexual behavior. In: Hormones, Brain and 
Behavior (DW Pfaff, A. A., Etgen A, ed), pp 3-137 New York Academic Press. 
Hull EM, Muschamp JW, Sato S (Dopamine and serotonin: influences on male sexual 
behavior. Physiol Behav 83:291-307.2004). 
Hyman SE, Malenka RC, Nestler EJ (Neural mechanisms of addiction: the role of 
reward-related learning and memory. Annu Rev Neurosci 29:565-598.2006). 
Insel TR, Harbaugh CR (Lesions of the hypothalamic paraventricular nucleus disrupt the 
initiation of maternal behavior. Physiol Behav 45:1033-1041.1989). 
Ismail N, Girard-Beriault F, Nakanishi S, Pfaus JG (Naloxone, but not flupenthixol, 
disrupts the development of conditioned ejaculatory preference in the male rat. 
Behav Neurosci 123:992-999.2009). 
Kalivas PW, Stewart J (Dopamine transmission in the initiation and expression of drug- 
and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 
16:223-244.1991). 
Karnani MM, Apergis-Schoute J, Adamantidis A, Jensen LT, de Lecea L, Fugger L, 
Burdakov D (Activation of central orexin/hypocretin neurons by dietary amino 
acids. Neuron 72:616-629.2011). 
Kauer JA (Addictive drugs and stress trigger a common change at VTA synapses. Neuron 
37:549-550.2003). 
Kauer JA, Malenka RC (Synaptic plasticity and addiction. Nat Rev Neurosci 8:844-
858.2007). 
Kavaliers M, Choleris E, Colwell DD (Brief exposure to female odors "emboldens" male 
mice by reducing predator-induced behavioral and hormonal responses. Horm 
Behav 40:497-509.2001). 
Kavaliers M, Devidze N, Choleris E, Fudge M, Gustafsson JA, Korach KS, Pfaff DW, 
Ogawa S (Estrogen receptors alpha and beta mediate different aspects of the 
facilitatory effects of female cues on male risk taking. Psychoneuroendocrinology 
33:634-642.2008). 
36 
 
Keeney A, Jessop DS, Harbuz MS, Marsden CA, Hogg S, Blackburn-Munro RE 
(Differential effects of acute and chronic social defeat stress on hypothalamic-
pituitary-adrenal axis function and hippocampal serotonin release in mice. J 
Neuroendocrinol 18:330-338.2006). 
Keer SE, Stern JM (Dopamine receptor blockade in the nucleus accumbens inhibits 
maternal retrieval and licking, but enhances nursing behavior in lactating rats. 
Physiol Behav 67:659-669.1999). 
Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters 
EE, Wang PS (The epidemiology of major depressive disorder: results from the 
National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-
3105.2003). 
Kieran N, Ou XM, Iyo AH (Chronic social defeat downregulates the 5-HT1A receptor 
but not Freud-1 or NUDR in the rat prefrontal cortex. Neurosci Lett 469:380-
384.2010). 
Kita I, Yoshida Y, Nishino S (An activation of parvocellular oxytocinergic neurons in the 
paraventricular nucleus in oxytocin-induced yawning and penile erection. 
Neurosci Res 54:269-275.2006). 
Kleiman DG (Monogamy in mammals. Q Rev Biol 52:39-69.1977). 
Kling MA, Roy A, Doran AR, Calabrese JR, Rubinow DR, Whitfield HJ, Jr., May C, 
Post RM, Chrousos GP, Gold PW (Cerebrospinal fluid immunoreactive 
corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's 
disease and major depression: potential clinical implications. J Clin Endocrinol 
Metab 72:260-271.1991). 
Koob G, Kreek MJ (Stress, dysregulation of drug reward pathways, and the transition to 
drug dependence. Am J Psychiatry 164:1149-1159.2007). 
Koob GF (A role for brain stress systems in addiction. Neuron 59:11-34.2008). 
Koob GF (The role of CRF and CRF-related peptides in the dark side of addiction. Brain 
Res.2009). 
Koob GF, Heinrichs SC (A role for corticotropin releasing factor and urocortin in 
behavioral responses to stressors. Brain Res 848:141-152.1999). 
Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, Laplant Q, Graham 
A, Lutter M, Lagace DC, Ghose S, Reister R, Tannous P, Green TA, Neve RL, 
Chakravarty S, Kumar A, Eisch AJ, Self DW, Lee FS, Tamminga CA, Cooper 
DC, Gershenfeld HK, Nestler EJ (Molecular adaptations underlying susceptibility 
and resistance to social defeat in brain reward regions. Cell 131:391-404.2007). 
Krishnan V, Nestler EJ (The molecular neurobiology of depression. Nature 455:894-
902.2008). 
Krishnan V, Nestler EJ (Animal models of depression: molecular perspectives. Curr Top 
Behav Neurosci 7:121-147.2011). 
Lammers GJ, Pijl H, Iestra J, Langius JA, Buunk G, Meinders AE (Spontaneous food 
choice in narcolepsy. Sleep 19:75-76.1996). 
Larsson K, Heimer L (Mating Behaviour of Male Rats after Lesions in the Preoptic Area. 
Nature 202:413-414.1964). 
Lett BT (Repeated exposures intensify rather than diminish the rewarding effects of 
amphetamine, morphine, and cocaine. Psychopharmacology (Berl) 98:357-
362.1989). 
37 
 
Li Y, Acerbo MJ, Robinson TE (The induction of behavioural sensitization is associated 
with cocaine-induced structural plasticity in the core (but not shell) of the nucleus 
accumbens. Eur J Neurosci 20:1647-1654.2004). 
Li Y, Kolb B, Robinson TE (The location of persistent amphetamine-induced changes in 
the density of dendritic spines on medium spiny neurons in the nucleus 
accumbens and caudate-putamen. Neuropsychopharmacology 28:1082-
1085.2003). 
Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, 
Mignot E (The sleep disorder canine narcolepsy is caused by a mutation in the 
hypocretin (orexin) receptor 2 gene. Cell 98:365-376.1999). 
Liu QS, Pu L, Poo MM (Repeated cocaine exposure in vivo facilitates LTP induction in 
midbrain dopamine neurons. Nature 437:1027-1031.2005). 
Lopez HH, Olster DH, Ettenberg A (Sexual motivation in the male rat: the role of 
primary incentives and copulatory experience. Horm Behav 36:176-185.1999). 
Lu L, Grimm JW, Hope BT, Shaham Y (Incubation of cocaine craving after withdrawal: 
a review of preclinical data. Neuropharmacology 47 Suppl 1:214-226.2004). 
Lu L, Hope BT, Dempsey J, Liu SY, Bossert JM, Shaham Y (Central amygdala ERK 
signaling pathway is critical to incubation of cocaine craving. Nat Neurosci 
8:212-219.2005). 
Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist 
JK (Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp 
Neurol 435:6-25.2001). 
Marini F, Pozzato C, Andreetta V, Jansson B, Arban R, Domenici E, Carboni L (Single 
exposure to social defeat increases corticotropin-releasing factor and 
glucocorticoid receptor mRNA expression in rat hippocampus. Brain Res 
1067:25-35.2006). 
Martel P, Fantino M (Mesolimbic dopaminergic system activity as a function of food 
reward: a microdialysis study. Pharmacol Biochem Behav 53:221-226.1996). 
Mathews IZ, Mills RG, McCormick CM (Chronic social stress in adolescence influenced 
both amphetamine conditioned place preference and locomotor sensitization. Dev 
Psychobiol 50:451-459.2008). 
Matsuo E, Mochizuki A, Nakayama K, Nakamura S, Yamamoto T, Shioda S, Sakurai T, 
Yanagisawa M, Shiuchi T, Minokoshi Y, Inoue T (Decreased intake of sucrose 
solutions in orexin knockout mice. J Mol Neurosci 43:217-224.2011). 
Matuszewich L, Lorrain DS, Trujillo R, Dominguez J, Putnam SK, Hull EM (Partial 
antagonism of 8-OH-DPAT'S effects on male rat sexual behavior with a D2, but 
not a 5-HT1A, antagonist. Brain Res 820:55-62.1999). 
Meaney MJ (Maternal care, gene expression, and the transmission of individual 
differences in stress reactivity across generations. Annu Rev Neurosci 24:1161-
1192.2001). 
Mehrara BJ, Baum MJ (Naloxone disrupts the expression but not the acquisition by male 
rats of a conditioned place preference response for an oestrous female. 
Psychopharmacology (Berl) 101:118-125.1990). 
Melis MR, Argiolas A (Dopamine and sexual behavior. Neurosci Biobehav Rev 19:19-
38.1995). 
38 
 
Ménard S, Coria-Avila GA, Gélèz H, Godfrey J, Sorochinski M, Pfaus JG (2005) 
Activation of oxytocin and vasopressin neurons following the presentation 
of an odour associated with sexual reward in the male rat. . In: Society for Behavioral 
Neuroendocrinology. 
Mendelson SD, Pfaus JG (Level searching: a new assay of sexual motivation in the male 
rat. Physiol Behav 45:337-341.1989). 
Mitchell JB, Stewart J (Facilitation of sexual behaviors in the male rat associated with 
intra-VTA injections of opiates. Pharmacol Biochem Behav 35:643-650.1990). 
Morgane PJ, Galler JR, Mokler DJ (A review of systems and networks of the limbic 
forebrain/limbic midbrain. Prog Neurobiol 75:143-160.2005). 
Mos J, Mollet I, Tolboom JT, Waldinger MD, Olivier B (A comparison of the effects of 
different serotonin reuptake blockers on sexual behaviour of the male rat. Eur 
Neuropsychopharmacol 9:123-135.1999). 
Moss FA (Study of Animal Drives. J Exp Psychol 3:165-185.1924). 
Muschamp JW, Dominguez JM, Sato SM, Shen RY, Hull EM (A role for hypocretin 
(orexin) in male sexual behavior. J Neurosci 27:2837-2845.2007). 
Myers BM, Baum MJ (Facilitation by opiate antagonists of sexual performance in the 
male rat. Pharmacol Biochem Behav 10:615-618.1979). 
Nair SG, Golden SA, Shaham Y (Differential effects of the hypocretin 1 receptor 
antagonist SB 334867 on high-fat food self-administration and reinstatement of 
food seeking in rats. Br J Pharmacol 154:406-416.2008). 
Nemeroff CB, Vale WW (The neurobiology of depression: inroads to treatment and new 
drug discovery. J Clin Psychiatry 66 Suppl 7:5-13.2005). 
Nestler EJ (Molecular basis of long-term plasticity underlying addiction. Nat Rev 
Neurosci 2:119-128.2001). 
Nestler EJ, Hyman SE (Animal models of neuropsychiatric disorders. Nat Neurosci 
13:1161-1169.2010). 
Newport DJ, Stowe ZN, Nemeroff CB (Parental depression: animal models of an adverse 
life event. Am J Psychiatry 159:1265-1283.2002). 
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (Hypocretin (orexin) deficiency 
in human narcolepsy. Lancet 355:39-40.2000). 
Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, Okun M, 
Rogers W, Brooks S, Mignot E (Low cerebrospinal fluid hypocretin (Orexin) and 
altered energy homeostasis in human narcolepsy. Ann Neurol 50:381-388.2001). 
Numan M (Medial preoptic area and maternal behavior in the female rat. J Comp Physiol 
Psychol 87:746-759.1974). 
Numan M (Motivational systems and the neural circuitry of maternal behavior in the rat. 
Dev Psychobiol 49:12-21.2007). 
Numan M, Corodimas KP (The effects of paraventricular hypothalamic lesions on 
maternal behavior in rats. Physiol Behav 35:417-425.1985). 
Numan M, Rosenblatt JS, Komisaruk BR (Medial preoptic area and onset of maternal 
behavior in the rat. J Comp Physiol Psychol 91:146-164.1977). 
Olivier JD, de Jong TR, Jos Dederen P, van Oorschot R, Heeren D, Pattij T, Waldinger 
MD, Coolen LM, Cools AR, Olivier B, Veening JG (Effects of acute and chronic 
apomorphine on sex behavior and copulation-induced neural activation in the 
male rat. Eur J Pharmacol 576:61-76.2007). 
39 
 
Paredes RG (Evaluating the neurobiology of sexual reward. ILAR J 50:15-27.2009). 
Paredes RG, Agmo A (Has dopamine a physiological role in the control of sexual 
behavior? A critical review of the evidence. Prog Neurobiol 73:179-226.2004). 
Paredes RG, Highland L, Karam P (Socio-sexual behavior in male rats after lesions of the 
medial preoptic area: evidence for reduced sexual motivation. Brain Res 618:271-
276.1993). 
Paredes RG, Karam P, Highland L, Agmo A (GABAergic drugs and socio-sexual 
behavior. Pharmacol Biochem Behav 58:291-298.1997). 
Paredes RG, Martinez I (Naloxone blocks place preference conditioning after paced 
mating in female rats. Behav Neurosci 115:1363-1367.2001). 
Pecina S, Berridge KC (Opioid site in nucleus accumbens shell mediates eating and 
hedonic 'liking' for food: map based on microinjection Fos plumes. Brain Res 
863:71-86.2000). 
Pecina S, Smith KS, Berridge KC (Hedonic hot spots in the brain. Neuroscientist 12:500-
511.2006). 
Perello M, Sakata I, Birnbaum S, Chuang JC, Osborne-Lawrence S, Rovinsky SA, 
Woloszyn J, Yanagisawa M, Lutter M, Zigman JM (Ghrelin increases the 
rewarding value of high-fat diet in an orexin-dependent manner. Biol Psychiatry 
67:880-886.2010). 
Perrine SA, Sheikh IS, Nwaneshiudu CA, Schroeder JA, Unterwald EM (Withdrawal 
from chronic administration of cocaine decreases delta opioid receptor signaling 
and increases anxiety- and depression-like behaviors in the rat. 
Neuropharmacology 54:355-364.2008). 
Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, 
Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, 
Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino 
S, Mignot E (A mutation in a case of early onset narcolepsy and a generalized 
absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991-
997.2000). 
Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS 
(Neurons containing hypocretin (orexin) project to multiple neuronal systems. J 
Neurosci 18:9996-10015.1998). 
Pfaus JG (Pathways of sexual desire. J Sex Med 6:1506-1533.2009). 
Pfaus JG, Damsma G, Nomikos GG, Wenkstern DG, Blaha CD, Phillips AG, Fibiger HC 
(Sexual behavior enhances central dopamine transmission in the male rat. Brain 
Res 530:345-348.1990a). 
Pfaus JG, Gorzalka BB (Opioids and sexual behavior. Neurosci Biobehav Rev 11:1-
34.1987). 
Pfaus JG, Mendelson SD, Phillips AG (A correlational and factor analysis of anticipatory 
and consummatory measures of sexual behavior in the male rat. 
Psychoneuroendocrinology 15:329-340.1990b). 
Pfaus JG, Phillips AG (Role of dopamine in anticipatory and consummatory aspects of 
sexual behavior in the male rat. Behav Neurosci 105:727-743.1991). 
Pfaus JG, Wilkins MF (A novel environment disrupts copulation in sexually naive but not 
experienced male rats: reversal with naloxone. Physiol Behav 57:1045-
1049.1995). 
40 
 
Pitchers KK, Balfour ME, Lehman MN, Richtand NM, Yu L, Coolen LM 
(Neuroplasticity in the mesolimbic system induced by natural reward and 
subsequent reward abstinence. Biol Psychiatry 67:872-879.2010). 
Pitchers KK, Schmid S, Di Sebastiano AR, Wang X, Laviolette SR, Lehman MN, Coolen 
LM (Natural reward experience alters AMPA and NMDA receptor distribution 
and function in the nucleus accumbens. PLoS One 7:e34700.2012). 
Post RM, Rose H (Increasing effects of repetitive cocaine administration in the rat. 
Nature 260:731-732.1976). 
Powell WS, Dominguez JM, Hull EM (An NMDA antagonist impairs copulation and the 
experience-induced enhancement of male sexual behavior in the rat. Behav 
Neurosci 117:69-75.2003). 
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK 
(Comorbidity of mental disorders with alcohol and other drug abuse. Results from 
the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511-2518.1990). 
Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, Bonci A, Bartlett SE 
(Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced 
reinstatement of ethanol and sucrose seeking in Long-Evans rats. 
Psychopharmacology (Berl) 199:109-117.2008). 
Richardson NR, Roberts DC (Progressive ratio schedules in drug self-administration 
studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 
66:1-11.1996). 
Robinson TE, Berridge KC (The neural basis of drug craving: an incentive-sensitization 
theory of addiction. Brain Res Brain Res Rev 18:247-291.1993). 
Robinson TE, Gorny G, Savage VR, Kolb B (Widespread but regionally specific effects 
of experimenter- versus self-administered morphine on dendritic spines in the 
nucleus accumbens, hippocampus, and neocortex of adult rats. Synapse 46:271-
279.2002). 
Robinson TE, Kolb B (Persistent structural modifications in nucleus accumbens and 
prefrontal cortex neurons produced by previous experience with amphetamine. J 
Neurosci 17:8491-8497.1997). 
Robinson TE, Kolb B (Alterations in the morphology of dendrites and dendritic spines in 
the nucleus accumbens and prefrontal cortex following repeated treatment with 
amphetamine or cocaine. Eur J Neurosci 11:1598-1604.1999). 
Robinson TE, Kolb B (Structural plasticity associated with exposure to drugs of abuse. 
Neuropharmacology 47 Suppl 1:33-46.2004). 
Rodgers RJ, Halford JC, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JR, 
Upton N, Porter RA, Johns A, Blundell JE (SB-334867, a selective orexin-1 
receptor antagonist, enhances behavioural satiety and blocks the hyperphagic 
effect of orexin-A in rats. Eur J Neurosci 13:1444-1452.2001). 
Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F (Activation of 
corticotropin-releasing factor in the limbic system during cannabinoid 
withdrawal. Science 276:2050-2054.1997). 
Rosen RC, Lane RM, Menza M (Effects of SSRIs on sexual function: a critical review. J 
Clin Psychopharmacol 19:67-85.1999). 
Sakurai T (Roles of orexins and orexin receptors in central regulation of feeding behavior 
and energy homeostasis. CNS Neurol Disord Drug Targets 5:313-325.2006). 
41 
 
Sakurai T (The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. 
Nat Rev Neurosci 8:171-181.2007). 
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, 
Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, 
Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, 
Bergsma DJ, Yanagisawa M (Orexins and orexin receptors: a family of 
hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding 
behavior. Cell 92:573-585.1998). 
Salamone JD, Cousins MS, Bucher S (Anhedonia or anergia? Effects of haloperidol and 
nucleus accumbens dopamine depletion on instrumental response selection in a T-
maze cost/benefit procedure. Behav Brain Res 65:221-229.1994). 
Saldivar A, Rios C, Fernandez-Guasti A (Differential role of serotonin and noradrenaline 
on anxiety reduction after ejaculation in the rat. Pharmacol Biochem Behav 
38:807-812.1991). 
Sarnyai Z (Neurobiology of stress and cocaine addiction. Studies on corticotropin-
releasing factor in rats, monkeys, and humans. Ann N Y Acad Sci 851:371-
387.1998). 
Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G (Brain corticotropin-
releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in 
rats. Brain Res 675:89-97.1995). 
Sarnyai Z, Shaham Y, Heinrichs SC (The role of corticotropin-releasing factor in drug 
addiction. Pharmacol Rev 53:209-243.2001). 
Sarti F, Borgland SL, Kharazia VN, Bonci A (Acute cocaine exposure alters spine 
density and long-term potentiation in the ventral tegmental area. Eur J Neurosci 
26:749-756.2007). 
Scammell TE (The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 
53:154-166.2003). 
Schuld A, Blum WF, Pollmacher T (Low cerebrospinal fluid hypocretin (orexin) and 
altered energy homeostasis in human narcolepsy. Ann Neurol 51:660; author 
reply 660-661.2002). 
Schuld A, Hebebrand J, Geller F, Pollmacher T (Increased body-mass index in patients 
with narcolepsy. Lancet 355:1274-1275.2000). 
Schultz W (Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 
57:87-115.2006). 
Segal DS, Mandell AJ (Long-term administration of d-amphetamine: progressive 
augmentation of motor activity and stereotypy. Pharmacol Biochem Behav 2:249-
255.1974). 
Shansky RM, Morrison JH (Stress-induced dendritic remodeling in the medial prefrontal 
cortex: effects of circuit, hormones and rest. Brain Res 1293:108-113.2009). 
Sharf R, Sarhan M, Brayton CE, Guarnieri DJ, Taylor JR, DiLeone RJ (Orexin signaling 
via the orexin 1 receptor mediates operant responding for food reinforcement. 
Biol Psychiatry 67:753-760.2010). 
Sheffield FD, Wulff JJ, Backer R (Reward value of copulation without sex drive 
reduction. J Comp Physiol Psychol 44:3-8.1951). 
42 
 
Shippenberg TS, Heidbreder C, Lefevour A (Sensitization to the conditioned rewarding 
effects of morphine: pharmacology and temporal characteristics. Eur J Pharmacol 
299:33-39.1996). 
Siegel JM (Narcolepsy: a key role for hypocretins (orexins). Cell 98:409-412.1999). 
Sinha R (Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 
1141:105-130.2008). 
Sinha R (Stress and addiction: a dynamic interplay of genes, environment, and drug 
intake. Biol Psychiatry 66:100-101.2009). 
Stout SC, Mortas P, Owens MJ, Nemeroff CB, Moreau J (Increased corticotropin-
releasing factor concentrations in the bed nucleus of the stria terminalis of 
anhedonic rats. Eur J Pharmacol 401:39-46.2000). 
Straiko MM, Gudelsky GA, Coolen LM (Treatment with a serotonin-depleting regimen 
of MDMA prevents conditioned place preference to sex in male rats. Behav 
Neurosci 121:586-593.2007). 
Swanson LW, Sawchenko PE, Rivier J, Vale WW (Organization of ovine corticotropin-
releasing factor immunoreactive cells and fibers in the rat brain: an 
immunohistochemical study. Neuroendocrinology 36:165-186.1983). 
Tenk CM, Wilson H, Zhang Q, Pitchers KK, Coolen LM (Sexual reward in male rats: 
effects of sexual experience on conditioned place preferences associated with 
ejaculation and intromissions. Horm Behav 55:93-97.2009). 
Terkel J, Bridges RS, Sawyer CH (Effects of transecting lateral neural connections of the 
medial preoptic area on maternal behavior in the rat: nest building, pup retrieval 
and prolactin secretion. Brain Res 169:369-380.1979). 
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford 
M, Siegel JM (Reduced number of hypocretin neurons in human narcolepsy. 
Neuron 27:469-474.2000). 
Thomas MJ, Malenka RC (Synaptic plasticity in the mesolimbic dopamine system. Philos 
Trans R Soc Lond B Biol Sci 358:815-819.2003). 
Thomas MJ, Malenka RC, Bonci A (Modulation of long-term depression by dopamine in 
the mesolimbic system. J Neurosci 20:5581-5586.2000). 
Thompson JL, Borgland SL (A role for hypocretin/orexin in motivation. Behav Brain Res 
217:446-453.2011). 
Thorpe AJ, Cleary JP, Levine AS, Kotz CM (Centrally administered orexin A increases 
motivation for sweet pellets in rats. Psychopharmacology (Berl) 182:75-83.2005). 
Thorpe AJ, Kotz CM (Orexin A in the nucleus accumbens stimulates feeding and 
locomotor activity. Brain Res 1050:156-162.2005). 
Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM (Distribution of orexin 
receptor mRNA in the rat brain. FEBS Lett 438:71-75.1998). 
Tzschentke TM (Measuring reward with the conditioned place preference (CPP) 
paradigm: update of the last decade. Addict Biol 12:227-462.2007). 
Ulrich-Lai YM, Christiansen AM, Ostrander MM, Jones AA, Jones KR, Choi DC, 
Krause EG, Evanson NK, Furay AR, Davis JF, Solomon MB, de Kloet AD, 
Tamashiro KL, Sakai RR, Seeley RJ, Woods SC, Herman JP (Pleasurable 
behaviors reduce stress via brain reward pathways. Proc Natl Acad Sci U S A 
107:20529-20534.2010). 
43 
 
van Furth WR, van Ree JM (Sexual motivation: involvement of endogenous opioids in 
the ventral tegmental area. Brain Res 729:20-28.1996). 
Vaughan E, Fisher AE (Male sexual behavior induced by intracranial electrical 
stimulation. Science 137:758-760.1962). 
Verma S, Chhina GS, Mohan Kumar V, Singh B (Inhibition of male sexual behavior by 
serotonin application in the medial preoptic area. Physiol Behav 46:327-
330.1989). 
Volkow ND (The reality of comorbidity: depression and drug abuse. Biol Psychiatry 
56:714-717.2004). 
Vucetic Z, Reyes TM (Central dopaminergic circuitry controlling food intake and reward: 
implications for the regulation of obesity. Wiley Interdiscip Rev Syst Biol Med 
2:577-593.2010). 
Waldherr M, Neumann ID (Centrally released oxytocin mediates mating-induced 
anxiolysis in male rats. Proc Natl Acad Sci U S A 104:16681-16684.2007). 
Waldherr M, Nyuyki K, Maloumby R, Bosch OJ, Neumann ID (Attenuation of the 
neuronal stress responsiveness and corticotrophin releasing hormone synthesis 
after sexual activity in male rats. Horm Behav 57:222-229.2010). 
Wang JB, Murata T, Narita K, Honda K, Higuchi T (Variation in the expression of orexin 
and orexin receptors in the rat hypothalamus during the estrous cycle, pregnancy, 
parturition, and lactation. Endocrine 22:127-134.2003). 
Watson NV, Gorzalka BB (DOI-induced inhibition of copulatory behavior in male rats: 
reversal by 5-HT2 antagonists. Pharmacol Biochem Behav 39:605-612.1991). 
Wenkstern D, Pfaus JG, Fibiger HC (Dopamine transmission increases in the nucleus 
accumbens of male rats during their first exposure to sexually receptive female 
rats. Brain Res 618:41-46.1993). 
Willner P (Chronic mild stress (CMS) revisited: consistency and behavioural-
neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90-
110.2005). 
Witt DM, Insel TR (Increased Fos expression in oxytocin neurons following masculine 
sexual behavior. J Neuroendocrinol 6:13-18.1994). 
Wolf ME, Sun X, Mangiavacchi S, Chao SZ (Psychomotor stimulants and neuronal 
plasticity. Neuropharmacology 47 Suppl 1:61-79.2004). 
Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, 
Yagami K, Sugiyama F, Goto K, Yanagisawa M, Sakurai T (Hypothalamic orexin 
neurons regulate arousal according to energy balance in mice. Neuron 38:701-
713.2003). 
Yap JJ, Covington HE, 3rd, Gale MC, Datta R, Miczek KA (Behavioral sensitization due 
to social defeat stress in mice: antagonism at mGluR5 and NMDA receptors. 
Psychopharmacology (Berl) 179:230-239.2005). 
Yoshida M, Yokoo H, Mizoguchi K, Kawahara H, Tsuda A, Nishikawa T, Tanaka M 
(Eating and drinking cause increased dopamine release in the nucleus accumbens 
and ventral tegmental area in the rat: measurement by in vivo microdialysis. 
Neurosci Lett 139:73-76.1992). 
Young KA, Gobrogge KL, Liu Y, Wang Z (The neurobiology of pair bonding: insights 
from a socially monogamous rodent. Front Neuroendocrinol 32:53-69.2011). 
44 
 
45 
 
Young LJ, Lim MM, Gingrich B, Insel TR (Cellular mechanisms of social attachment. 
Horm Behav 40:133-138.2001). 
Zhang M, Gosnell BA, Kelley AE (Intake of high-fat food is selectively enhanced by mu 
opioid receptor stimulation within the nucleus accumbens. J Pharmacol Exp Ther 
285:908-914.1998). 
Zheng H, Corkern MM, Crousillac SM, Patterson LM, Phifer CB, Berthoud HR 
(Neurochemical phenotype of hypothalamic neurons showing Fos expression 23 h 
after intracranial AgRP. Am J Physiol Regul Integr Comp Physiol 282:R1773-
1781.2002). 
 
 
 
 
 
 
 
Sections 2.1-2.5 were published in Hormones and Behavior 58 (3): 397-404, 2010 
 
 
CHAPTER 2 
Orexin mediates initiation of sexual behavior in sexually naive 
male rats, but is not critical for sexual performance. 
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2.1 INTRODUCTION 
Orexin, also known as hypocretin, is a hypothalamic neuropeptide critical for 
feeding behavior (de Lecea et al., 1998, Sakurai et al., 1998, Sakurai, 2006, Benoit et al., 
2008) arousal and sleep (Chemelli et al., 1999, Lin et al., 1999, Furlong and Carrive, 
2007, Sakurai, 2007b, Carter et al., 2009, Furlong et al., 2009). Orexin neurons are 
localized to the lateral hypothalamic area (LHA) and perifornical dorsomedial 
hypothalamus (PFA-DMH) and produce two neuropeptides, orexin-A and B (de Lecea et 
al., 1998, Sakurai et al., 1998). Orexin neurons have been shown to project to brain 
structures involved in mediation of arousal including the locus coeruleus, 
tuberomammillary nucleus and peduculopontine tegmental nucleus (Peyron et al., 1998, 
Hagan et al., 1999, Horvath et al., 1999, Baldo et al., 2003). Orexin has also been 
implicated in reward and motivation, specifically related to food and drugs of abuse 
(Aston-Jones et al., 2009a, Aston-Jones et al., 2009b) and orexin neurons have been 
shown to project to reward-related brain structures in the mesolimbic system including 
the ventral tegmental area (VTA) and nucleus accumbens (NAc) (Peyron et al., 1998, 
Fadel and Deutch, 2002, Martin et al., 2002, Baldo et al., 2003). Orexin neurons are 
activated by conditioned contextual cues associated with food and drug reward (Harris et 
al., 2005, de Lecea L, 2006, Choi et al., 2010) and have been shown to play a role in 
reward-based feeding behavior (Choi et al., 2010). Moreover, intracerebroventricular 
(ICV) or intraperitoneal administration of an orexin receptor 1 (ORX1) antagonist results 
in reduced motivation for palatable food (Thorpe et al., 2005, Nair et al., 2008), whereas 
ICV orexin-A administration can reinstate this motivation (Boutrel et al., 2005). 
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The role of orexin in other rewarding behaviors is currently unclear, although 
several studies have implicated a role for orexin in control of sexual behavior in male 
rats. It has previously been shown that orexin neurons are activated by copulation in male 
rats (Muschamp et al., 2007). In addition, administration of orexin-A into the medial 
preoptic area (mPOA) resulted in enhanced sexual performance evidenced by reduced 
latencies to mount and intromit, and increased frequencies of mounts and intromission 
(Gulia et al., 2003). In contrast, ICV administration of orexin-A attenuated sexual 
motivation by reducing female preference, although only in highly sexually motivated 
males (Bai et al., 2009). Studies using ORX1 antagonists have also demonstrated 
contradictory data, as systemic administration of ORX1 antagonist slightly impaired 
sexual performance by increasing latency to intromit without affecting other parameters 
of sexual behavior (Muschamp et al., 2007), while ICV administration of ORX1 
antagonist had no effect on sexual motivation (Bai et al., 2009). Together these studies 
suggest that administration of exogenous orexin-A affects sexual performance and 
motivation; however, endogenous orexin may not play an important role in mediating 
sexual behavior (Bai et al., 2009). Therefore, the goal of the present study was to 
determine if endogenous orexin is essential for male rat sexual motivation and 
performance. 
First, it was determined when during sexual behavior orexin neurons are 
activated, testing the hypothesis that orexin neurons are activated upon introduction of 
the rewarding stimulus. Moreover, as it has been shown that sexual experience influences 
sexual performance (Dewsbury, 1969) and the rewarding properties of sexual behavior 
(Tenk et al., 2009), it was determined whether sexual experience influences orexin 
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neuron activation during mating. Finally, it was tested whether orexin plays a critical role 
in sexual motivation and performance using cell body specific lesions of orexin neurons. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Animals 
Adult male Sprague–Dawley rats (200–250 g) were obtained from Harlan 
(Indianapolis, IN) or Charles River Laboratories (Sherbrooke, Quebec, Canada) and 
housed individually or in pairs depending on the individual experiment (see below) in 
Plexiglas cages. The colony room was maintained on a 12/12 reversed light–dark cycle 
(lights off at 10 am) and food and water were available ad libitum except during 
behavioral testing. Female Sprague–Dawley rats were obtained from Harlan 
(Indianapolis, IN) or Charles River Laboratories (Sherbrooke, Quebec, Canada) were 
bilaterally ovariectomized and implanted subcutaneously with 5% 17-β-estradiol 
benzoate silastic capsules. Sexual receptivity was induced by subcutaneous injections of 
progesterone (500 μg in 0.1 mL of sesame oil) approximately 4 h prior to mating 
sessions. All procedures were approved by the Animal Care Committees at the University 
of Cincinnati and the University of Western Ontario and conformed to the guidelines 
outlined by the National Institute of Health and the Canadian Council on Animal Care. 
All behavioral testing was conducted during the first half of the dark phase under dim red 
illumination, except when noted otherwise. 
 
2.2.2 Experimental design 
2.2.2A cFos expression studies 
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Male rats (n = 48) were housed individually and half of the animals gained sexual 
experience in the home cage during 5 twice weekly mating sessions. Mating tests were 
performed in the home cage to eliminate arousal and cFos expression induced by 
exposure to a different mating arena and exposure to conditioned cues associated with 
prior mating (Balfour et al., 2004). A receptive female was introduced into the home cage 
and males were allowed to mate until one ejaculation or for 60 min. During each test 
sexual behavior was observed. The total number of mounts and intromissions, as well as 
the latencies to first mount and intromission (the time from presentation of the receptive 
female to the first mount or intromission), and ejaculation (the time from the first 
intromission to ejaculation), was recorded (Agmo, 1997). The remaining half of the 
animals remained sexually naive. These animals were housed in the same room as the 
sexually experienced males, were handled and exposed to odors and sounds associated 
with mating, however did not mate. Naive and experienced animals were each further 
subdivided into 6 experimental groups (n = 4 per group). The 6 naive and experienced 
groups included: control males with no exposure to sexual behavior (home cage); males 
exposed to a non-receptive female in the home cage for 15 min (anestrous female). Males 
could investigate and interact, however did not mate due to lack of female receptivity; 
males exposed to the smells of a receptive female placed in a wire mesh box on top of the 
home cage for 15 min (estrous female); males that displayed mounts, but not 
intromissions or ejaculation with vaginally masked females (mount); males that displayed 
mounts and intromissions only (intromission); and males that mated to one ejaculation 
(ejaculation). One hour after the end of the test, males were sacrificed to analyze cFos 
expression. Sexually experienced groups were matched on parameters of sexual behavior 
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and there were no significant differences between groups prior to the final test. Moreover, 
there were no significant differences between naive and experienced groups in numbers 
of mounts plus intromissions during the final test. 
 
2.2.2A Perfusions: cFos expression 
All males were deeply anaesthetised with sodium pentobarbitol (270 mg/mL) and 
were transcardially perfused with 4% paraformaldehyde (500 mL; PFA). Following 
perfusion brains were removed immediately and post-fixed for 1 h in the same fixative 
then transferred to 20% sucrose solution for cryoprotection. Brains were sectioned on a 
freezing microtome (Microm, Walldorf, Germany) in coronal sections of 35 µm and 
collected in 4 parallel series in cryoprotectant solution (30% sucrose in 0.1 M PB 
containing 30% ethylene glycol and 0.01% sodium azide) and stored at −20 °C until 
further processing. 
 
2.2.2B Immunohistochemistry 
All incubations were performed at room temperature with gentle agitation. Free 
floating sections were washed extensively with 0.1 M saline buffered sodium phosphate 
(PBS). Sections were blocked with 1% H2O2 (30% stock solution) in PBS for 10 min, 
then extensively rinsed again with PBS. Sections were incubated with an incubation 
solution (PBS containing 0.1% bovine serum albumin and 0.4% Triton X-100) for 1 h. 
Primary antibody incubations were performed in the incubation solution overnight at 
room temperature. Following staining sections were rinsed in PBS, mounted onto plus 
charged glass slides and coverslipped with dibutyl phthalate xylene (DPX). 
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2.2.2C cFos/orexin 
One series of sections was immunoprocessed for cFos and orexin. Sections were 
incubated overnight with a rabbit-raised antibody recognizing cFos (rabbit anti-cFos, sc-
52; 1:10 000, Santa Cruz Biotechnology, Santa Cruz, CA) followed by 1 hour incubations 
with biotinylated goat anti-rabbit (1:500, Vector Laboratories, Burlingame, CA) and an 
avidin horseradish peroxidase complex (1:1000, ABC kit, Vector Laboratories, 
Burlingame, CA). Sections were incubated for 10 min in 0.02% diaminobenzidine (DAB) 
(Sigma, St. Louis, MO) in 0.1 M phosphate buffer (PB) containing 0.012% hydrogen 
peroxide and 0.08% nickel sulfate, resulting in a blue-black reaction product. Sections 
were then incubated overnight with a rabbit-raised antibody recognizing orexin-A (rabbit 
anti-orexin-A, H-003-30; 1:20 000, Phoenix Pharmaceuticals, Burlingame, CA) followed 
by a 1 hour incubation with biotinylated goat anti-rabbit and ABC, as described above. 
Finally, the sections were incubated for 10 min with 0.02% DAB in 0.1 M PB containing 
0.012% hydrogen peroxide, resulting in a reddish brown reaction product.  
All antibodies have been characterized previously (Chen et al., 1999, Satoh et al., 
2004, Solomon et al., 2007) Immunohistochemical controls included omission of primary 
antibodies, western blot analysis demonstrating single bands at appropriate weight (cFos), 
and loss of immunohistochemical orexin signal with orexin-B-saporin lesions (orexin). 
2.2.2D Data analysis 
cFos/orexin: Neurons labelled for orexin or orexin and cFos were counted 
bilaterally in three representative sections per animal known to contain maximal numbers 
of the orexin neuronal population (Sakurai et al., 1998) spanning −2.3 mm to −3.6 mm 
from bregma (Paxinos and Watson, 1998) (Figure 2.1), using a drawing tube attached to a 
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Leica microscope (Leica Microsystems; Wetzlar Germany), by an observer blinded to 
experimental groups. The PFA-DMH and LHA were delineated based on the location of 
the fornix (Figure 2.1a). Percentages of orexin neurons expressing cFos were calculated 
and averaged per hemisphere for each animal, and group means were calculated. 
Statistical significance between groups was determined using a two-way ANOVA with 
sexual experience and sexual behavior during the final test as factors followed by Fisher's 
LSD tests with a 95% confidence level. 
 
2.2.3 Orexin lesion studies 
2.2.3A Surgery 
Males were housed individually and given one pre-test mating session with a 
receptive female prior to lesion and sham surgery. Sexual behavior was recorded as 
described above and groups were matched based on parameters of mating behavior. Male 
rats were anaesthetised with isoflurane (Abbot Laboratories, St. Laurent, Quebec, 
Canada) using a Surgivet Isotec4 gas apparatus (Smiths Medical Vet Division, Markham, 
Ontario, Canada) and placed in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA) 
with a gas mask covering the nose and mouth to maintain anaesthesia. An incision was 
made to expose the skull and lambda and bregma were found and determined to be level. 
A hole was drilled in the skull using a dremel drill (Dremel, Racine, WI) and glass 
micropipettes (40 µm diameter, World Precision Instruments Inc, Sarasota, FL) filled 
with a targeted toxin orexin-B-saporin (IT-20, Advanced Targeting Systems, San Diego, 
CA; 200 ng/µL in PBS); or unconjugated toxin BLANK-saporin (IT-21, Advanced  
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Figure 2.1. Location of orexin neurons in the hypothalamus. (A) Anatomical location of 
orexin neurons in the hypothalamus (Paxinos and Watson, 1998). Scale bar: 200 µm. (B) 
Single labelled orexin neurons in the PFA-DMH in an unmated control animal. (C) 
Orexin neurons in the PFA-DMH expressing cFos following mating. Scale bar: 50 µm. 
White arrow indicates a single labelled orexin neuron; arrowhead indicates a cFos 
positive neuron; black arrow indicates an orexin neuron expressing cFos. Abbreviations: 
PFA-DMH, perifornical dorsomedial hypothalamus; LHA, lateral hypothalamic area; f, 
fornix. 
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Targeting Systems, San Diego, CA; 200 ng/µL in PBS; sham controls) were lowered into 
the hypothalamus. This targeted toxin has been shown to bind with a high affinity to cells 
expressing orexin receptor 2 (ORX2) and with a significantly lower affinity for cells 
expressing ORX1 (Gerashchenko et al., 2001), and has been shown to specifically ablate 
orexin neurons in the hypothalamus (Frederick-Duus et al., 2007). Bilateral infusions of 
1 µL (2 per hemisphere) were injected at the following coordinates: AP = −2.8 and −3.2; 
ML = 0.7 and 0.8; DV = −9.0 (Paxinos and Watson, 1998). After each infusion the needle 
was left in place for 3 min to allow diffusion. Needles were slowly removed and wounds 
were closed with wound clips. Two weeks following lesion surgery, all males were tested 
for sexual experience during four mating trials and were then subjected to the runway 
and/or elevated plus maze test (see below). Surgeries were performed in three different 
cohorts, separated by several weeks, to reach sufficient numbers of animals per group. 
2.2.3B Sexual behavior 
All males were tested for sexual behavior during 4 mating sessions conducted 
every second day in the home cage. During each session, males mated with a receptive 
female to one ejaculation or for 60 min, whichever came first. Mating behavior was 
recorded as described above and copulation efficiency was also calculated [numbers of 
intromissions / (numbers of mounts + numbers of intromissions)]. Statistical differences 
in parameters of sexual performance were compared between lesion and sham groups for 
each trial using a one-way ANOVA with lesion surgery as a factor and Fisher's LSD test 
with a 95% confidence level, or when appropriate, non-parametric tests were run using a 
Kruskal–Wallis one-way ANOVA with lesion surgery as a factor and Dunn's test with a 
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95% confidence level. In addition, data for each group were compared to the pre-surgery 
data using paired t-tests. 
 
2.2.3C Sexual motivation: runway test 
Following testing of sexual behavior, a subgroup of the now sexually experienced 
males were tested for sexual motivation using a straight runway apparatus (MED 
Associates Inc., St. Albans, VT) (120 cm long;(Lopez et al., 1999)). Males habituated to 
the runway apparatus over two subsequent 10 minute trials conducted on the same day. 
Next, two test trials were conducted. During the first trial, a stimulus animal (estrous 
female, anestrous female or male) was placed in a goal box with perforated dividers at the 
end of the runway. A fan was used to blow the scents of the stimulus animals towards the 
male. Experimental males were placed in the start box, the door was opened to allow 
access to the runway, and time to reach the goal box was recorded. Once reaching the 
goal box, males were given 30 s to interact with the stimulus animal behind the screen. 
An identical second trial followed 1 h later. Statistical significance between times to 
reach the goal box between trial 1 and trial 2 was analyzed using paired t-tests with a 
95% confidence level. Statistical significance between groups was determined using a 
one-way ANOVA with lesion surgery as a factor followed by Fisher's LSD tests with a 
95% confidence level. 
 
2.2.3D Anxiety-like behavior: elevated plus maze 
A subgroup of the now sexually experienced males was tested for anxiety-like 
behavior to determine if effects of orexin lesions on sexual performance or motivation 
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were due to changes in anxiety or arousal. Males were exposed to the elevated plus maze 
apparatus (EPM; MED Associates Inc., St. Albans, VT) in a brightly lit room during the 
end of the light phase. The EPM consisted of 4 arms each 50 cm in length extending from 
a central junction and was elevated 75 cm. Two arms of the maze were open to the 
outside environment and the other two were enclosed with dark siding 40 cm high. 
Animals were placed on the EPM and monitored for 5 min. Time spent in open and 
closed arms, and total numbers of entries into each arm were recorded using photobeam 
arrays. Statistical significance between groups was determined using a one-way ANOVA 
with lesion as a factor followed by Fisher's LSD tests with a 95% confidence level. 
 
2.2.3E Perfusions and mating-induced cFos 
Following all behavioral testing, all males were deeply anaesthetised with sodium 
pentobarbitol (270 mg/mL) and were transcardially perfused with 500 mL of 4% PFA for 
lesion verification as described previously. In addition, to test the effects of orexin lesions 
on mating-induced cFos expression, groups of sham and lesion males mated until one 
ejaculation. One hour following ejaculation, males were transcardially perfused with 4% 
PFA as described above. Half of the males in this group were not introduced to a female 
and were perfused from the home cage to serve as unmated controls. 
 
2.2.3F Immunohistochemistry 
Brains were sectioned using a freezing microtome in 4 parallel series of 35 μm 
coronal sections and stored as described above. For lesion verification, one series of 
sections containing the hypothalamus from all lesion experiments was single labelled for 
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orexin using the same rabbit anti-orexin-A and DAB protocol as described above. One 
series of sections from the animals that mated was stained for cFos and orexin as 
described above. 
 
2.2.3G Lesion verification 
In each animal, numbers of orexin neurons immunoreactive for orexin were 
counted bilaterally in the PFA-DMH and LHA in 3 sections expressing maximal numbers 
of orexin cells in non-surgery controls, −2.3 mm to −3.6 mm from bregma as described 
above. Cells per hemisphere were averaged for each animal, and group means were 
calculated. Non-surgery control animals (from cFos experiments) were used to determine 
intact/baseline numbers of orexin neurons and data are expressed as percentages 
compared to the non-surgery control males (Figure 2.2). Males that had fewer than 20% 
orexin cells compared to non-surgery control animals were included in the lesion group. 
Animals with greater than 20%, but fewer than 80% of orexin neurons remaining were 
included in a partial lesion group. Sham controls did not have significant changes in 
numbers of orexin cells. Statistical significance between sham, partial and complete 
lesion animals was calculated using a one-way ANOVA and Fisher's LSD test with a 
95% confidence level. 
  
2.2.3H Lesion specificity 
To verify that lesions were restricted to orexin neurons, one series of sections 
containing the hypothalamus from a subset of sham and lesion animals (n = 20) was  
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Figure 2.2. Lesion verification. Representative images showing orexin (A) and MCH (B) 
cells in a sham lesion animal injected with BLANK-saporin. Representative images showing loss 
of orexin cells (C), but intact MCH cells (D) in a lesion animal injected with orexin-B-saporin. 
Scale bar: 400 µm; (E) quantification of orexin neurons in the PFA-DMH (E) and LHA (F) of 
sham, partial and lesion males, expressed as percentages of non-surgery controls.*Indicates 
significant difference from all other groups (p < 0.001). Sham: n = 35; partial lesion: n = 45; 
lesion: n = 19. Abbreviations: PFA-DMH: perifornical dorsomedial hypothalamus; LHA: lateral 
hypothalamic area; f: fornix. 
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immunoprocessed for melanocyte concentrating hormone (MCH), a hypothalamic 
peptide that has overlapping location (but no colocalization) with orexin neurons 
(Broberger et al., 1998), using a rabbit-raised antibody recognizing MCH (rabbit anti-
MCH, H-070-47; 1:150 000, Phoenix Pharmaceuticals, Burlingame, CA) and DAB as 
described previously. MCH neurons express ORX1 (Backberg et al., 2002) but not 
ORX2, and are not significantly reduced following orexin-B-saporin treatment 
(Frederick-Duus et al., 2007). MCH immunoreactive cells were counted bilaterally in two 
sections per animal (sham: n = 7; lesion n = 5), using alternate sections to those analyzed 
for orexin neurons. Lesions did not significantly reduce numbers of MCH neurons in 
either PFA-DMH or LHA (Table 2.1, Figure 2.2B and D; PFA-DMH: p = 0.47; LHA: 
p = 0.33). Furthermore, mating-induced cFos expression was counted bilaterally in one 
representative section per animal (sham: n = 4; lesion n = 3), using alternate sections to 
those analyzed for orexin neurons. Lesions did not affect mating-induced cFos expression 
in the PFA-DMH or LHA (Table 2.1; PFA-DMH: p = 0.53; LHA: p = 0.82). Finally, 
representative sections used for orexin cell counts (animals: sham: n = 6; lesion: n = 6) 
were Nissl counterstained using cresyl violet (5 g cresyl violet acetate (C-5042, Sigma, 
St. Louis, MO), 0.5 g of sodium acetate trihydrate (S209, Thermo Fisher Scientific, 
Ottawa, Ontario, Canada), and 1 L double distilled water with glacial acetic acid 
(AX0073-6, EMD Chemicals, Mississauga, Ontario, Canada) at pH: 3.14). Counts of 
Nissl-stained neurons were performed in standard areas of analysis (250 µm × 200 µm) in 
the general location of orexin neurons. Numbers of Nissl-stained neurons did not differ 
between sham and lesion groups (Table 2.1, PFA-DMH: p = 0.23; LHA: p = 0.33). Since 
a deficiency in orexin has been shown to contribute to narcolepsy in mice  
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Table 2. 1. Verification of lesion specificity: analysis of the numbers of neurons stained 
for Nissl, MCH or mating-induced cFos demonstrated that there was no significant loss 
of neurons in general, MCH cells, or mating-induced neural activation in the PFA-DMH 
or LHA following infusions of orexin-B-saporin. Abbreviations: PFA-DMH, perifornical 
dorsomedial hypothalamus; LHA, lateral hypothalamic area; MCH, melanocyte 
concentrating hormone. 
 
 
 
 
 
 
 
 
 
 Sham Lesion 
 PFA-DMH LHA PFA-DMH LHA 
Nissl 93.3 ± 7.2 84.1 ± 7.4 82.8 ± 3.9 75.3 ± 4.6 
MCH 101.3 ±  4.1 136.2 ± 8.1 88.2 ± 16.6 119.1 ± 13.5 
Mating-induced cFos 45.5 ± 6.5 30.1 ± 2.7 40.0 ± 3.8 32.0 ± 5.0 
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dogs (Lin et al., 1999) and humans (Siegel, 1999, Nishino et al., 2000, Peyron et al., 
2000, Thannickal et al., 2000) animals were observed to ensure the absence of a 
narcoleptic phenotype. Animals were observed for the duration of all behavioral tests 
reported in this study and did not display characteristics of narcolepsy. 
 
2.2.3I Mating-induced cFos expression in lesion animals 
Numbers of cFos-immunoreactive cells were counted bilaterally in 3 sections per 
animals in standard areas of analysis in the ventral tegmental area (VTA; 900 × 900 µm), 
mPOA (400 × 600 µm); nucleus accumbens (NAc) core and shell (400 × 600 µm) and the 
prelimbic, infralimbic and anterior cingulate subregions of the medial prefrontal cortex 
(mPFC) (600 × 800 µm per subregion) by an observer blinded to experimental groups. 
Counts were averaged for each animal, and group means were calculated. Statistical 
significance was calculated using a two-way ANOVA with sexual experience and lesion 
as factors followed by Fisher's LSD test with a 95% confidence level. 
 
2.3 RESULTS 
2.3.1 Orexin neuron activation during sexual behavior 
A significant increase in cFos expression in orexin neurons was observed 
following sexual behavior in both the PFA-DMH (F(5,31) 63.4; p < 0.001; Figure 2.3a) and 
LHA (F(5,31) 10.4; p < 0.001; Figure 2.3b), with no effect of sexual experience. 
Specifically, in both sexually naive and experienced animals, all experimental groups of 
males displaying different parameters of sexual behavior (investigation of anestrous 
female, exposure to estrous female odors, display of mounting, intromissions, or 
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ejaculation) showed equal induction of cFos compared to home cage controls with a 
higher percentage of orexin cells activated in the PFA-DMH (60–80%) versus the LHA 
(14–33%), without differences between the experimental groups. These results suggest 
that orexin neurons are activated following exposure to the stimulus female without 
further activation during sexual performance. Moreover, the activation is not dependent 
on incentive salience of the female stimulus as both non-receptive and receptive females 
induced activation in sexually experienced males. 
 
2.3.2 Effects of orexin lesions 
2.3.2A Sexual behavior 
Orexin lesions resulted in facilitation of sexual behavior (mount latency: F(2,47) 
3.962; p = 0.034; intromission latency: H = 9.104; p = 0.011). During the first mating 
trial, lesion males showed shorter latencies to mount and intromission compared to sham 
animals (mount latency: p = 0.03; intromission latency: p = 0.01; Figures 2.4a and b) and 
compared to latencies during the pre-surgery mating trial (mount latency: p = 0.02; 
intromission latency: p = 0.03; data not shown). Partial lesion males did not differ 
significantly from sham males, and neither group differed from the pre-surgery mating 
trial. Effects of lesions on mount and intromission latencies were attenuated with sexual 
experience, as there were no differences between groups, during any of the subsequent 
trials (trial 4 shown in Figures 2.4a and b). Ejaculation latencies (Figure 2.4c), numbers 
of mounts (Figure 2.4d) and intromissions (Figure 2.4e) as well as copulation efficiency 
(Figure 2.4f) did not significantly differ between groups during any of the trials or within 
each group between the first mating trial and the pre-surgery test. 
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Orexin neurons in PFA-DMH (A) and LHA (B) expressed cFos following all 
parameters of mating behavior in naive and experienced animals. Abbreviations: HC, 
home cage; AF: anestrous female; EF, estrous female; M, mount; IM, intromission; E, 
ejaculation. *Indicates significant difference from all other groups (p < 0.001). n = 4 per 
group. 
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Figure 2.4. Orexin lesions shortened latencies to mount and intromission in sexually 
naive males during trial 1. Orexin lesions did not affect mating during trial 4, after males 
gained sexual experience. (A) Mount latency. (B) Intromission latency. (C) Ejaculation 
latency. (D) Number of Mounts. (E) Number of intromissions. (F) Copulation efficiency. 
*Indicates significant difference from sham. Sham: n = 19; partial lesion: n = 23; lesion: 
n = 7. 
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2.3.2B Runway test 
Orexin lesions did not affect sexual motivation assessed in a straight runway test 
in sexually experienced males. Over the course of two test trials, lesion males ran 
significantly faster towards an estrous female in the second trial compared to the first trial 
(p = 0.03; Figure 2.5). Such increased run time is indicative of sexual motivation (Lopez 
et al., 1999). Partial lesion and sham males also ran faster towards an estrous female 
during trial 2 (p = 0.03), although this failed to reach significance in sham males 
(p = 0.052). None of the groups showed increased speed to run towards an anestrous 
female or a male during trial 2. Moreover, no significant differences were observed 
between sham, partial and lesion males on speed to run towards any stimulus animal on 
neither trial 1 nor trial 2, demonstrating lack of differences in general activity on the 
runway. 
 
2.3.2C Anxiety-like behavior 
Results thus far suggest that lesions may facilitate initiation of sexual behavior in 
naive animals via a potential effect on responses to novelty and/or anxiety-like behaviors 
when the males encounter a novel female. In support, lesion males showed decreased 
anxiety-like behavior on the EPM, seen as a decreased percentage of time spent in the 
closed arms, (p = 0.012; Figure 2.6) and an increased percentage of time on the open 
arms (p = 0.023; Figure 2.6) compared to sham males. Partial lesions had no significant 
effect. These data further support that lesion decreased anxiety-like behavior. 
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Figure 2.5. Orexin lesions did not affect sexual motivation in sexually experienced 
males. Shown are times to reach an estrous female in the runway test during both trials 1 
and 2. *Indicates significant reduction in time to reach the female in trial 2 compared to 
trial 1. Sham: n = 24; partial lesion: n = 26; lesion: n = 12. 
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Figure 2.6. Orexin lesions decreased anxiety-like behavior on the elevated plus maze. 
Percentage of time spent in the closed arms (left) were decreased and percentage of time 
spent in open arms (right) were increased in lesioned males. *Indicates significant 
difference from sham. Sham: n = 27; partial lesion: n = 36; lesion: n = 12. 
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2.2.3D cFos expression 
To assess whether endogenous orexin contributes to mating-induced neuronal 
activation in orexin-innervated brain regions, analysis of mating-induced cFos expression 
in the VTA, NAc core and shell, mPOA and the mPFC was conducted. In both lesion and 
sham males, mating significantly increased cFos in all of the analyzed brain areas 
compared to unmated controls (Table 2.2) Lesions did not affect neural activation, as 
sham and lesion animals did not differ in baseline or mating-induced cFos expression. 
 
2.4 DISCUSSION 
These studies investigated the role of endogenous orexin in sexual performance 
and motivation in the male rat. It was found that orexin is not essential for sexual 
motivation or performance. Instead, orexin neurons are activated by the female stimulus, 
independent of the hormonal status of the female or sexual experience of the male. 
Moreover, removal of endogenous orexin by orexin cell-specific lesions decreased 
anxiety-like behaviors and facilitated initiation of sexual behavior in sexually naive 
males. Thus, the results of this study support a role for orexin in arousal (de Lecea et al., 
2006, Harris and Aston-Jones, 2006, Furlong and Carrive, 2007, Sakurai, 2007a, Boutrel 
et al., 2009, Furlong et al., 2009) and anxiety (Suzuki et al., 2005, Davis et al., 2009, Li et 
al., 2010), but do not support a critical role for orexin in sexual motivation or 
performance. 
The results of these studies further clarify the role of endogenous orexin and the 
apparent contrasting findings of the previous studies examining the role of orexin in male 
sexual behavior using pharmacological tools. Intra-mPOA infusions of exogenous orexin- 
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Brain Area                    Non Mating                                                Mating 
 Sham  Partial Lesion Sham Partial  Lesion 
VTA 13.2 ± 9 5.8  ± 3.3 3.2 ± 2.2 83.3 ± 3.3 * 79.4 ± 4.4 * 63.3 ± 20 * 
NAc Core 7.9 ± 1.3 7.0 ± 3.0 2.7 ± 1.2 54.8  ±  3.4 * 61.4 ± 5.3 * 53.8  ± 24.2 * 
NAc Shell 5.3 ± 3.2 5.0  ± 3.9 2.1 ± 1.2 57.4 ± 2.7 * 60.3 ±  5.2 * 38.6 ± 13.7 * 
mPOA 5.9 ± 3.3 7.9 ± 3.3 8.3 ± 5.7 197.8 ± 21.4 * 184.3 ± 11.7 * 224.1 ± 22.4 * 
mPFC 28.0 ± 13.2 24.0 ± 11.3 8.6 ± 6.2 296.3 ± 79.9 * 309.8 ± 44.3 * 263.4 ± 98.2 * 
 
Table 2.2. Mating-induced cFos in sham, partial and lesion groups compared to non-
mating controls of the same lesion status. *Indicates significant difference from non-
mating control (p < 0.001 for all groups). No differences between groups were detected in 
either baseline or mating-induced cFos expression. Abbreviations: VTA: ventral 
tegmental area; NAc: nucleus accumbens, mPOA: medial preoptic area; mPFC: medial 
prefrontal cortex. There were no significant differences between cFos counts in any 
subregion of the mPFC, thus the combined expression of the three subregions is shown. 
Sham: n = 8; partial lesion: n = 9; lesion: n = 6. 
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A led to increased sexual arousal and improved sexual performance, suggesting that 
orexin may act in the mPOA to increase motivation and performance of sexual behavior 
(Gulia et al., 2003). However, in contrast, ICV infusions of orexin-A attenuated sexual 
motivation and arousal (Bai et al., 2009), while an orexin receptor antagonist had no 
effect on sexual arousal (Bai et al., 2009), indicating that endogenous orexin may not 
play a role in sexual motivation. Finally, ORX1 blockade by systemic injections was 
shown to only slightly impair copulatory performance (Muschamp et al., 2007). From 
these conflicting studies, a few conclusions can be drawn. First, application of exogenous 
orexin-A may affect behavior, but ORX1 blockade is without major effects, suggesting a 
minor role for endogenous orexin in regulation of male sexual behavior (Bai et al., 2009). 
The current results support this possibility. The current studies using removal of orexin, 
by orexin cell-specific lesions indicate that endogenous orexin is not essential for sexual 
motivation or performance, in line with observations by Bai et al., (2009). It is important, 
however to note that lack of effects of orexin lesions on sexual motivation in the runway 
may be due to the fact that animals had gained sexual experience prior to sexual 
motivation testing, therefore lack of effect in the runway test may have been due to the 
sexual experience of the males. Future experiments may address this caveat by testing the 
effects of orexin lesions on sexual motivation in naive males. 
It is also possible that the two orexin ligands and the two subtypes of orexin 
receptors (ORX1 and ORX2; Sakurai et al., 1998) may regulate sexual behavior in 
opposite directions. By utilizing orexin cell lesion techniques, the ligands for both 
subtypes of orexin receptors (orexin-A and B) were eliminated in the current study. The 
two receptor subtypes are expressed in different brain areas (Trivedi et al., 1998, Marcus 
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et al., 2001) and have been shown to differentially regulate memory for cue induced 
cocaine-seeking (Smith et al., 2009). Previous studies on sexual behavior have primarily 
focused on the role of orexin-A and ORX1 (see discussion above). The orexin receptor 
antagonist SB334867 used in the studies thus far specifically targets ORX1 which has a 
high affinity for orexin-A and significantly lower affinity for orexin-B (Sakurai et al., 
1998). Likewise, orexin-A has been used as the exogenous orexin in previous studies 
(Gulia et al., 2003, Bai et al., 2009). Future studies are needed to investigate the role of 
orexin-B and ORX2 in regulation of male sexual behavior. 
The current study tested the effects of long term loss of orexin. Muschamp et al., 
(2007) suggested that a long term reduction of orexin following castration may account 
for the loss of sexual motivation and performance. This hypothesis was contradicted by 
the current findings as orexin cell lesions did not reduce sexual motivation or 
performance. It is possible that the long term orexin loss in the current study may have 
resulted in compensatory mechanisms, although no changes in mating-induced neural 
activation within the circuit mediating sexual behavior were detected. Nonetheless, it is 
clear that reduced or lack of orexin does not prevent sexual behavior. Moreover, the 
results of the current study do not support a major role for orexin in induction of cFos 
expression by sexual behavior. It has been clearly established that orexin contributes to 
activation of neurons in the VTA (Korotkova et al., 2003, Borgland et al., 2006, Narita et 
al., 2006, Vittoz et al., 2008). However, orexin cell lesions did not block mating-induced 
neural activation in the VTA, or in any other reward-related brain regions analyzed, 
despite the presence of orexin-immunoreactive fibers in close proximity to the activated 
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neurons in sham males. Thus, mating-induced neural activation in these brain regions 
does not appear to be dependent on orexin action. 
A somewhat unexpected finding of the current study was the effect of orexin 
lesions on facilitation of the initiation of sexual behavior in sexual naive, but not 
experienced animals. This was shown to be correlated with a reduction in anxiety-like 
behaviors. Therefore, the effects of orexin lesions on sexual motivation and performance 
may be secondary to its effects on anxiety and arousal. Indeed previous studies have 
suggested a role for orexin in anxiety as ICV infusion of orexin-A decreased time on the 
open arms of the EPM in mice (Suzuki et al., 2005). Infusion of orexin-A into the 
paraventricular nucleus of the thalamus of male rats decreased time spent in the center 
area of an open field chamber and decreased novel object exploration, indicating that 
orexin may be involved in the generation of anxiety-like behavior (Li et al., 2010). In 
addition, dominant male rats that show increased risk taking on the EPM have increased 
levels of ORX1 mRNA in the mPFC (Davis et al., 2009). Orexin has also been shown to 
alter responses to stress (Ida et al., 1999, Ida et al., 2000), and stimulation of orexin 
receptors increases release of corticotrophin releasing factor (Al-Barazanji et al., 2001, 
Singareddy et al., 2006), corticosterone (Ida et al., 2000, Kuru et al., 2000) and 
adrenocorticotropic hormone (Kuru et al., 2000). Orexin antagonists are currently in 
clinical trials for treatment of insomnia, a disorder which is often comorbid with anxiety 
disorders (Sullivan and Neria, 2009), and it is hypothesized that orexin antagonists could 
potentially be used to treat anxiety disorders  (Mathew et al., 2008). Given the growing 
body of evidence of a role for orexin in anxiety and arousal it appears that orexin lesions 
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may facilitate the initiation of sexual behavior in naive males by reducing anxiety-like 
responses associated with the introduction of a novel stimulus, i.e. the female. 
Significant activation of orexin neurons was seen following sexual arousal and 
sexual behavior in both sexually naive and experienced animals in both the PFA-DMH 
and LHA, with 60–80% and 14–33% of orexin cells expressing cFos, respectively. There 
is a body of evidence supporting a dichotomy in orexin neuronal function within the 
orexin cell population, with the PFA-DMH being critically involved in arousal and the 
LHA being critical for reward-related behaviors (Harris et al., 2005, Harris and Aston-
Jones, 2006, Aston-Jones et al., 2009a). Hence, activation of the PFA-DMH orexin cells 
by the female stimulus supports the hypothesis that orexin is activated by and is critical 
for arousal, including sexual arousal in naive and experienced males, and anxiety 
associated with the novel female stimulus in naive males. However, PFA-DMH cells 
were activated to similar levels independent of the experience of the males and the 
hormonal status of the female, suggesting that the PFA-DMH cells were activated during 
general arousal and not specifically by sexual arousal. Moreover, our studies do not fully 
support the existence of a completely dichotomous orexin cell population as there was a 
significant activation of the LHA following exposure to all parameters of sexual arousal 
and performance, regardless of whether the behaviors were associated with reward. Thus, 
experienced males exposed to an anestrous female showed equal levels of orexin cell 
activation in the LHA compared to experienced males that copulated to ejaculation. 
However, only the latter group will form a conditioned place preference for mating (Tenk 
et al., 2009); suggesting that copulation to ejaculation is more rewarding than other 
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elements of mating. The current study did not specifically test the role of orexin in sexual 
reward; hence future studies are needed to address that question. 
In summary, the results of these studies demonstrate that orexin is not critical for 
sexual performance or motivation. Instead, orexin cell lesions were demonstrated to 
reduce anxiety, suggesting that endogenous orexin is involved in increasing anxiety. 
Moreover, removal of orexin resulted in facilitation of initiation of sexual behavior in 
sexually naive males, suggesting that endogenous orexin may inhibit initiation of mating, 
possibly by increasing anxiety in response to the novel stimulus, i.e. the female. These 
findings further elucidate the neural circuitry involved in sexual performance and anxiety, 
and add to a growing body of literature on the role of orexin in mediation of arousal and 
anxiety. 
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CHAPTER 3 
 
Lesions of orexin neurons block conditioned place preference 
for sexual behavior in male rats. 
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3.1 INTRODUCTION 
The hypothalamic neuropeptide orexin (hypocretin) is found exclusively in the 
lateral hypothalamic area (LHA) and the perifornical-dorsomedial hypothalamus (PFA-
DMH) and consists of two active peptides, orexin-A and orexin-B (de Lecea et al., 1998, 
Sakurai et al., 1998).  Orexin is critical for food intake (de Lecea et al., 1998, Sakurai et 
al., 1998, Sakurai, 2006, Benoit et al., 2008), arousal and sleep (Chemelli et al., 1999, Lin 
et al., 1999, Sakurai, 2007a, b, Carter et al., 2009). Recent studies have shown that orexin 
also plays a critical role in mediation of reward (DiLeone et al., 2003, Aston-Jones et al., 
2009, Aston-Jones et al., 2010) and orexin cells have extensive projections throughout 
the brain, including to reward associated brain areas such as the nucleus accumbens 
(NAc) and ventral tegmental area (VTA) (Peyron et al., 1998, Fadel and Deutch, 2002, 
Martin et al., 2002).   
Orexin neurons are activated by conditioned contextual cues associated with food 
and drug reward in a conditioned place preference (CPP) paradigm (de Lecea et al., 
2006), a standard paradigm used to determine reward seeking behavior (Tzschentke, 
2007). Moreover, excitotoxic lesions of orexin neurons in the LHA or orexin receptor-1 
antagonists in the VTA significantly reduce morphine preference in a CPP paradigm 
(Harris et al., 2007). In addition, LHA orexin neuronal stimulation, and intra-VTA 
orexin-A administration reinstate morphine CPP following extinction (Harris et al., 
2005). Orexin-A administration into the LHA increases self administration of palatable 
food (Thorpe et al., 2005) while orexin receptor-1 antagonists block self administration of 
food (Nair et al., 2008), ethanol (Lawrence et al., 2006) and nicotine (Hollander et al., 
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2008). Thus, there is ample evidence that orexin plays a role in reward processing related 
to food intake and drugs of abuse. 
Orexin neurons are activated by sexual behavior in male rats (Muschamp et al., 
2007, Di Sebastiano et al., 2010). In addition, exogenous orexin-A administration into the 
medial preoptic area enhances copulatory performance in male rates, evidenced by 
shortened latencies to mount and intromission, and increased frequency of mounts and 
intromissions (Gulia et al., 2003). However, a critical role for endogenous orexin in 
sexual behavior is not supported by findings that orexin cell-specific lesions do not 
disrupt sexual motivation or performance (Di Sebastiano et al., 2010), that 
intracerebroventricular (ICV) administration of an orexin receptor-1 antagonist does not 
disrupt sexual motivation (Bai et al., 2009), and that systemic administration of 
antagonist only slightly inhibits sexual performance (Muschamp et al., 2007). However, a 
role for endogenous orexin in mediation of sexual reward has yet to be elucidated. 
Therefore, the goal of the current study was to test the hypothesis that orexin plays a 
critical role in processing of sexual reward. First, it was determined whether orexin 
neurons are activated by conditioned cues predicting sexual reward by exposing male rats 
to an environment associated with prior sexual behavior. Next, orexin cell-specific 
lesions were utilized to determine a specific role for orexin in sexual reward processing 
using a CPP paradigm (Agmo and Gomez, 1993, Tenk et al., 2009). 
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3.2 MATERIALS AND METHODS 
3.2.1 Animals 
Adult male Sprague Dawley rats (200-250g) were obtained from Harlan 
(Indianapolis, IN) or Charles River Laboratories (Sherbrooke, Quebec, Canada) and were 
pair housed for the duration of experiments in Plexiglas cages. The colony room was 
maintained on a 12/12 reversed light-dark cycle (lights off at 10 am) with food and water 
available at all times except during behavioral testing. Female Sprague-Dawley rats were 
obtained from Harlan (Indianapolis, IN) or Charles River Laboratories (Sherbrooke, 
Quebec, Canada), were bilaterally ovariectomized and received subcutaneous implants of 
5% 17-β-estradiol benzoate in silastic capsules. Sexual receptivity was induced by 
subcutaneous progesterone injections (500 μg in 0.1 ml of sesame oil) approximately 4 h 
prior to mating sessions. All procedures were approved by the Animal Care Committees 
at the University of Cincinnati and the University of Western Ontario and conform to 
guidelines outlined by the National Institute of Health and the Canadian Council on 
Animal Care.  
 
3.2.2 Experiment 1: cFos Expression Studies 
 
3.2.2A Apparatus   
The CPP apparatus (MED Associates, St. Albans, VT) consisted of three 
chambers with different visual and tactile cues. The two test chambers (28 x 22 x 21 cm) 
had black walls and parallel bar flooring or white walls and metal grid flooring and were 
separated by a central compartment (13 x 22 x 21) with grey walls and a smooth, grey 
Plexiglas floor. The three chambers were connected by guillotine doors in colors 
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matching the chamber with which they were attached and males were confined to one 
chamber or allowed to move freely between chambers.  
 
3.2.2B Experimental Design 
On the day 1 (pre-test) males (n=5; paired males) were allowed free access to the 
entire apparatus for 15 min and the initial preference for each animal was determined. As 
a group, animals did not display preference for one chamber, but each animal had a slight 
(less than 60 second) preference (Pitchers et al., 2009, Tenk et al., 2009). On days 2 and 3 
(conditioning trials), males mated to one ejaculation in the home cage and mating 
behavior was observed and recorded (Agmo, 1997). A receptive female was placed in the 
home cage and total numbers of mounts and intromissions as well as latencies to first 
mount and intromission (time from presentation of a receptive female to first mount or 
intromission) as well as latency to ejaculation (time from the first intromission to 
ejaculation) were recorded during each trial. Immediately following ejaculation males 
were placed into the paired chamber (initially non-preferred chamber for 30 minutes. For 
control pairings, males were placed into the unpaired (initially preferred) chamber 
without mating for 30 minutes. Half of the animals received sex pairing on day 2 and 
control pairing on day 3. The remaining animals received sex pairing on day 3 and 
control pairing on day 2. On day 4, a post-test procedurally identical to the pre-test was 
conducted and conditioned preference was determined. Another group of males (n=5; 
unpaired males) served as a control group and were placed in the chambers without 
mating on both conditioning days. A preference score (percentage of time spent in the 
sex-paired chamber) and difference score (time spent in the sex-paired chamber minus 
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the time spent in the control chamber) were calculated for each animal and compared 
using a paired t-test, with a 95% confidence level. Indeed, males formed a significant 
CPP for the sex paired chamber seen as an increased preference score (p=0.038) and 
difference score (p=0.04) in the post-test compared to the pre-test following one pairing 
with ejaculation, confirming previous reports (Straiko et al., 2007, Tenk et al., 2009, 
Webb et al., 2009a, Webb et al., 2009b), while control males did not form a preference 
for either chamber. 
 
3.2.2C Tissue Processing 
One hour following the end of the post-test, males were anesthetised with sodium 
pentobarbitol (270mg/mL) and were transcardially perfused with a 0.9% saline solution 
followed by 500 mL of 4% paraformaldehyde (PFA) in 0.1M phosphate buffer (PB). 
Brains were quickly removed and post-fixed for one hour in the same fixative and 
transferred to a 20% sucrose solution for cryoprotection. Brains were sectioned into 35 
µm coronal sections on a freezing microtome (Microm, Walldorf, Germany) and 
collected in 4 parallel series in cryoprotectant solution (30% sucrose in 0.1 M PB 
containing 30% ethylene glycol and 0.01% sodium azide).  Brains were stored at -20 C 
until further processing.   
 
3.2.2C Immunohistochemistry: cFos/Orexin 
Incubations were performed with gentle agitation at room temperature. Free 
floating sections were extensively washed in 0.1M saline buffered sodium phosphate 
(PBS). Sections were blocked for 10 minutes in 1% H2O2 (30% stock solution) in PBS, 
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then again rinsed extensively with PBS. Sections were then incubated for 1 hour in an 
incubation solution (PBS containing 0.1% bovine serum albumin and 0.4% Triton X-
100). Primary antibody incubations were performed overnight at room temperature in the 
same incubation solution. Following staining sections were rinsed extensively with PBS, 
mounted onto plus charged glass slides and coverslipped with dibutyl phthalate xylene 
(DPX). 
One series of sections was immunoprocessed for cFos and orexin. Sections 
underwent an overnight incubation with a rabbit raised antibody recognizing cFos (rabbit 
anti-cFos, SC52; 1:10,000, Santa Cruz Biotechnology, Santa Cruz, CA) which was 
followed by incubation with biotinylated goat anti-rabbit (1:500, Vector Laboratories, 
Burlingame, CA) for 1 hour and a 1 hour incubation with avidin horseradish peroxidase 
complex (1:1000, ABC kit – Vector Laboratories, Burlingame, CA). Finally, sections 
underwent incubation for 10 minutes in 0.02% diaminobenzidine (DAB) (Sigma, St. 
Louis, MO) in 0.1M PB containing 0.012% hydrogen peroxide and 0.08% nickel sulfate, 
which resulted in a blue-black reaction product. Next, sections were incubated overnight 
with a rabbit raised antibody recognizing orexin-A (rabbit anti-orexin-A, H-003-30; 
1:20,000, Phoenix Pharmaceuticals, Burlingame, CA) followed by 1 hour incubation with 
biotinylated goat anti-rabbit and ABC, as described above. Immunoreactivity was 
visualized by a 10 minute incubation with 0.02% DAB in 0.1M PB containing 0.012% 
hydrogen peroxide, resulting in a reddish brown reaction product. 
All antibodies were previously characterized (Chen et al., 1999, Satoh et al., 2004, 
Solomon et al., 2007). Controls for immunohistochemistry included: primary antibody 
omission, western blot analysis demonstrating bands of appropriate weight (cFos) and 
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loss of immunohistochemical signal following lesions of orexin neurons with orexin-
saporin (orexin). 
 
3.2.2E Data Analysis 
Neurons labelled for orexin or orexin and cFos (Figure 3.1) were bilaterally 
counted in the PFA-DMH and LHA in 3 sections per animal known to contain maximal 
numbers of orexin neurons, spanning a distance from -2.3 mm to -3.6mm (Paxinos and 
Watson, 1998), using a Leica microscope (Leica Microsystems; Wetzlar Germany). 
Anatomical location of the PFA-DMH and LHA was determined based on location of the 
fornix. Data were expressed as percentages of orexin cells that expressed cFos and 
averages were calculated per hemisphere, per section, for each animal, and group means 
were calculated. Statistical significance between paired and unpaired groups was 
determined for PFA-DMH and LHA using student’s t-test with a 95% confidence level. 
 
3.2.3 Experiment 2: Orexin Cell-Specific Lesion Studies 
3.2.3A Lesion Surgery 
Males underwent one pre-test mating session in a clean Plexiglas mating cage 
(60×45×50 cm
3
) prior to undergoing lesion or sham surgery. A receptive female was 
placed into the cage and males were allowed to mate to one ejaculation or for 60 minutes. 
Sexual behavior was recorded as described above and groups were matched on 
parameters of mating behavior. Male rats were anesthetized with isoflurane (Abbot 
Laboratories, St. Laurent, Quebec, Canada) in a Surgivet Isotec4 gas apparatus (Smiths 
Medical Vet Division,  
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Figure 3.1. Orexin and cFos immunoreactivity in PFA-DMH (A,C) and LHA (B,D) in 
unpaired control (A,B) and paired (C,D) males. White arrow indicates an example single 
labelled orexin neuron; arrowhead indicates an example single labelled cFos neuron; 
black arrow indicates an example orexin neuron expressing cFos; Scale bar: 50 µm. 
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Markham, Ontario, Canada). A gas mask was placed over the nose and mouth to maintain 
anaesthesia and males were secured in a stereotaxic apparatus (Kopf Instruments, 
Tujunga, CA). An incision was made, the skull was exposed, and lambda and bregma 
were found and determined to be level horizontally. A hole was drilled into the skull 
using a dremel drill (Dremel, Racine, WI). Glass micropipettes (40µm diameter, World 
Precision Instruments Inc, Sarasota, FL) were filled with the targeted toxin orexin B-
saporin (Advanced Targeting Systems, San Diego, CA; 200ng/µL in PBS) or 
unconjugated toxin BLANK-saporin (Advanced Targeting Systems, San Diego, CA; 
200ng/µL in PBS; sham controls) and were lowered into the hypothalamus. This toxin 
has a high affinity for orexin receptor 2 expressing cells, and a significantly lower affinity 
for orexin receptor 1 expressing cells (Gerashchenko et al., 2001), and has been shown to 
specifically lesion orexin neurons in the hypothalamus (Frederick-Duus et al., 2007, Di 
Sebastiano et al., 2010). To ensure the toxin spread would encompass the majority of the 
orexin neuronal population, two injections were made per hemisphere at different rostro-
caudal coordinates. 1 µL infusions (2 per hemisphere) were infused bilaterally at the 
following coordinates: AP = -2.8 and -3.2, ML = 0.7 and 0.8, DV = -9.0. Following each 
infusion the needles were left in place for 3 minutes to allow diffusion. Micropipettes 
were removed slowly and incisions were closed with wound clips.  
Following a two week recovery from surgery, males received four mating 
sessions to gain sexual experience and were subsequently subjected to either a 
conditioned place preference (CPP) or conditioned place aversion (CPA) paradigm. All 
tests were performed during the second half of the dark phase under dim red illumination.  
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3.2.3B Conditioned Place Preference (CPP)  
The CPP test was conducted as described above, with conditioning trials repeated 
twice over the course of 4 consecutive days. A separate group of sham control males 
(n=15) was included that did not receive mating paired with either chamber and served as 
a negative control group to demonstrate lack of non-specific change in preference. The 
post-test was conducted on the sixth day as described previously and preference score 
(percentage of time spent in paired chamber) and difference score (time spent in paired 
chamber minus the time spent in the control chamber) were calculated. Time in the paired 
chamber in the post-test compared to the pre-test was also calculated. Statistical 
differences in the pre-test and post-test data were compared using a paired t-test, with a 
95% confidence level. Formation of CPP was defined as a significant increase in both 
preference score and difference score in the post-test compared to the pre-test. 
  
3.2.3C Conditioned Place Aversion (CPA)   
The CPA experiment was conducted in the same apparatus used in the CPP 
paradigm using lithium chloride (LiCl) induced visceral illness as the aversive stimulus. 
Males underwent a pre-test as described above. Over the course of 4 consecutive 
conditioning days immediately following the pre-test, males were injected with a 20 
mL/kg dose of 0.15M LiCl and placed into the initially preferred chamber. On alternate 
days males were injected with a 20 mL/kg dose of 0.9% saline and placed into the 
initially non-preferred chamber. The post-test was conducted on the sixth day as 
described above, and preference score and difference score were calculated in the same 
manner. Statistical differences in the pre-test and post-test data were compared using a 
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paired t-test, with a 95% confidence level. Formation of CPA was defined as a significant 
decrease in both preference score and difference score in the post-test compared to the 
pre-test.  
 
3.2.3D Tissue Processing 
Following completion of all experimental testing, males were anesthetized with 
sodium pentobarbital (270mg/mL) and perfused transcardially with 4% PFA as described 
above. Brains were removed and stored in cryoprotectant for further processing and 
lesion analysis. 
 
3.2.3E Immunohistochemistry 
Orexin: One series of sections from the CPP and CPA experiments was 
immunoprocessed for orexin using the same rabbit raised antibody recognizing orexin-A 
(rabbit anti-orexin-A, H-003-30; 1:20,000, Phoenix Pharmaceuticals, Burlingame, CA) 
and DAB for lesion verification. 
 
3.2.3F Lesion Verification 
Numbers of orexin neurons in the PFA-DMH and LHA were bilaterally counted 
in 3 sections per animal, containing the maximum number of orexin neurons, spanning a 
distance from -2.3 mm to -3.6mm relative to bregma (Paxinos and Watson, 1998) using a 
Leica microscope (Leica Microsystems; Wetzlar Germany). Cells per hemisphere, per 
section were averaged for each animal, and group means were calculated. Numbers of 
orexin cells were also counted in a separate group of males that had not undergone 
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surgery (n=20) and counts in lesion males were expressed as percentages of these non-
surgery control values. Lesions were classified as follows: males that had fewer than 20% 
of the total number of orexin cells compared to non-surgery control animals were 
included in the lesion group. Animals with greater than 20%, but fewer than 80% of 
orexin cells were included in a separate partial lesion group (Figure 3.2). Sham control 
animals did not have significant changes in numbers of orexin cells when compared to 
non-surgery controls (Table 1). Statistical significance between sham, partial and lesion 
animals was calculated using a one-way ANOVA and Fisher’s LSD test with a 95% 
confidence level. Experiments were performed on multiple separate surgical cohorts of 
animals due to the low portion of orexin-B saporin treated animals that were verified to 
have complete lesions. For CPP two separate experiments were performed to include 
intact sham controls (exp.1: n=8 and exp. 2: n=10; combined n=18), males with partial 
lesions (exp. 1: n=8 and exp. 2: n=17; combined n=25) and males with complete lesions 
(combined n=8). The CPA experiment was performed using a third surgical cohort of 
animals. In this experiment 10 males had complete lesions, 19 were partial lesions and 17 
were intact sham controls.  
 
3.2.3G Lesion Specificity 
In order to determine if lesions specifically targeted orexin neurons, analysis of 
melanocyte concentrating hormone (MCH) and Nissl stained neurons in the PFA-DMH 
and LHA were conducted, as these markers have been shown previously to be unaltered  
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Figure 3.2. Representative images showing orexin neurons in the hypothalamus of a 
sham animal injected with BLANK-saporin (A) and loss of orexin neurons in the 
hypothalamus of a lesion animal injected with orexin-B-saporin (B). Abbreviations:  
PFA-DMH: perifornical-dorsomedial hypothalamus; LHA: lateral hypothalamic area; f: 
fornix. Scale bar: 200 µm. 
 
95 
 
following administration of orexin-B saporin (Frederick-Duus et al., 2007, Di Sebastiano 
et al., 2010). One series of sections from a subset of animals (n=20) was 
immunoprocessed for MCH, another hypothalamic peptide with overlapping location, but 
no colocalization with orexin neurons (Broberger et al., 1998) using a rabbit-raised 
antibody recognizing MCH (rabbit anti-MCH, H-070-47; 1:150,000, Phoenix 
Pharmaceuticals, Burlingame, CA). Analysis of MCH immunoreactivity was quantified 
in two bilateral sections per animal, using alternate sections to those quantified for orexin 
neurons, and no significant damage to the MCH population was observed, indicating 
lesions were specific to orexin neurons. To further verify lesion specificity representative 
sections from animals used for orexin cell counts (sham: n=6; lesion: n=6) were Nissl 
counterstained using cresyl violet. Nissl stained neurons were counted in standard areas 
of analysis (250 µm x 200 µm) in the general location of the orexin neuronal population 
and there were no significant differences in numbers of Nissl stained neurons in lesion 
animals compared to sham.  
 
3.4 RESULTS 
3.4.1 Orexin neuron activation by sexual reward 
To determine if orexin neurons are activated during seeking of sexual reward, 
cFos expression was analyzed in animals that formed a mating-induced CPP and 
compared to unpaired control males (Figure 3.3). Exposure to the CPP apparatus resulted 
in a significantly greater percentage of orexin neurons that expressed cFos in paired 
compared to unpaired males in the PFA-DMH (p=0.0019) and LHA (p=0.026). In both  
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 Sham Partial Lesion 
 PFA-DMH LHA PFA-
DMH 
LHA PFA-
DMH 
LHA 
CPP 97.5 ± 
2.6% 
 
97.6 ± 
3.7% 
49.1 ± 
3.2% 
58.0 ± 
2.9% 
7.1 ± 
2.1% 
24.0 ± 
2.9% 
CPA 108.8 ± 
3.6% 
103.8 ± 
3.4% 
48.9 ± 
3.6% 
51.4 ± 
3.9% 
9.3 ± 
2.1% 
22.7 ± 
4.6% 
 
Table 3.1. Quantitative data for orexin lesion verification. The percentages of orexin 
neurons relative to non-surgery control males are listed for the CPP and CPA 
experiments. In each experiment, percentages of orexin neurons are significantly lower in 
the partial and lesion groups compared to sham controls in the PFA-DMH and LHA 
(p<0.001). All data represent mean percentages ± standard error of the mean (SEM). * 
indicates significant difference from sham control PFA-DMH; # indicates significant 
difference from sham control LHA. Abbreviations: PFA-DMH: perifornical-dorsomedial 
hypothalamus; LHA: lateral hypothalamic area; CPP: conditioned place preference; CPA: 
conditioned place aversion. Numbers of animals per group: CPP: Sham n=18; Partial 
n=25; Lesion n=8. CPA: Sham: n=17; Partial: n=19; Lesion: n=10.  
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unpaired and paired males, exposure to the CPP chamber resulted in higher percentages 
of cFos-positive orexin cells in the PFA-DMH compared to the LHA orexin population 
(unpaired: p=0.003; paired: p<0.0001). Although the increase in percentages of activated 
orexin cells in paired compared to unpaired males appeared greater in the PFA-DMH 
(28%) than LHA (7.6%), the fold change in orexin activation was similar in both regions 
(1.7 fold increase). These results indicate that orexin neurons in PFA-DMH and LHA are 
activated by contextual cues associated with sexual reward. 
 
3.4.2 Mating-induced Conditioned Place Preference (CPP) 
To determine if orexin is critically involved in sexual reward processing, effects 
of orexin lesions on mating-induced CPP were determined. Lesions did not affect any 
parameter of sexual behavior during the CPP pairing test (Table 2), confirming our 
previous report that orexin lesions do not alter sexual behavior in sexually experienced 
male rats (Di Sebastiano et al., 2010) However, lesion males failed to develop a 
conditioned preference for a mating-paired chamber, while sham and partial lesion males 
did form a mating-induced CPP. In particular, sham and partial lesion males, but not 
lesion males, showed a significant increase in preference score (percentage of time spent 
in the sex-paired chamber; sham: p=0.003; partial: p=0.04; Figure 3.4a) and a significant 
increase in difference score (time spent in the sex-paired chamber minus time spent in the 
control chamber; sham p=0.005; partial: p=0.04; Figure 3.4b) during the post-test. 
Control unpaired males that did not associate mating with either chamber of the CPP 
apparatus did not form a preference for either chamber, confirming that repeated 
exposure to the CPP apparatus did not result in preference (Figure 3.4a/b). Sham males 
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Figure 3.3. Percentages of orexin neurons expressing cFos in the PFA-DMH and LHA 
following exposure to the CPP apparatus in unpaired control males (black bars) and 
mating-paired males (white bars). All data are mean ± SEM ; n= 5 animals per group. * 
indicates significant difference from unpaired group.  
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Table 3.2. Sexual behavior during the CPP conditioning trial. All data are mean ± SEM. 
No significant differences between groups were detected in any parameter of sexual 
behavior. Numbers of animals per group: CPP: Sham n=18; Partial n=25; Lesion n=8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sham Partial Lesion 
Mount Latency (s) 13.0 ± 2.1 13.3 ± 2.1 12.3 ± 3.0 
Intromission Latency (s) 18.5 ± 4.1 21.3 ± 5.3 24.2 ± 7.9 
Ejaculation Latency (s) 449.0 ± 53.1 541.5 ± 58.4 412.1 ± 70.5 
# of Mounts 6.1 ± 1.7 5.3 ± 1.0 4.3 ± 1.3 
# of Intromissions 11.8 ± 1.0 11.7 ± 0.9 9.1 ± 1.8 
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spent significantly more time in the paired chamber during the post-test than pre-test, 
compared to control unpaired males (95.4 ± 29.7s versus 30.6 ± 13.7s; p=0.017). Lesion 
males did not spend more time in the paired chamber during the post-test than pre-test (-
10.9 ± 56.2s). Although partial lesion males spent 67.7 ± 32.5s in the paired chamber 
during the post-test than pre-test, this failed to reach statistical significance. 
Finally, as described in the methods, the CPP experiment was conducted in two 
separate surgical cohorts and in both experiments sham (n=8 and n=10 resp.) as well as 
partial lesioned (n=8 and n=17 resp.) males showed a significant preference (p=0.03-
0.004) and difference score (p=0.04-0.005). Hence, the failure to detect significant 
mating induced CPP in lesion animals is not a result of a smaller number of animals in 
that group (n=8), but rather a result of the orexin lesions. 
 
3.4.3 Conditioned Place Aversion (CPA) 
To determine if orexin lesions blocked CPP by affecting associative learning for a 
particular context, males underwent a CPA paradigm. Lesion males, as well as sham and 
partial lesion males, formed a significant aversion for the LiCl paired chamber. 
Specifically all groups showed a significant decrease in preference score (p<0.001; 
Figure 3.5a) and a significant decrease in difference score (p<0.001; Figure 3.5b). 
Therefore, orexin lesions do not disrupt associative learning and memory in general. 
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Figure 3.4. Orexin lesions prevent mating-induced CPP. (A) Percentages of time spent in 
the sex-paired chamber (preference score) during pre- and post-test. (B) Time (s) spent in 
the sex-paired chamber minus the time spent in the control chamber (difference score) 
during pre- and post-test. All data are mean ± SEM. * indicates significant difference 
from pre-test.  Numbers of animals per group: Control: n=16; Sham: n=18; Partial: n=25; 
Lesion: n=8. 
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Figure 3.5. Orexin lesions do not prevent CPA for an aversive stimulus. (A) Percentages 
of time spent in the sex-paired chamber (preference score) during pre- and post-test. (B) 
Time (s) spent in the sex-paired chamber minus the time spent in the control chamber 
(difference score) during pre- and post-test. All data are mean ± SEM * indicates 
significant difference from pre-test. Numbers of animals per group: Sham: n=17; Partial: 
n=19; Lesion: n=10. 
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3.4 DISCUSSION 
Results of this study showed that orexin neurons are activated during exposure to 
sexual reward-associated contextual signals and are critical for cue-induced seeking of 
sexual reward. Thus, the present results expand on a growing body of literature  
demonstrating a critical role for orexin in reward processing (Harris and Aston-Jones, 
2006, Aston-Jones et al., 2009, Aston-Jones et al., 2010) . These results also add to 
findings on the role of orexin in sexual behavior and sexual reward processing. It has 
been shown previously that orexin neurons are activated by sexual behavior in male rats 
(Muschamp et al., 2007). However, endogenous orexin does not appear to be essential for 
sexual performance. In a previous study, it was demonstrated that orexin lesions facilitate 
initiation of sexual behavior in sexually naive males (Di Sebastiano et al., 2010). Orexin 
lesions also reduced anxiety-like behavior, hence the effect of orexin lesions on initiation 
of mating may be due to reduced anxiety associated with the introduction of a novel 
female stimulus . The facilitative effects of orexin lesions were attenuated with sexual 
experience and orexin lesions did not affect any parameter of sexual performance in 
sexually experienced male rats (Di Sebastiano et al., 2010). In addition, orexin lesions did 
not alter sexual motivation as determined using a straight runway test (Lopez et al., 1999, 
Di Sebastiano et al., 2010). In agreement, Bai and coworkers showed that ICV 
administration of orexin receptor antagonists did not disrupt sexual motivation (Bai et al., 
2009). In the current study sexually experienced males with orexin lesions did not show 
impaired sexual behavior, therefore endogenous orexin does not appear to be essential for 
sexual performance or motivation, but may be critical for processing of sexual reward 
and conditioned cue-induced sexual reward seeking behavior.  
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The current findings that orexin is essential for sexual reward processing and 
specifically for mating-induced CPP are consistent with previous findings that orexin is 
critical for the acquisition and expression of food and drug induced CPP (Harris et al., 
2005, Harris et al., 2007). In addition, orexin is essential for conditioned responses, but 
not for the reinforcement of cocaine (Aston-Jones et al., 2010). Specifically, the orexin 
receptor antagonist SB-334867 attenuated reinstatement of extinguished cocaine (Smith 
et al., 2009) and ethanol (Lawrence et al., 2006) seeking induced by conditioned cues, but 
not induced by cocaine priming (Smith et al., 2009). Perhaps along the same lines, the 
current study shows that orexin lesions prevented conditioned seeking of sexual reward, 
but did not affect initiation (seeking) or expression of sexual behavior in the presence of 
the receptive female. A potential alternate explanation for these findings is that orexin is 
involved in the acquisition or expression of associative memory in general (Jaeger et al., 
2002, Aou et al., 2003, Smith and Pang, 2005, Akbari et al., 2008) and thus effects of 
manipulations could be caused by disruption of associative memory in the CPP paradigm, 
rather than disruption of conditioned reward seeking. Therefore, the current study set out 
to demonstrate that males with orexin lesions maintained the ability to form a conditioned 
aversion to lithium chloride induced visceral illness in the same contextual environment 
as was used for CPP. Hence, orexin lesions in the current experiment did not disrupt the 
ability to form associative contextual memories.  
There is ample evidence supporting a dichotomy in orexin neuronal function, with 
PFA-DMH neurons critically involved in arousal and waking and LHA neurons involved 
in reward (Harris and Aston-Jones, 2006, Aston-Jones et al., 2009, Aston-Jones et al., 
2010). LHA orexin neurons, but not PFA-DMH orexin neurons, are activated by 
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conditioned cues associated with cocaine, morphine, or food reward (Harris et al., 2007) 
and stimulation of LHA orexin neurons induces or reinstates conditioned preference for 
drug reward (Harris et al., 2005, Aston-Jones et al., 2010). The findings in the current 
study do not conform with this dichotomy, as neurons in both LHA and PFA-DMH were 
activated by cues associated with sexual reward. Other recent evidence also suggests a 
role for the PFA-DMH in reward processing, as this population of neurons becomes 
activated following exposure to contextual cues associated with cocaine reward and is 
involved in cocaine seeking behavior (Hamlin et al., 2008). In addition, intra-NAc 
injections of the µ-opioid receptor agonist DAMGO leading to high fat palatable food 
intake caused activation of the PFA-DMH and not LHA, further implicating the PFA-
DMH may have some role in reward processing (Zheng et al., 2007). In further support, 
PFA-DMH orexin neurons have projections to the VTA (Fadel and Deutch, 2002, Geisler 
and Zahm, 2005). Future studies are needed to determine the specific role of each of the 
two orexin neuronal subpopulations in sexual reward processing using pharmacological 
manipulations rather than cell-specific lesions, as the latter resulted in lesions of both 
LHA and PFA-DMH.  
The results of this study implicate a role for orexin in conditioned cue-induced 
seeking of sexual reward. However, the mechanism by which orexin contributes to this 
aspect of sexual function is currently unclear. Orexin activates VTA dopamine neurons 
(Korotkova et al., 2003, Borgland et al., 2006, Narita et al., 2006, Borgland et al., 2008) 
and thus it is possible that orexin-dopamine interactions may be a critical mediator of 
sexual reward induced CPP. However, dopamine neurotransmission does not appear to be 
critical for mating-induced CPP (Agmo and Berenfeld, 1990, Garcia Horsman and 
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Paredes, 2004, Paredes and Agmo, 2004, Ismail et al., 2009). Instead, endogenous 
opioids appear involved in development and expression of mating-induced CPP (Agmo 
and Berenfeld, 1990, Mehrara and Baum, 1990, Agmo and Gomez, 1993, Paredes and 
Martinez, 2001, Ismail et al., 2009). During sexual behavior, endogenous opioids are 
acting on µ-opioid receptors in the medial preoptic area (Coolen et al., 2004), a brain 
region critical for mating induced CPP (Agmo and Gomez, 1993). Moreover, in the VTA, 
µ-opioid receptors are activated by exposure to conditioned contextual cues associated 
with sexual reward (Balfour et al., 2004). Hence, orexin may be interacting with the 
endogenous opioid system to mediate conditioned-cue induced seeking of sexual reward.  
Indeed, orexin-A induced feeding behavior is blocked by opioid receptor antagonists 
naloxone (Clegg et al., 2002) and naltrexone (Sweet et al., 2004). In addition, ICV 
administration of the orexin receptor-1 antagonist SB 334867 reduced the effects of the 
µ-opioid receptor agonist DAMGO on high fat diet intake (Zheng et al., 2007). Orexin 
neurons that respond to the exogenous opioid morphine have been shown to express µ-
opioid receptors (Georgescu et al., 2003) and orexin-1 antagonists block morphine 
induced CPP (Harris et al., 2007). Furthermore, injection of orexin-A into the 
hypothalamus leads to increased enkephalin release in the VTA, the paraventricular 
nucleus of the hypothalamus and the central amygdala (Karatayev et al., 2009) indicating 
a role for orexin in mediation of opioid release in the brain. Therefore with ample 
evidence for the role of orexin-opioid interactions in mediation of natural and drug 
reward, future studies may address a role for these interactions in development of mating-
induced CPP. 
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In conclusion, the current study demonstrates a role for orexin in conditioned cue-
induced seeking of sexual reward and contributes novel information to our knowledge of 
the role of orexin in reward processing. These findings provide further elucidation of the 
neural circuitry involved in natural reward and sexual reward in particular. 
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Loss of Sexual Reward Causes Depression-like Behavior in 
Male Rats 
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4.1 INTRODUCTION 
Depression is mood disorder in which feelings of sadness, loss, anger, or 
frustration interfere with everyday life for a prolonged period of time (Krishnan and 
Nestler, 2008). It is estimated that 16.2% of adults in the United States will experience a 
major depressive episode at some point in their lifetime (Kessler et al., 2003). Depression 
is often triggered by stressful life events such as childhood abuse or neglect, chronic 
stress or chronic abuse. In addition, depression can also be caused by loss of rewarding 
social interactions such as death of partner, friend or relative, or loss of job (Newport et 
al., 2002, Henn and Vollmayr, 2005, Krishnan and Nestler, 2008, Nestler and Hyman, 
2010, Krishnan and Nestler, 2011).  
Animal models used to study depression frequently rely on exposing animals to 
stressful stimuli. Rodents subjected to early life stress such as maternal separation 
(Newport et al., 2002, Millstein and Holmes, 2007), chronic stress via exposure to a daily 
unpredictable stressor (Henn and Vollmayr, 2005, Krishnan and Nestler, 2008) or chronic 
social defeat by daily encounters with an aggressor (Nestler and Hyman, 2010, Krishnan 
and Nestler, 2011) all develop depression-like behaviors, including passive stress coping 
behavior, anhedonia, and increased anxiety. In contrast, there is currently no established 
animal model to study development of depression following loss of social reward. 
Monogamous pair bonded male prairie voles displayed depression-like behavior 
following loss of partner (Bosch et al., 2009), but few other mammals establish pair 
bonds (Kleiman, 1977). Therefore, the goal of the current study was to determine if loss 
of social reward in male rats can cause depression-like behavior. In male rats the most 
rewarding social interaction is sexual behavior. Males will perform operant tasks (Everitt 
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et al., 1987, Everitt and Stacey, 1987) climb barriers (Sheffield et al., 1951) or cross 
electrified grids (Moss, 1924) to gain access to a sexually receptive female, and form a 
conditioned place preference for sexual reward (Agmo and Berenfeld, 1990, Tenk et al., 
2009).  
Sexual behavior affects stress and anxiety-related behaviors, including decreased 
anxiety-like behavior (Fernandez-Guasti et al., 1989, Saldivar et al., 1991, Waldherr and 
Neumann, 2007) and decreased fear responses (Bai et al., 2009) shortly following mating. 
However, the effects of a prolonged period of abstinence from sexual reward on anxiety 
and depression-like behaviors have not been tested. Recently, it has been shown that an 
abstinence period from sexual reward increases vulnerability for drugs of abuse in male 
rats (Frohmader et al., 2010, Pitchers et al., 2010) while drug craving was not altered 
shortly after mating. Therefore, we hypothesize that long term loss of sexual reward will 
also cause vulnerability to other disorders related to reward processing, in particular 
depression-like behavior. The current studies demonstrate that a prolonged loss of sexual 
reward in male rats causes depression-like behavior, including increased passive stress 
coping and decreased social interaction, and support the potential development of using 
deprivation of this natural reward behavior in male rats as a paradigm to study depression 
following loss of social reward. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Animals 
Adult male Sprague Dawley rats (200-250g) were obtained from Charles River 
Laboratories (Sherbrooke, Quebec, Canada or Wilmington, MA, USA) and were housed 
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in same-sex pairs for the duration of experimental testing in Plexiglas cages. To identify 
animals, tails were labeled with permanent marker. In all experiments, cages mates 
underwent the same experimental treatment. The colony room was maintained on a 12/12 
reversed light-dark cycle (lights off at 10 am) with food and water available ad libitum 
except during behavioral testing. Female Sprague-Dawley rats were obtained from 
Charles River Laboratories (Sherbrooke, Quebec, Canada or Wilmington, MA, USA), 
were bilaterally ovariectomized and received subcutaneous implants of 5% 17-β-estradiol 
benzoate in silastic capsules. Females were administered a subcutaneous progesterone 
injection (500 μg in 0.1 ml of sesame oil) to induce sexual receptivity 4 hours prior to 
mating sessions. All procedures were approved by the Animal Care Committees at the 
University of Western Ontario and University of Michigan and conform to guidelines 
outlined by the Canadian Council on Animal Care and the National Institute of Health. 
 
4.2.2 Sexual Behavior 
All sexual behavior testing took place during the first half of the dark phase, 3-6 
hours after lights off. Adult male Sprague-Dawley rats were randomly divided into two 
groups that either mated (experienced group) or were handled and remained sexually 
naïve (naïve group) over the course of five consecutive days. On each day, males in the 
experienced group were placed in a clean Plexiglas mating cage (60×45×50 cm3) for 10 
minutes to acclimate. Subsequently, a sexually receptive female was placed into the cage 
and males were allowed to mate to one ejaculation (females were removed after 
completion of the post ejaculatory interval) or for 60 minutes, which ever occurred first. 
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Durations of the mating sessions averaged 16.7 minutes on the first trial and reduced to 
8.7 minutes average on the fifth trial, reflecting the effects of sexual experience on faster 
initiation and completion of mating (Pitchers et al., 2012). Mating behavior was observed 
and analyzed as described previously (Di Sebastiano et al., 2010, Di Sebastiano et al., 
2011). During each trial latencies to first mount and intromission as well as latency to 
ejaculation (time from the first intromission to ejaculation) were recorded. For 
experiments that included multiple sexually experienced groups, all groups were matched 
on parameters of sexual behavior, including latencies to mount, intromission and 
ejaculation during the final mating session as well as numbers of ejaculations during the 5 
sessions. Numbers of mounts and intromissions were also recorded. Males in the naïve 
group were handled and placed in a clean Plexiglas cage (60×45×50 cm3) for 60 minutes 
in the same rooms as sexually experienced males and thus were exposed to the same 
levels of disturbance and to distant female odors and sounds of mating. 
 
4.2.3 Forced Swim Test 
Sexually experienced or sexually naïve males were tested for depression-like 
behavior following a one day, one week or one month period of abstinence from sexual 
behavior (n=16 per time point) or handling (n=12 per time point), using the forced swim 
test. The forced swim test was conducted in a large cylindrical container, 25.5 cm in 
diameter; 45 cm in height, filled with cold tap water (20 ± 1˚C) to a depth of 30 cm. 
Testing was conducted during the light phase, 2-6 hours after lights on. 1,7 or 28 days 
following last sexual experience or handling males underwent a pre-exposure session to 
the forced swim apparatus in which they were placed in the water for 15 minutes. 24 
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hours following this pre-test (hence 2, 8 and 29 days following last mating or handling) 
males underwent a test session in which they were placed in the water again for 5 minutes 
(Porsolt et al., 1977a, Porsolt et al., 1977b, Detke et al., 1995, Porsolt et al., 2001). 
Following each swimming session rats were removed from the water, towel dried and 
placed under a heat lamp until fur was dry. Forced swimming sessions were recorded 
from above with video cameras. Behavior videos were scored by an observer blind to 
animal’s treatment using automatic timer software (Stopwatch+; Center for Behavioral 
Neuroscience, Atlanta, GA: (http://www.cbnatl.org/research/behavioralcore.shtml (Bosch 
et al., 2009). Behavior was scored as follows: Struggling (Climbing): movements when 
forelimbs break the surface of the water; Swimming: coordinated movements of the 
forelimbs and hindlimbs propelling the animal forward, without breaking the water’s 
surface; Floating (Immobility): very slight movements of the limbs sufficient to keep the 
trunk at equilibrium. The percentage of time animals spent floating (immobile) during the 
second test is considered indicative of a passive stress coping and depression-like 
behavior (Porsolt et al., 1977b). Statistical significance in percentage of time animals 
displayed immobility was compared between naïve and experienced males using 
Student’s t-test with a 95% confidence level. 
 
4.2.4 Tail suspension test 
The same groups of sexually experienced or sexually naïve males (1, 7 or 28 days 
following last sexual experience (n=16 per time point) or handling (n=12  per time 
point)) were then tested for depression-like behavior using the tail suspension test, 24 
hours after forced swim test, during the light phase 2-6 hours after lights on. Male rats 
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were suspended by their tail from a hook 90 cm off the ground for one minute (Steru et 
al., 1985) (Chermat et al., 1986). Test sessions were recorded using a video camera. The 
duration of immobility, defined as passive hanging was scored using Stopwatch+ 
software (Bosch et al., 2009) by an observer blind to the animal’s treatment as a measure 
of passive stress coping. Statistical significance in the percentage of time animals were 
immobile was compared between naïve and experienced males using Student’s t-test with 
a 95% confidence level.  
 
4.2.5 Social Interaction Test 
Another group of sexually experienced (n=14) and sexually naïve (n=10) animals 
were tested for anhedonia using the social interaction test 28 days following last mating 
or handling, during the dark phase, 3-6 hours after lights off. The social interaction 
apparatus was a large plastic open field arena (84 x 42 x 30 cm) with a wire mesh box (18 
x 11.5 x 8 cm) along the short wall. Males were placed into the apparatus for a 5 minute 
habituation period with an empty wire mesh goal box. Following habituation, males were 
removed from the apparatus and placed back in the home cage for 1 hour. Next, a social 
target animal (unfamiliar adult male Sprague Dawley rat) was placed in the wire mesh 
goal box and experimental males were placed back in the arena for 5 minutes to measure 
social interaction. Approximately 1 hour later, a sexually receptive female 
(ovariectomized, estradiol and progesterone-primed, adult Sprague Dawley rat) was 
placed in the wire mesh box and experimental males were again placed in the box for 5 
minutes to measure social interaction. The social interaction arena was cleaned with 70% 
ethanol between trials. All social interaction sessions were recorded from above using a 
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video camera. Social interaction was measured using video tracking software (Stoelting 
Any-Maze, Wood Dale, IL) to measure time spent in the interaction zone (28 x 42 cm 
area around the wire mesh cage), the avoidance zone (28 x 42 cm) and the neutral zone 
(remaining center area of the chamber, 28 x 42 cm). Time spent in each zone was 
calculated and statistical differences between naïve and experienced animals were 
calculated using a two-way ANOVA and Tukey’s test with a 95% confidence interval. 
 
4.2.6 Sucrose Preference Test 
Another group of sexually experienced (n=20) or naïve (n=20) or male rats 
underwent a sucrose preference test for anhedonia using methods described by (Willner 
et al., 1987) 28 days following last mating or handling. Males were individually housed 
on Day 1 of the test and were given two bottles of tap water in the home cage for 48 
hours (Days 1 & 2) to allow for habituation. On Days 3 & 4 one of the water bottles were 
substituted for a bottle containing a 1% (w/v) sucrose solution, and animals were once 
again given 48 hours to habituate to drinking the sucrose solution. On Day 5, animals 
were food and water deprived for 6 hours during the second half of the dark phase prior 
to testing to maximize sucrose consumption. Bottles containing 1% sucrose or tap water 
were weighed and placed into the home cage for 1 hour to measure sucrose preference, 
during the first hour of the light phase. Following the 1 hour test bottles were removed, 
weighed again and sucrose preference was calculated as follows: (sucrose consumed 
(g)/(sucrose consumed (g) + water consumed (g) x 100). Statistical difference in sucrose 
consumption between naïve and experienced animals was calculated using Student’s t-
test with a 95% confidence level. 
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4.2.7 Conditioned Place Preference 
Adult male Sprague Dawley rats mated (n=12) or were handled and remained sexually 
naïve (n=12). 28 days following last sexual experience or handing males were tested for 
CPP for sexual reward, using an unbiased apparatus (MED Associates, St. Albans, VT) 
consisting of three distinct chambers. On Day 1 (pre-test) males were given free access to 
the entire CPP apparatus for 15 minutes to determine initial preference for either chamber 
(Di Sebastiano et al., 2011). On Days 2 and 3 (conditioning trials), males were placed 
into a larger mating cage and mated until 1 ejaculation and were then placed into the 
initially non-preferred chamber (paired chamber) for 30 minutes, or were taken from the 
home cage and placed into the initially preferred chamber (unpaired chamber). Pairings 
were conducted in a counter-balanced design. A post-test procedurally identical to the 
pre-test was conducted on the fourth day to determine CPP. A preference score (percent 
of time spent in the sex-paired chamber) was calculated for each animal. Statistical 
significance between pre-test and post-test were compared using a two-way repeated 
measures ANOVA and Holm-Sidak test with a 95% confidence level.  
 
4.2.8 Antidepressant Administration  
Next, it was tested whether passive stress coping can be blocked by antidepressant 
administration, and hence can be considered depression-like behavior. A group of adult 
male Sprague-Dawley rats mated (experienced) or were handled and remained sexually 
naïve (naïve) over the course of five consecutive conditioning days. Mating behavior was 
recorded as described above and males were matched on parameters of mating behavior 
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and divided into 4 groups: naïve males treated with saline (n=10), experienced males 
treated with saline (n=12), naïve males treated with antidepressant (n=12), experienced 
males treated with antidepressant (n=12). 28 days following last sexual experience or 
handling males underwent the forced swim test. Sexually naïve or experienced males 
underwent a 15 minute pre-exposure session to the forced swim test and were then 
administered the antidepressant imipramine (Sigma-Aldrich, St. Louis MO, Cat #I7379; 
10 mg/kg in 0.9% saline, intraperitoneal) or saline vehicle (10 mg/kg i.p.) 24, 5 and 1 
hours before testing in the 5 minute forced swim test  (29 days following last mating or 
handling, n=12 per group). Behavior was recorded using video cameras and analyzed as 
described above by an observer blind to animal’s treatment. Statistical significance 
between naïve and experienced saline or imipramine treated males was determined using 
a one-way ANOVA and Fishers LSD test with a 95% confidence level. 
 
4.2.9 Rescue of depression-like behavior by sexual experience 
To determine if abstinence from sexual behavior during the 28 day period is 
essential for development of depression-like behavior, adult male Sprague-Dawley rats 
mated or were handled and remained sexually naïve over the course of 5 consecutive 
trials as described above. One group of experienced males (n=11) mated twice weekly 
during the 28 day period and were then tested for depression in the forced swim test to 
determine if development of depression-like behavior is dependent on an abstinence 
period from mating and not caused by other explanations, i.e. length of time from onset 
of mating behavior. These males had their final mating session on day 27, underwent the 
forced swim pre-test on day 28 and were tested for depression-like behavior in the forced 
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swim test 24 hours following the pre-test (day 29). A second group of experienced males 
(n=11) underwent a 27 day period of abstinence and mated to ejaculation on day 27, 
underwent the forced swim pre-test on day 28 and the forced swim post-test 24 hours 
following the pre-test, to determine if development of depression-like behavior can be 
rescued by a single re-exposure to sexual behavior. Finally, animals in the experienced 
control (n=9) and naïve control (n=8) groups were tested on the forced swim test 28-29 
days following last handling or sexual experience, with no mating during the entire 28 
day abstinence period. Behavior in the forced swim test was recorded and analyzed as 
described above. Statistical significance between groups was determined using a one way 
ANOVA and Fishers LSD test with a 95% confidence level. 
 
4.2.10 Anxiety-like behavior: Elevated plus maze 
As depression is often comorbid with anxiety in both humans (Kessler et al., 
1994) and animal models (Berton et al., 2006) the same groups of sexually experienced 
(n=16 per time point) or sexually naïve (n=12 per time point) males used for the FST and 
tail suspension tests in 4.2.3 and 4.2.4 were tested for anxiety-like behaviors 1, 7 or 28 
days following last sexual experience or handling. Anxiety-like behavior was tested using 
the elevated plus maze apparatus (EPM; MED Associates Inc., St. Albans, VT) during 
the end of the light phase in a brightly lit room, prior to the forced swim pre-test. The 
EPM was elevated 75 cm off the ground and consisted of 4 arms of equal length (50 cm) 
extending from a central junction. Two of the arms were enclosed with dark siding 40 cm 
high and the other two arms were open to the external environment. Males were placed 
on the central junction and were allowed to freely explore the EPM for five minutes and 
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time spent in closed and open arms was monitored using photobeam arrays. Statistical 
significance in time spent in open or closed arms between naïve and experienced males 
was determined using Student’s t-test with a 95% confidence level. 
 
4.3 RESULTS 
4.3.1 Forced Swim Test and Tail Suspension Test 
A 28 period of abstinence from sexual behavior caused significantly higher 
display of passive stress coping behavior. Sexually experienced males demonstrated a 
significantly higher percentage of immobility behavior in the forced swim test and tail 
suspension test compared to sexual naïve males 28 days following last sexual experience 
(Figure 4.1a; p=0.012 and p=0.036 respectively), but not 1 (Figure 4.1c) or 7 days 
(Figure 4.1b) following last sexual experience.  
 
4.3.2 Antidepressant Treatment 
Antidepressant administration prevented development of passive stress coping 
behavior following a 28 day abstinence period from sexual behavior (Figure 4.2a; F(3,40) 
5.551; p<0.003). Sexually experienced males pre-treated with imipramine spent 
significantly less time immobile compared to experienced saline treated males (Figure 
4.2a; p<0.001). Moreover, sexually experienced males pre-treated with saline showed 
increased time immobile during the post-test compared to naïve saline treated controls 
(Figure 4.2a; p=0.003), confirming previous results. These results confirm that passive 
stress coping behavior seen following 28 days of abstinence from mating is indeed 
depression-like behavior, as this behavior can be rescued by antidepressant treatment. 
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Figure 4.1.Percentage of time spent immobile in forced swim test and tail suspension test 
of sexually naïve (white bars) and experienced (black bars) males at 28 (A), 7 (B), or 1 
(C) days following last handling or mating session. Data are presented mean ± SEM.* 
Indicates significant difference from naïve males in the same test and same time point.  
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4.3.3 Rescue of depression-like behavior by sexual experience 
Development of depression-like behavior is dependent on a period of abstinence 
from mating, as males that mated twice weekly during the 28 day period did not develop 
increased passive stress coping behavior in the forced swim test (Figure 4.2b; F(3,30) 
4.643; p=0.01). First, sexually experienced males that underwent a 28 day abstinence 
period from mating displayed longer duration of floating compared to sexually naïve 
males, confirming our results from the previous experiments (Figure 4.2b; p=0.005). In 
contrast, males that mated twice weekly during the 28 days following the initial 5 daily 
mating sessions, spent significantly less time immobile in the forced swim test compared 
to experienced males that underwent a 28 day period of sex abstinence (Figure 4.2b; 
p=0.007) and did not differ significantly in time immobile compared to naïve males. 
Males that underwent a 27 day period of abstinence and mated one day prior to first 
exposure to the forced swim test still demonstrated higher immobility compared to naïve 
males (Figure 4.2b; p=0.032) and experienced males that mating during the 28 day period 
(Figure 4.2b; p=0.041) but were not significantly different from sexually experienced 
males with prolonged abstinence (p=0.214), indicating that a single experience with 
sexual behavior following a 27 day abstinence period from mating did not rescue 
development of depression-like behavior. This was not due to a deficit in mating 
behavior, as parameters of initiation and performance did not differ after 27 days of 
abstinence compared to the same animals’ final mating session of the five consecutive 
daily mating sessions (Mount Latency: Day 5, 53.6 ±14.9 s vs. Day 27 46.5± 15.7 s; 
p=0.67; Intromission Latency: Day 5, 54.4 ±15 s vs. Day 27, 64.2 ± 18.4 s; p=0.8; 
Ejaculation Latency: Day 5, 656.8 ± 137.5s vs. Day 27, 893 ±156.4; p=0.35). These 
results confirm facilitation of sexual behavior is maintained following a one month period 
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of abstinence from mating (Pitchers et al., 2012), and indicate that lack of a rescue effect 
of mating one day prior to testing on the forced swim test on development of depression-
like behavior in sexually experienced animals is not due to impairments in copulatory 
performance or sexual motivation. 
 
4.3.4 Anhedonia: Social Interaction 
28 days of abstinence from mating caused anhedonia seen as decreased social 
interaction (Figure 4.3a; F1,62  9.368; p=0.003). Sexually experienced males spent 
significantly less time interacting with a novel male (Figure 4.3a; p=0.038) and receptive 
female (Figure 4.3a; p=0.03) compared to sexually naïve males. Naïve and experienced 
males did not differ in time spent interacting with an empty goal box during habituation 
(p=0.357). 
 
4.3.5 Anhedonia: Sucrose Preference 
 Abstinence from sexual reward did not cause anhedonia in the sucrose preference 
test, as sexually experienced males did not differ significantly in volume of sucrose 
consumed compared to sexually naïve males 28 days following last mating or handling 
(Figure 4.3b). 
 
4.3.6 Mating-induced Conditioned Place Preference 
A 28 day period of abstinence from sexual reward did not affect mating-induced 
CPP, as sexually naïve and experienced males both formed a significant preference for a 
sexual reward-paired chamber (Figure 4.3c F1,47 8.45; p=0.008). Both sexually naïve and  
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Figure 4.2. (A) Percentage of time spent immobile in saline-treated sexually naïve males 
(Naïve Saline) and sexually experienced males (Exp Saline); and in imipramine-treated 
experienced (Exp AD) and sexually naïve (Naïve AD) males. (B) Percentage of time 
spent immobile in sexually naïve males (Naïve) and sexually experienced males with a 
28 day period of sex abstinence (Exp), experienced males that mated twice weekly during 
the 28 day period (Exp + 2x wk sex), or sexually experienced males that mated once 1 
day prior to testing on the forced swim test (Exp + 1x sex). Data are presented as mean 
±SEM * indicates significant difference from naïve saline (A) or naïve (B) controls.  
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experienced males showed a significant increase in preference score (percentage of time 
spent in the sex-paired chamber) during the post-test compared to the pre-test: naive: 
(Figure 4.3c; 0.037); experienced: (Figure 4.3c; p=0.037). Moreover, initiation or 
performance of sexual behavior were not affected by the 28 day abstinence period as 
sexually experienced males did not differ in any parameters from their final day of 
mating during the 5 consecutive days and were significantly facilitated compared to 
sexually naïve males (Mount Latency: Naïve, 559.5 ± 193.8 s vs. Experienced, 104.4 ± 
18 s; p=0.02; Intromission Latency: Naïve, 813.5±228.3 vs. Experienced;161.8 ± 36.4 
p=0.01; Ejaculation Latency: Naïve, 1934.3 ± 322.4 vs. Experienced, 678.75 ± 46.4; 
p<0.001). 
 
4.3.7 Anxiety-like Behavior: Elevated Plus Maze 
Neither sexual behavior nor a period of abstinence caused alterations in anxiety-
like behaviors. There were no significant differences in time spent in the open arms 
(Figure 4.4a ) and closed arms (Figure 4.4b) on the EPM between sexually naïve and 
experienced males 1, 7 or 28 days following last sexual experience.  
 
4.4 Discussion 
  
 
The results of these studies demonstrate that an extended abstinence period from 
sexual behavior; a powerful social reward behavior, causes a depression-like phenotype 
in male rats. Depression-like behavior was evident as enhanced passive stress-coping 
behavior in the forced swim and tail suspension tests. Immobility in these tests is 
indicative of depression-like behavior and was blocked by treatment with the tricyclic 
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Figure 4.3 (A) Percentage of time spent interacting with an empty goal box (habituation) 
novel male and estrous female in the social interaction test in sexually naïve (white bars) 
and sexually experienced (black bars) males, 28 days following last handling or mating. 
(B) Percentage of sucrose consumed in the sucrose preference test in sexually naïve 
(white bars) and sexually experienced males (black bars) 28 days following last handling 
or mating. (B) Preference score: % time spent in sex reward paired chamber in the pre- 
and post-test during the CPP test 28 days following last handling or mating. Data are 
presented mean ± SEM.* Indicates significant difference from naïve males in the same 
test and same time point.  
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Figure 4.4. Time spent in (A) open arms and (B) closed arms on the elevated plus maze 
in sexually naïve (white bars) and experienced males (black bars) 1, 7, or 28 days 
following last handling or mating session. Data are presented as mean ± SEM. 
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antidepressant imipramine (Porsolt et al., 1977a, Porsolt et al., 1977b). Development of 
depression-like behavior was dependent on a period of abstinence from mating, as mating 
twice weekly during the 28 day period prevented enhanced passive-stress coping 
behavior in the forced swim test. Furthermore, engaging in sexual activity one time prior 
to testing in the forced swim test was not sufficient to rescue depression-like behavior, 
confirming that development of depression-like behavior requires loss of social reward, 
and is not caused by other explanations such as length of time following first mating 
session. Thus, theses studies suggest that development of depression-like behavior 
following loss of sexual reward is dependent on a prolonged period of abstinence from 
mating, and may provide a new model to study human depression following loss of social 
reward.            
In the current studies we observed depression-like behavior, including increased 
passive stress coping following a prolonged abstinence period from sexual reward, 
comparable to depression-like phenotypes observed in stress models of depression. In the 
social defeat model of depression, defeated animals also demonstrate increased 
immobility in the forced swim test to a similar magnitude as that observed in the current 
study in both rats (Hollis et al., 2010) and mice (Keeney et al., 2006). Maternal separation 
in rats has also been shown to lead to increases in passive stress coping behavior, again to 
a similar magnitude as that seen in the current studies (Aisa et al., 2007, Lee et al., 2007). 
(Hulshof et al., 2011). Finally, in the chronic mild stress model of depression, mice and 
rats also demonstrate increased passive stress coping (Bielajew et al., 2003, Mineur et al., 
2006). Thus, loss of sexual reward appears to induce depression-like behavior to a similar 
magnitude of that seen in stress models of depression, such as social defeat, maternal 
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separation and chronic mild stress. Alterations in passive stress coping behaviors provide 
an effective method for screening depression-like behaviors in rodents, due to the 
responsivity of the forced swim and tail suspension tests to antidepressant activity 
(Porsolt et al., 1977a, Porsolt et al., 1977b, Chermat et al., 1986). However, these stress 
models of depression are also associated with alterations in stress axis activity (Ayensu et 
al., 1995, Francis et al., 1999, Francis et al., 2002, Kieran et al., 2010), as well 
neuropathology similar to that observed in human depression (Francis et al., 1999, Stout 
et al., 2000, Keeney et al., 2006, Marini et al., 2006). Thus, loss of sexual reward may 
also lead to alterations in stress responsivity and underlying neuropathology of 
depression. 
Loss of sexual reward also caused anhedonia, another hallmark of depression 
(Nestler and Hyman, 2010) seen as decreased social interaction with a novel male and an 
estrous female 28 days following last mating. However, social defeat appears to induce a 
higher magnitude of social avoidance than the current study, in both rats (Hollis et al., 
2010) and mice (Berton et al., 2006). This difference in magnitude is likely due to the 
fact that in the social defeat paradigm, animals are chronically being attacked by another 
conspecific, and may thus develop a higher level of avoidance, whereas in the current 
study decreased social interaction more likely reflects a loss of motivation for social 
interaction. The effects of maternal separation in the social interaction test are unclear, as 
maternally separated animals have been shown to have decreased social interaction 
(Maciag et al., 2002), while other studies have shown that maternal separation does not 
alter social interaction (Hulshof et al., 2011). Finally, it has been shown that animals 
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exposed to the chronic mild stress paradigm do not show alterations in the social 
interaction test (D'Aquila et al., 1994). 
Loss of sexual reward did not cause reduced sucrose preference. The chronic mild 
stress model of depression has been shown to reliably induce anhedonia in the sucrose 
preference test following long-term exposure to stressors (Willner et al., 1987, 
Pucilowski et al., 1993, Willner, 2005). Likewise, chronic social defeat in rats (5 
consecutive weeks of defeat) (Rygula et al., 2005) or mice (10 consecutive days of 
defeat) (Krishnan et al., 2007) causes decreased sucrose preference. In contrast, rats 
exposed to shorter term social defeat (4 consecutive days) did not demonstrate anhedonia 
in the sucrose preference test (Hollis et al., 2010), even though they did develop 
increased passive stress coping in the forced swim and tail suspension tests, as well as 
decreased social interaction. Moreover, male rats exposed to maternal separations do not 
demonstrate decreased sucrose preference (Matthews et al., 1996, Shalev and Kafkafi, 
2002). These results suggest that development of anhedonia in the sucrose preference test 
requires long term exposure to a stressor and provide a potential explanation for the lack 
of decreased sucrose preference in the current study. Moreover, we hypothesize that lack 
of anhedonia for sucrose in the current study may be due to the need in this paradigm to 
expose the animals to the rewarding sucrose stimulus for 2 days prior to testing, 
potentially preventing development of anhedonia.  
Another measure of anhedonia is animal’s interest in pleasurable activities such as 
sexual behavior (Nestler and Hyman, 2010). We have demonstrated that following a 28 
day period of abstinence from mating males do not display decreased sexual motivation 
or performance (Pitchers et al., 2012), and have unaltered sexual reward. Thus, these 
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results suggest loss of sexual reward induces anhedonia in the form of reduced social 
interaction, but there is no loss of reward associated with the consumption of a rewarding 
substance or consummatory behavior with a rewarding stimulus. Hence, abstinence from 
sexual reward induced decreased “wanting” or incentive motivation for a salient stimulus, 
but did not alter the “liking” or reward for the consumption of the salient stimulus 
(Robinson and Berridge, 1993). In contrast, males that have been socially defeated 
demonstrate decreased attempts to copulate with a receptive female (Rygula et al., 2005). 
In the chronic mild stress paradigm, sexually experienced males show impairments in 
copulatory performance seen as increased latencies to mount and intromission, and 
decreased frequency of mounts and ejaculations (Gronli et al., 2005). Maternally 
separated males are also impaired in their copulatory performance during their first 
mating trial in adulthood, as latencies to mount and intromission are lengthened, and 
ejaculation frequency is decreased (Rhees et al., 2001). Likewise, human depressed 
patients often lose interest in sex and demonstrate sexual dysfunction (Mathew and 
Weinman, 1982, Dell'Osso et al., 2009, Galecki et al., 2011). However, depressed 
humans have also been reported to engage in sexual risk behaviors, including multiple 
partners and decreased condom use (Shrier et al., 2001, Khan et al., 2009). In our lab, we 
have shown that 28 days of abstinence from mating not only causes depression-like 
behavior, but also causes increased vulnerability for drugs of abuse (Pitchers et al., 2010). 
As sexual risk behavior is also associated with drug taking (Peugh and Belenko, 2001, 
Rawson et al., 2002, Raj et al., 2007, Fisher et al., 2011), and depressed patients have a 
high incidence of substance abuse (Volkow, 2004), loss of sexual reward may be a 
valuable model to study comorbid depression and substance abuse. 
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Abstinence from mating did not result in anxiety-like behavior. Thus, in contrast 
to the anxiolytic effects of sexual behavior shortly following mating, there do not appear 
to be long term effects of sexual behavior on anxiety. Moreover, this finding is in contrast 
to the induction of anxiety in other depression models, in which animals are exposed to 
stressors. Stress models of depression such as social defeat, chronic stress or maternal 
separation all lead to alterations in anxiety-like behavior as well as in depression-like 
behavior (Daniels et al., 2004, Vyas and Chattarji, 2004, Krishnan et al., 2007). As an 
abstinence period from sexual behavior is not a stressor such as attack, restraint, cold, or 
physical separation from the mother, it does not cause anxiety-like behavior. Moreover, 
in the current studies males were housed with a same sex cage mate and some 
environmental enrichment during the entire abstinence period, to avoid social isolation 
stress, which has also been shown to cause anxiety and depression-like behavior (Karim 
and Arslan, 2000, Dandekar et al., 2009, Djordjevic et al., 2012). Thus, loss of sexual 
reward appears to be an animal model of depression without anxiety that is not caused by 
stress or agonistic attacks. Even though in humans anxiety can be comorbid with 
depression, this is not the case for all individuals suffering depression (Prigerson et al., 
1995, Kessler et al., 1996) 
Recently it was shown that monogamous, pair bonded male prairie voles that are 
separated from their partner for 3-5 days develop depression-like behavior, seen as 
increased immobility in the forced swim and tail suspension tests (Bosch et al., 2009). 
These males also demonstrated increased anxiety-like behavior, seen as decreased 
numbers of entries into the open arms of the EPM (Bosch et al., 2009). However males 
that were separated from a same sex sibling partner also demonstrated decreased entries 
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into the open arms (Bosch et al., 2009), a suggesting that effects on anxiety may be due to 
the fact that these males are socially isolated during partner separation. In order to form a 
pair bond males prairie voles were housed for five consecutive days with a female, during 
which mating behavior occurred (Bosch et al., 2009). In the current studies males were 
only housed with females during a once daily mating session for course of 5 consecutive 
days. Mating sessions lasted on average 16.7 minutes on the first trial, and were reduced 
to 8.7 minutes by the fifth trial, suggesting that development of depression-like behavior 
following loss of sexual reward requires only brief daily exposure to sexual behavior, as 
opposed to long-term cohabitation with a female. Moreover, in the current studies, 
development of depression-like behavior was observed following a prolonged (28-29 
day) abstinence period from sexual behavior, and not at earlier timepoints, (1 or 7 days), 
whereas prairie voles separated from their partner developed depression depression-like 
behavior following 3-5 days of partner separation (Bosch et al., 2009). It is currently 
unknown whether depression-like behavior following partner separation is maintained at 
longer intervals of partner separation.  
In conclusion, the current study demonstrates that loss of sexual reward causes 
depression-like behavior in the absence of chronic stressors or social isolation. The 
primary difference of the current findings compared to established rodent models for 
depression is that development of depression in the latter are dependent on chronic stress 
or long-term exposure to agonistic attacks. Instead, the findings presented here may 
resemble depression induced by loss of socially rewarding events and we propose this to 
be a useful model to study depression-like behavior following loss of social reward in 
rodents. This model meets criteria to validate animal models of depression, as loss of 
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social reward causes anhedonia and passive stress coping, giving this model homology to 
symptomology seen in human depression or face validity (Krishnan and Nestler, 2010). 
Furthermore, this model has pharmacological validity (Krishnan and Nestler, 2010) as 
passive stress coping following loss of social reward can be blocked by antidepressants. 
This model also displays construct validity (Krishnan and Nestler, 2010), as development 
of depression-like behavior is dependent on a period of abstinence from mating, and as 
such requires loss of social reward, similar to development of depression-like behavior 
following loss of social rewards in humans. Moreover, abstinence from sexual reward has 
also been shown to cause increased vulnerability for psychostimulant abuse in male rats 
(Pitchers et al., 2010) and increased ethanol consumption in drosophila (Shohat-Ophir et 
al., 2012). Given the comorbidity of depression and substance abuse, it will be important 
to determine which neural alterations are caused by loss of sexual/social reward to cause 
such behavioral pathology. 
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5.1 INTRODUCTION 
In humans, mood disorders such as depression can be triggered by stressful life 
events (Kessler, 1997, Brown, 1998, Kendler et al., 1999, Pine et al., 2002). Stress 
activates the hypothalamic-pituitary-adrenal (HPA) axis, causing release of corticotropin 
releasing factor (CRF) from the paraventricular nucleus of the hypothalamus (PVN), 
which stimulates the anterior pituitary to secrete adrenocorticotropic hormone (ACTH), 
leading to release of cortisol (humans) or corticosterone (cort; rodents) from the adrenal 
glands. These adrenal steroids then regulate the stress response via negative feedback and 
activation of glucocorticoid receptors in hypothalamus (Jones et al., 1977, Keller-Wood 
and Dallman, 1984, Evanson et al., 2010), pituitary (Cole et al., 2000, Russell et al., 
2010), hippocampus (Sapolsky et al., 1984, Jacobson and Sapolsky, 1991, Furay et al., 
2008), and prefrontal cortex (PFC) (Hill et al., 2011, Radley and Sawchenko, 2011). CRF 
is also produced and released from neurons in extra-hypothalamic brain regions, namely 
the bed nucleus of the stria terminalis (BnST) and central amygdala (CeA) (Koob and 
Heinrichs, 1999, Bale and Vale, 2004). CRF acts on two receptors, CRF receptor 1 
(CRFR1) and CRF receptor 2 (CRFR2) (De Souza, 1987, Bale and Vale, 2004) expressed 
in areas such as the nucleus accumbens (NAc) and prefrontal cortex (PFC) (Van Pett et 
al., 2000), brain areas that are critical for mediation of the emotional aspects of the stress 
response (Menzaghi et al., 1993, Morgane et al., 2005, Jankord and Herman, 2008). 
CRFR1 and CRFR2 have been shown to play opposite roles in mediation of the stress 
response, with CRFR1 inducing stress responses and CRFR2 attenuating stress responses 
(Bale and Vale, 2004, Contarino and Papaleo, 2005).  
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Human depression is associated with hyperactivity of the HPA axis (Holsboer, 
2000). Depressed patients show increased CRF levels in the cerebrospinal fluid 
(Nemeroff et al., 1984) as well as  increased CRF mRNA in the hypothalamus (Kling et 
al., 1991). In addition, depressed suicide patients show atrophy of the PFC and NAc 
(Manji et al., 2001) as well as decreased CRF receptor binding sites in the PFC 
(Nemeroff et al., 1988). In animal models of depression that are dependent on exposure 
to stressful stimuli, such as social defeat, chronic stress or maternal separation these 
animals show increased CRF mRNA in the PVN (Francis et al., 1999, Stout et al., 2000, 
Keeney et al., 2006, Marini et al., 2006). Furthermore, development of depression-like 
behavior in the chronic stress model of depression can be blocked by systemic 
administration of CRF receptor antagonists (Ducottet et al., 2003), while intra-NAc 
infusion of CRF induces depression-like behavior (Chen et al., 2012). Both CRFR1 and 
CRFR2 have been shown to play a role in development of depression, again with some 
evidence for opposing roles, with a pro-depressant role for CRFR1 activation and anti-
depressant effects of CRFR2 activation. (Shaham et al., 1998, Hammack et al., 2003, 
Wang et al., 2005, Henry et al., 2006, Wang et al., 2006, Wang et al., 2007).  
In the previous chapter (Chapter 4), it was demonstrated that an extended (28 day) 
period of abstinence from sexual behavior caused depression-like behavior, including 
enhanced passive stress-coping behaviors and decreased social interaction. However, it is 
unknown if the CRF system plays a regulatory role in these behavioral alterations. 
Therefore, the goal of the current studies was to test the hypothesis that loss of sexual 
reward leads to increased HPA axis activity, including increased CRF levels in the PVN 
as well as enhanced cort and ACTH release in response to an acute stressor. In addition, 
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we tested the hypothesis that the CRF system is critical for the development of 
depression-like behavior following loss of sexual reward by chronically infusing CRF 
receptor antagonists either into the cerebroventricular system or locally into the NAc or 
PFC, mesolimbic brain regions that are important for development of depression 
(Krishnan and Nestler, 2008), during the final week of mating abstinence. 
 
5.2 MATERIALS MATERIALS 
5.2.1 Animals 
Adult male Sprague Dawley rats (200-250g) were obtained from Charles River 
Laboratories (Sherbrooke, Quebec, Canada or Wilmington, MA, USA). For the duration 
of experimental testing males were housed in same-sex pairs in Plexiglas cages. To 
identify animals, tails were labeled with permanent marker. In all experiments, cage 
mates underwent the same experimental treatment. The colony room was maintained on a 
12/12 reversed light-dark cycle (lights off at 10 am). Food and water were available ad 
libitum except during behavioral testing. Female Sprague-Dawley rats were obtained 
from Charles River Laboratories (Sherbrooke, Quebec, Canada or Wilmington MA, 
USA). Females were ovariectomized bilaterally and were implanted subcutaneously with 
5% 17-β-estradiol benzoate in silastic capsules. 4 hours prior to mating sessions females 
were administered a subcutaneous progesterone injection (500 μg in 0.1 ml of sesame oil) 
to induce sexual receptivity. All procedures were approved by the Animal Care 
Committees at the University of Western Ontario and University of Michigan and 
conform to guidelines outlined by the Canadian Council on Animal Care and the USA 
National Institute of Health. 
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6.2.2 Sexual Behavior 
Testing for sexual behavior took place 3-6 hours after lights off, during the first 
half of the dark phase. Over the course of five consecutive days, adult male Sprague-
Dawley rats were either mated (experienced group) or were handled and remained 
sexually naïve (naïve group). Males in the experienced group were placed in a clean 
Plexiglas mating cage (60×45×50 cm) on each of the five conditioning days for 10 
minutes. Following the 10 minute habituation, a sexually receptive female was placed 
into the cage and males were allowed to copulate ejaculation or for 60 minutes. Mating 
behavior was recorded and analyzed as previously described (Di Sebastiano et al., 2010, 
Di Sebastiano et al., 2011). Latencies to first mount and intromission and latency to 
ejaculation were recorded during each trial as well as numbers of mounts and 
intromissions. Males in the sexually naïve group were placed into clean Plexiglas cages 
(60×45×50 cm3) for 60 minutes, in the same rooms and at the same time as the 
experienced males were allowed to mate and were thus exposed to the same handling and 
environment, but without mating. 
 
5.2.3 Activation of CRF neurons by sexual behavior 
5.2.3A Tissue Collection 
To determine if CRF neurons are activated by sexual behavior, cFos expression 
was determined after mating in sexually naïve or experienced males. Adult male 
Sprague-Dawley rats were divided into experimental groups as follows: Naïve no sex 
(NNS): handled for five consecutive days. Experienced no sex (ENS): mated to one 
ejaculation on five consecutive days. Both of these groups were perfused 24 hours after 
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last handling or mating from the home cage and served as controls. Naïve sex (NS): 
handled for four consecutive days, and mated to one ejaculation on fifth day. Experienced 
sex (ES): mated to one ejaculation on five consecutive days (n=5 per group). Both of 
these groups were perfused one hour following the end of mating. Males were perfused 
transcardially with 0.9% saline followed by 500 mL of 4% paraformaldehyde (PFA) in 
0.1M phosphate buffer (PB). Brains were quickly removed and post-fixed for one hour in 
the same fixative, then transferred to 20% sucrose for cryoprotection. Brains were 
sectioned into 35 µm coronal sections on a freezing microtome (Microm, Walldorf, 
Germany) and collected in 4 parallel series in a cryoprotectant solution (30% sucrose in 
0.1M PB containing 30% ethylene glycol and 0.01% sodium azide) and were stored at     
-20ºC until further processing.   
 
5.2.3B Immunohistochemistry 
One series of sections for each animal was immunoprocessed for CRF and cFos 
as a marker for neural activation using immunohistochemistry. Free floating sections 
were washed extensively with 0.1M saline buffered sodium phosphate (PBS) between 
incubation steps and all incubations were performed at room temperature using gentle 
agitation. Sections were pre-incubated for 10 minutes using 1% H2O2 (30% stock 
solution) in PBS and for 1 hour in the incubation solution (PBS with 0.1% bovine serum 
albumin and 0.4% Triton X-100). Sections were incubated overnight with a rabbit raised 
antibody recognizing cFos (rabbit anti-cFos, SC52; 1:10,000 in incubation solution, Santa 
Cruz Biotechnology, Santa Cruz, CA), followed by biotinylated goat anti-rabbit (1 hour; 
1:500 in incubation solution, Vector Laboratories, Burlingame, CA) and avidin 
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horseradish peroxidase complex (ABC; 1 hour; 1:1000 in PBS; Vector Laboratories, 
Burlingame, CA). cFos-immunoreactivity was visualized using nickel-enhanced 
diaminobenzidine (DAB; Sigma, St. Louis, MO; 0.02% in 0.1M PB containing 0.012% 
hydrogen peroxide (Fisher, Pittsburg, PA) and 0.08% nickel sulfate (Sigma, St. Louis, 
MO) resulting in a blue-black reaction product. Sections were next incubated overnight 
with a rabbit raised antibody recognizing CRF (rabbit anti-CRF, T-4036 1:2,000, 
Peninsula Labs, San Carlos CA) followed biotinylated goat anti-rabbit and ABC, as 
described above. CRF immunoreactivity was visualized with DAB (10 minutes; 0.02% in 
0.1M PB containing 0.012% hydrogen peroxide). Both antibodies have been 
characterized previously (Bovetto et al., 1996, Di Sebastiano et al., 2010, Di Sebastiano 
et al., 2011). Following completion of staining sections were rinsed extensively with PB, 
mounted onto plus charged glass slides and coverslipped with dibutyl phthalate xylene 
(DPX). 
 
5.2.3C Analysis 
Neurons labeled for CRF or CRF and cFos were counted bilaterally in all sections 
containing CRF positive neurons in the, PVN, CeA and BnST using a Leica microscope 
(DMR5; Leica, Walldof, Germany). Counts were averaged per hemisphere for each 
animal, group means were calculated and statistical significance between naïve and 
experienced groups was determined using a two-way ANOVA with a 95% confidence 
level. 
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5.2.4 Changes in CRF mRNA following mating abstinence 
5.2.4A Tissue Collection 
Adult male Sprague Dawley rats gained sexual experience over the course of five 
consecutive mating trials (n=10) or were handled and remained sexual naïve (n=10). 1 or 
28 days following last sexual experience or handling males were euthanized with sodium 
pentobarbital (270mg/kg); brains were rapidly removed and flash frozen on dry ice in 
sterile RNAse free conditions. Microdissections of the BnST, CeA and PVN were 
performed by isolating tissue with a sterile blunt end needle from frozen coronal sections.  
 
5.2.4B mRNA isolation and real-time polymerase chain reactions 
Tissue punches were homogenized and RNA was isolated using TriZol reagent 
(Invitrogen, Carlsbad CA) for quantitative real time reverse transcription polymerase 
chain reaction (qRT-PCR). RNA was checked for concentration and quality using 
spectrophotometer (Nanodrop; Thermo Scientific, Wilmington, DE). Reverse 
transcription of RNA was performed using a High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems Inc., Foster City, CA) according to manufacturers’ instructions 
and a BioRad Thermal Cycler (Hercules, CA), using equal amounts of RNA for each 
sample. Quantitative analysis of gene expression was determined using real-time qRT-
PCR. Each reaction for was performed with TaqMan chemistry using 2µL of cDNA, 
10µL of TaqMan Universal PCR Master Mix 2X (Applied Biosystems Inc., Foster City, 
CA), 0.8µL of 25mM MgCl2 (Invitrogen, Carlsbad CA), 6.2µL DEPC and 1µL of 
TaqMan gene expression assay solution for the gene of interest. qRT-PCR reactions were 
performed for  CRF (Rn01462137_m1), and glyceraldehydes-3-phosphate dehydrogenase 
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(GAPDH; Rn99999916_s1) in the PVN, CeA and BnST. Reactions were performed 
using the Rotorgene (Corbett Life Sciences, Valencia CA) and the following PCR 
conditions: hold at 50ºC for 2 min, hold at 95ºC for 10 min, 40 cycles of 95ºC for 15 sec 
and 58ºC for 1 min. Cycle threshold (Ct) levels were determined using a optimal 
threshold line generated from standard curve 5-log dilutions of cDNA from the brain 
region of interest for each probe. Standard curves were considered optimal when a line of 
best fit through the Ct values of the dilutions had an efficiency value between 0.8-1 and 
an R2 greater than 0.99. Each sample was analyzed in triplicate and Cts for each 
experimental sample were determined and averaged over the replicates. CRF levels 
within a sample were normalized to their respective GAPDH levels to generate the ΔCt 
value. The ΔΔCt value was calculated as 2^(ΔCt (sample) - ΔCt (average of naïve control 
group)) x100 and, CRF in each animal was expressed as a change over the average of the 
naïve control group within each time point. Statistical significance between naïve and 
experienced groups were calculated using Student’s t-test with a 95% confidence level. 
 
5.2.5 Acute Restraint Stress and Blood Collection 
Sexually experienced (n=12) or naïve (n=10) males underwent acute restraint to 
measure stress responses according to methods described previously (Vahl et al., 2005). 
All stress testing was conducted during the light phase, 2-5 hours after lights on. 28 days 
following last mating or handling males were transported to a testing room and placed in 
a cylindrical polyethylene tail access restrainer (Model #51335, Stoelting, Wood Dale 
IL). Immediately, a small laceration was made at the base of the tail and a baseline blood 
sample was collected in an eppendorf tube filled with 10µL of 100µM EDTA. Males 
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were then restrained for 29 minutes, after which another blood sample was collected (30 
minutes, end of restraint). Males were placed back in the holding cage and blood was 
again collected 60 and 120 minutes post restraint. All blood samples (200-400µL) were 
collected within 1-2 minutes and immediately placed on ice. Blood samples were 
centrifuged; plasma was extracted and stored at -20ºC until further processing. Cort and 
ACTH were measure using ImmuChem™ 125I radioimmunoassay (RIA) kits (cort, cat 
#07120102; ACTH, cat # 07106102; MP Biomedicals, Solon, OH) according to 
manufacturer’s instructions. The cort assay required 10µL of plasma and intra- and 
interassay coefficients of variation were 7.1% and 7.2%. The ACTH assay required 
100µL of plasma and had intra- and interassay coefficients of variation of 4.1% and 
3.9%. Statistical differences in cort and ACTH levels between naïve and experienced 
males over time was calculated using a two way repeated ANOVA (factors: experience 
and time) and Tukey’s test, with a 95% confidence level. 
 
5.2.6 Chronic ICV CRF receptor antagonist administration via osmotic minipumps 
5.2.6A Surgery 
 Adult male Sprague-Dawley rats mated (experienced) or were handled and 
remained sexually naïve (naïve) over the course of five consecutive mating trials. 
Experienced groups were matched on parameters of sexual behavior. 21 days following 
last sexual experience males were implanted with an osmotic minipump (Model 2001, 
Alzet, Cupertino CA). Pumps were filled 12 hours prior to implantation, with CRF 
receptor 1 antagonist: CP 154-526 (n=8) 1mg/mL, in 0.45% acetic acid vehicle in sterile 
saline; Cat. # 2779, Tocris Bioscience, Ellisville MO), CRF receptor 2 antagonist: 
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Antisauvagine-30 (n=7) 2mg/ml in saline; Cat # 2071, Tocris Bioscience, Ellisville MO), 
or vehicle (acetic acid n=9 or saline n=10). Pumps were connected to the brain infusion 
cannula with vinyl catheter tubing (Alzet, Brain Infusion Kit 2, Cupertino CA) and stored 
in 37°C incubator with cannulas in sterile saline. Male rats were anesthetized with 
isoflurane (MWI, Boise ID) in a Surgivet Isotec4 gas apparatus (Smiths Medical Vet 
Division, Markham, Ontario, Canada), secured in a stereotaxic apparatus (Kopf 
Instruments, Tujunga, CA) with a gas mask secured over the nose and mouth to maintain 
anesthesia. An incision was made to expose the skull, lambda and bregma were found 
determined to be level. A hole was drilled into the skull using a Dremel drill (Dremel, 
Racine, WI) at coordinates relative to bregma: AP= -0.5mm, ML= 1.5mm, DV= -3.9mm. 
The unilateral brain infusion cannula (Alzet, Brain Infusion Kit 2, Cupertino CA) was 
implanted and secured with dental cement (Lang Dental Manufacturing Company, 
Wheeling IL) and the osmotic minipump was implanted (Alzet, Model 2001, Cupertino 
CA) under the flank. Surgical incisions were closed with wound clips and males were 
allowed one week to recover from surgery during which osmotic minipumps chronically 
infused vehicle, CRFR1 antagonist or CRFR2 antagonist at a rate of 1.0μL/hr for the 
remaining 6.5 days (infusions thus ended on day 27).  
 
5.2.6B Forced Swim Test 
One day after termination of chronic infusion and 28 days following last mating 
session, males were tested for depression-like behavior in the forced swim test. The 
forced swim test was conducted during the light phase, 2-6 hours after lights on. The 
forced swim apparatus was a large cylindrical container, 25.5 cm in diameter, 45 cm in 
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height, and was filled with cold tap water (20 ± 1˚C) to a depth of 30 cm. 28 days after 
last mating or handling, rats were pre-exposed to forced swim test and were placed in the 
water for 15 minutes. 24 hours following pre-exposure (thus, 29 days following last 
mating or handling) males underwent the test session and were placed in the water for 5 
minutes (Porsolt et al., 1977a, Porsolt et al., 1977b, Detke et al., 1995, Porsolt et al., 
2001). After swimming sessions were completed, males were removed from the water; 
towel dried and placed under a heat lamp until fur was dry. All forced swimming sessions 
were recorded from above. Behavior was scored using automatic timing software 
(Stopwatch+; Center for Behavioral Neuroscience, Atlanta, GA: (http://www.cbnatl.org/ 
research/behavioralcore.shtml) (Bosch et al., 2009) by an observer blind to the animal’s 
treatment. Behavior was scored as follows: Struggling (Climbing): movements of both 
the fore- and hindlimbs that break the surface of the water; Swimming: movements that 
propel the animal forward, requires coordinated movement of both the fore- and 
handlings. Floating (Immobility): slight movements of the fore- and hindlimbs to keep 
body at equilibrium, with very little movement.  Percentage of spent floating (immobile) 
during the second test is indicative of a passive stress coping and depression-like 
behavior (Porsolt et al., 1977b). Experimental groups included: naïve males treated with 
vehicle (saline; n=4 or 0.45% acetic acid vehicle; n=5; n=9 total), experienced males 
treated with vehicle (saline; n=5 or 0.45% acetic acid vehicle; n=5; n=10 total), 
experienced males treated with CRFR1 antagonist (n=9), experienced males treated with 
CRFR2 antagonist (n=8). Statistical significance in time spent immobile between groups 
was determined using a one-way ANOVA and Fisher’s LSD test with a 95% confidence 
level. 
156 
 
5.2.6C Tissue collection real time qPCR 
To determine if chronic administration of a CRFR1 antagonist during the final 
week of mating abstinence blocked the increase in CRF mRNA levels in the PVN 
observed following a 28 day period of abstinence from mating, males were overdosed 
with sodium pentobarbital (270mg/kg); brains were rapidly removed and flash frozen on 
dry ice in sterile RNAse free conditions. Microdissections of the PVN were performed, 
and qRT-PCR for CRF was conducted as described above. 
 
5.2.7 Acute ICV CRF receptor antagonist administration 
As males in the osmotic minipump experiment were tested in the forced swim test 
without antagonist infusions at the time of testing, another group of males was used to 
test the effects of acute CRFR1 antagonist administration on depression-like behavior. 
Adult male Sprague-Dawley rats mated or were handled and remained sexually naïve 
over the course of five consecutive mating trials. Experienced groups were matched on 
parameters of sexual behavior. All males were implanted with a 21 gauge unilateral guide 
cannula in the lateral ventricle (Plastics One, Roanoke VA), using the same stereotaxic 
surgical techniques and coordinates as described above. During the 1 week surgical 
recovery period, males were handled daily to habituate them to the process of intracranial 
injections. Following 1 week recovery from surgery males received a single intracranial 
infusion 15 minutes prior to the testing on the second day of the forced swim test session 
of vehicle (5 µL; 0.45% acetic acid in sterile saline; n=8) or CRFR1 antagonist, CP 154-
526 (n=8) 1mg/mL, in 0.45% acetic acid vehicle in sterile saline; Cat. # 2779, Tocris 
Bioscience, Ellisville MO). Infusions were conducted using a microinfusion pump 
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(Harvard Apparatus, Holliston, MA) connected to a 26 gauge microinjector (4.1mm with 
0.5 mm projection, Plastics One, Roanoke VA) over a 1 minute period after which 
microinjectors were left in place for 1 minute to allow diffusion. Behavior was recorded 
and scored as described above. Statistical significance in percentage of time spent 
immobile between groups was calculated using a one-way ANOVA and Fishers LSD test 
with a 95% confidence level. 
 
5.2.8 Local Manipulations CRFR1 in Nucleus Accumbens or Prefrontal Cortex 
Local manipulations of CRFR1 were conducted in a manner procedurally 
identically to described above, but bilateral brain infusion cannulas (Plastics One, 
Roanoke VA) were directed at the NAc (coordinates relative to AP = 1.7 mm, ML= 1.2 
mm, DV= -7.3 mm) or mPFC (coordinates relative to bregma AP = 2.7 mm, ML= 0.3 
mm, DV= -3.5mm) and CRFR1 antagonist (CP 154-526; 1mg/mL, in 0.45% acetic acid 
vehicle in sterile saline) was infused using osmotic minipumps Alzet, Model 1007D 
(Cupertino CA) at 0.5μL/hr for 6.5 days following surgery. Experimental groups 
consisted of: naïve males treated with vehicle (0.45% acetic acid in sterile saline, n=9; in 
the NAc), experienced males treated with vehicle (n=9, in the NAc), naïve males treated 
with CRFR1 antagonist in the NAC (n=9) or mPFC (n=10), experienced males treated 
with CRFR1 antagonist in the NAc (n=11) or mPFC (n=10). Statistical significance in 
time spent immobile between groups was calculated using a Kruskal-Wallis One Way 
ANOVA Ranks and Dunn’s test 95% confidence level. 
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5.3 Results 
5.3.1 Activation of CRF neurons by sexual behavior 
Sexual activity did not activate CRF neurons in the PVN, CeA, or BnST. 
Specifically, cFos was not expressed in any CRF neurons following mating in either 
sexually naïve or experienced males in the PVN, CeA, or BnST (Figure 5.1). cFos 
immunoreactive cells were detected in the vicinity of CRF neurons. However, sexual 
experience (independent of mating on final test day) reduced total numbers of CRF 
neurons in the CeA (Figure 5.2d; p=0.049) but did not affect numbers of CRF neurons in 
the in PVN (Figure 5.2e) or BnST (Figure 5.2f). 
 
5.3.2 Activation of CRF mRNA by abstinence from sexual behavior 
28 days of abstinence from sexual behavior caused significant up regulation of 
CRF mRNA in the PVN of sexually experienced males compared to sexually naïve males 
(Figure 5.3a; p=0.012). CRF mRNA in the PVN was not significantly different between 
experienced and naïve males 1 day following last mating or handling (Figure 5.3a). In the 
CeA, CRF mRNA levels were significantly decreased in sexually experienced animals 
both 1 and 28 days following last sexual experience compared to sexually naïve males 1 
and 28 days following handling respectively (Figure 5.3a; p=0.034 and p=0.0004, 
respectively). In the BnST, CRF mRNA did not differ significantly between sexually 
naïve and experienced males either 1 or 28 days following last handling or mating 
(Figure 5.3c).  
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Figure 5.1. Representative images of neurons in the (A) PVN, (B) CeA, (C) BnST 
expressing CRF (brown, cytosolic) and cFos (black, nuclear) at 10x magnification. (D)  
Representative image of CRF expressing neuron (white arrow) and cFos expressing 
neuron (black arrow) that are not colocalized in the BnST (40x magnification). 
Abbreviations: PVN, paraventricular nucleus of the hypothalamus; CeA, central 
amydgals; BnST, bed nucleus of the stria terminalis. 
 
 
 
 
C) BnST
A) PVN B) CeA
D) BnST
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Figure 5.2. Mean numbers of CRF neurons in naïve and experienced males that mated 1 
hour before (NS: naïve sex, ES: experienced sex) or 24 hours prior to tissue collection 
(ENS: experienced no sex, NNS: naïve no sex) in the PVN (A), CeA (B) and BnST (C). 
Mean numbers of cells based on all animals in naïve or experienced groups, independent 
of mating behavior immediately prior to tissue collection, in the PVN (D), CeA (E) and 
BnST (F). Data are presented mean ± SEM. * Indicates significant difference from naïve. 
 
 
0
5
10
15
20
25
30
35
40
45
Naïve Experienced
0
5
10
15
20
25
30
35
40
45
NNS NS ENS ES
N
u
m
be
rs
o
f
C
R
F
ce
lls
/h
e
m
is
e
ct
io
n
0
5
10
15
20
25
30
35
40
45
NNS NS ENS ES
N
u
m
be
rs
o
f
C
R
F
ce
lls
/h
e
m
is
e
ct
io
n
0
5
10
15
20
25
30
35
40
45
Naïve Experienced
0
5
10
15
20
25
30
35
40
45
Naïve Experienced
A
B
C
D
E
F
PVN
CeA
BnST
*
0
5
10
15
20
25
30
35
40
45
NNS NS ENS ES
N
u
m
be
rs
o
f
C
R
F
ce
lls
/h
e
m
is
e
ct
io
n
161 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. CRF mRNA expression in the PVN (A) CeA (B) and BnST (C) of sexually 
naïve and experienced males 1 and 28 days following last handling or mating. Data are 
presented mean ± SEM.* Indicates significant difference from naïve males. 
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5.3.3 Acute Stress Responses 
28 days of abstinence from sexual behavior did not alter baseline cort and ACTH 
release, as sexually naïve and experienced males did not differ in plasma cort or ACTH 
levels at the 0 minute timepoint. However, 28 days of abstinence from sexual behavior 
caused increased plasma cort (Figure 5.4a; F1,75 12.283, p<0.001) and ACTH (Figure 
5.4b; F1,56  20.031, p<0.001) release in response to acute restraint stress. Both sexually 
naïve and experienced males displayed enhanced cort and ACTH release in response to 
acute restraint stress at 30 minutes post restraint, and enhanced cort release at 60 minutes 
post restraint, compared to baseline levels (p<0.001 for cort and ACTH, both timepoints). 
However, sexually experienced males displayed significantly greater cort and ACTH 
release in response to acute restraint stress 28 days following last mating compared to 
sexually naïve males. Specifically, sexually experienced males showed a higher 
magnitude of peak cort at 30 (Figure 5.4a; p=0.042) and 60 minutes (Figure 5.4a; 
p<0.001) and ACTH at 30 (Figure 5.4b; p<0.001) and 60 minutes (Figure 5.4b; p=0.034) 
compared to sexually naïve males. Sexually experienced males also demonstrated 
prolonged cort and ACTH release as cort remained elevated from the 30 to the 60 minute 
timepoint in experienced males, but decreased significantly at 60 minute timepoint 
compared to the 30 minute timepoint in sexually naïve males (Figure 5.4b; p<0.001) . 
ACTH release was also prolonged in experienced males, as ACTH levels returned to 
baseline levels at the 60 minute timepoint in sexually naive males, but remained elevated 
compared to baseline in sexually experienced males (Figure 5.4b; p<0.043).  
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Figure 5.4. Plasma corticosterone (Cort) (A) and ACTH (B) levels in response to acute 
restraint stress in sexually naïve and experienced males 28 days following last handling 
or mating. Data are presented mean ± SEM. * indicates significant difference from naïve 
males at the same timepoint. # indicates significant difference from 0 minute timepoint. + 
indicates significant difference between the 30 and 60 minute timepoints.  
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5.3.4 Effects of chronic ICV treatment with CRF receptor antagonists 
Chronic treatment with a CRFR1 antagonist during days 21-27 of mating 
abstinence prevented development of depression-like behavior seen following a 28 day 
period of abstinence from mating (Figure 5.5a; F3,38 4.016; p=0.015). Specifically, males 
treated with CRFR1 antagonist-treated spent significantly less time immobile compared 
to experienced vehicle treated males (Figure 5.5a; p=0.002), and were not significantly 
different from naïve vehicle treated males. Males treated with a CRFR2 antagonist did 
not show less time immobile compared to experienced vehicle-treated males, but also did 
not show significantly more time immobile compared to naïve-vehicle-treated males 
(Figure 5.5a), suggesting that CRFR2 antagonist administration had a partial effect on 
this phenotype. A 28 day period of abstinence from mating induced depression-like 
behavior as experienced vehicle treated males spent significantly increased time 
immobile compared to naïve vehicle treated males (Figure 5.5a; p=0.015), confirming 
results of Chapter 4. Furthermore, chronic administration of CRFR1 receptor antagonist 
blocked the sex abstinence induced increase in CRF mRNA expression in the PVN. CRF 
mRNA in sexually experienced males treated with CRFR1 antagonist (109.8 ± 27.5%;) 
did not differ from sexually naïve males (101.1 ± 8.3%), while vehicle-treated sexually 
experienced males had a strong trend towards increased CRF mRNA (159.1 ± 30.8%; 
p=0.059) compared to naïve males 
 
5.3.5 Effects of acute CRFR1 antagonist administration on depression-like behavior 
Administration of CRFR1 antagonist immediately prior to the forced swim test 
prevented expression of depression-like behavior in sexually experienced male rats 
(Figure 5.5b; F2,37 3.855; p=0.031). Males treated with CRFR1 antagonist showed 
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decreased time immobile compared to experienced vehicle-treated males (Figure 5.5b; 
p=0.019) and did not differ from naïve vehicle-treated males. Experienced vehicle-treated 
males again spent increased time immobile compared to naïve vehicle-treated males 
(Figure 5.5b; p=0.037). 
 
5.3.6 Local Manipulations of CRFR1 in the Nucleus Accumbens and Medial 
Prefrontal Cortex 
To determine where in the brain CRF is acting on CRF1 receptors to cause 
depression-like behavior following loss of sexual reward, CRFR1 antagonists were 
infused into the NAc or mPFC for days 21-27 of the 28 day abstinence period. Indeed, 
CRFR1 antagonism in either NAc or mPFC prevented development of depression-like 
behavior (Figure 5.5c; H = 9.157; p=0.027). Specifically, Experienced vehicle treated 
males spent increased time immobile compared to naïve vehicle treated males (Figure 
5.5c; p<0.05) confirming the previous findings. Antagonism of CRFR1in either the NAc 
or mPFC prevented development of passive stress coping, as CRFR1 antagonist-treated 
males did not differ significantly in time spent immobile compared to naïve vehicle- or 
antagonist-treated males (Figure 5.5c). However, experienced NAc antagonist-treated or 
PFC antagonist-treated males also did not differ significantly in time spent immobile 
from experienced vehicle-treated males (Figure 5.5c), indicating a partial effect of the 
local CRFR1 antagonism. Therefore, these results suggest that CRFR1 may be acting 
simultaneously in multiple brain regions to cause development of depression-like 
behavior. 
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Fig. 5.5. (A) Percentage of time spent immobile in vehicle-treated sexually naïve males 
(Naïve Vehicle), sexually experienced males (Exp Vehicle); sexually experienced 
CRFR1 antagonist treated males (Exp CRFR1 Antag) and sexually experienced CRFR2 
antagonist treated males males (Exp CRFR2 Antag)  that received vehicle or antagonist 
infusions during the final 7 days of abstinence (B) Percentage of time spent immobile in 
vehicle-treated sexually naïve males (Naïve Vehicle), sexually experienced males (Exp 
Vehicle); sexually experienced CRFR1 antagonist treated males (Exp CRFR1 Antag) that 
were acutely treated with vehicle or CRFR1 antagonist 15 minutes prior to testing on the 
forced swim test. (C) Percentage of time spent immobile in sexually naïve (Naïve) or 
experienced (Exp) males treated with either vehicle or CRFR1 antagonist in the NAc or 
mPFC. Data are presented as mean ±SEM * indicates significant difference from naïve 
vehicle, # indicates significant difference from experienced vehicle.  
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5.4 DISCUSSION 
 Previously, we showed that sexual experience followed by a prolonged (28 days), 
but not short (1-7 days) period of abstinence from sexual reward caused increased 
depression-like behaviors, consisting of increased passive stress coping and decreased 
social interaction. In the current study, we demonstrated that these depression-like 
behaviors are associated with enhanced HPA activity, namely increased stress-induced 
ACTH and cort release and increased CRF mRNA in the PVN. Thus, these results 
provide further insights into the mechanisms by which loss of sexual reward causes 
development of depression and validation of loss of sexual reward in male rats as a model 
for depression-like behavior, as this model demonstrates homology to pathology seen in 
human depression, or pathological validity (Krishnan and Nestler, 2010). In humans, 
major depression is associated with hyperactivity of the HPA axis, increased CRF mRNA 
and protein levels in the PVN and CRF secretion into the cerebrospinal fluid (Kling et al., 
1991), as well as increased plasma and salivary cortisol (Nemeroff and Vale, 2005). 
A potential mechanism for the observed increases in PVN CRF and enhanced 
stress-induced release of cort and ACTH may be decreased glucocorticoid negative 
feedback (Reul and de Kloet, 1985, Nemeroff, 1993, Koob and Heinrichs, 1999). It is 
hypothesized that the hyperactivity of the HPA axis seen in depressed humans may be 
due to alterations in glucocorticoid negative feedback, as depressed patients fail to mount 
an appropriate negative feedback response in the dexamethasone (synthetic 
glucocorticoid) suppression test (Rush et al., 1996, Holsboer, 2000). Studies in depressed 
humans have demonstrated decreased glucocorticoid receptor (GR) mRNA expression in 
the hippocampus and prefrontal cortex (Webster et al., 2002). Rodents also demonstrate 
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reductions in GR binding in the hippocampus and hypothalamus following social defeat 
(Buwalda et al., 2001), in the hippocampus and PFC following maternal separation 
(Meaney et al., 1996) and in the hippocampus, hypothalamus, and PFC following chronic 
stress (Makino et al., 1995, Raone et al., 2007). Furthermore, early life stressors such as 
decreased maternal care which causes alterations in stress responses also leads to long-
lasting epigenetic modifications of GR in the hippocampus (Weaver et al., 2004, Weaver, 
2007). Specifically, rat pups that receive low maternal care have increased stress 
responses, associated with low levels and hypermethylation of  exon17 of the GR 
promoter in the hippocampus (Weaver et al., 2004, Weaver, 2007), and decreased 
binding of the GR promoter to the transcription factor  NGF1-A (Weaver et al., 2004, 
Weaver, 2007), suggesting an epigenetic mechanism by which social experience may 
cause long term adaptations to stress responses. Future studies will therefore determine if 
loss of sexual reward may cause increased stress responses via decreased GR expression 
and hypermethylation of GR exon I7 in the hippocampus. 
The second major finding of the current study was that the development of 
depression-like behavior was dependent on activation of CRFR1 in brain areas including 
the NAc and PFC, as CRFR1 antagonism during the final days of sex reward abstinence 
prevented the increase in passive stress coping behaviors. ICV infusion of a CRFR2 
antagonist had a partial effect on development of depression-like behavior. Activation of 
both CRFR1 and CRFR2 has been implicated in depression-like behaviors (Shaham et 
al., 1998, Hammack et al., 2003, Wang et al., 2005, Henry et al., 2006, Wang et al., 2006, 
Wang et al., 2007). Other reports have shown that activation of CRFR1 can be pro-
depressant and induces stress responses, while CRFR2 activation can have antidepressant 
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effects and cause attenuation of the stress response (Bale and Vale, 2004, Contarino and 
Papaleo, 2005). The current findings do not support opposite roles for CRFR1 and 
CRFR2 in the effects of sexual reward abstinence on development of depression, but 
rather a more dominant role for CRFR1. The greater role for CRFR1 may be based on the 
critical involvement of the NAc and PFC that both express high levels of CRFR1, but 
only low levels of CRFR2 (Van Pett et al., 2000). A potential mechanism by which CRF 
may mediate the development of depression-like behavior is via the dynorphin/kappa 
opioid system as CRFR1 receptor activation in either NAc or PFC, has been shown to 
activate the dynorphin/kappa opioid receptor system to induce depression-like behavior 
(Land et al., 2008, Tejeda et al., 2010). The dynorphin/kappa opioid receptor system has 
been shown to exert pro-depressant effects when activated and antidepressant effects 
when blocked (Mague et al., 2003, McLaughlin et al., 2003, Beardsley et al., 2005, 
Carlezon et al., 2006).  
The ligand that causes CRFR1 activation is potentially CRF. CRF has a 10x 
higher affinity for CRFR1 than CRFR2 (Bale and Vale, 2004), with CRFR2 having a 
higher affinity for urocortin II and III (Bale and Vale, 2004), suggesting that CRF via 
activation of CRFR1 during the 28 day period of abstinence causes development of 
depression-like behavior. In addition, urocortin I has equal affinity for both CRFR1 and 
CRFR2 (Lovenberg et al., 1995, Perrin et al., 1995), and therefore cannot be ruled out as 
an additional contributor to the development of depression-like behavior following loss 
of sexual reward. The sources of CRF projections to the NAc or the mPFC are not clear. 
Both regions receive inputs from PVN (Silverman et al., 1981, van der Kooy et al., 1984) 
and the NAc also received inputs from the BnST and CeA, as part of the extended 
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amygdala (Koob, 1999). The current study was not able to identify which CRF neurons in 
PVN or extra hypothalamic sites were activated during sexual behavior, as cFos 
expression was not observed in CRF neurons following mating in either naïve or 
experienced males, suggesting that CRF neurons are not activated by sexual behavior. 
Previous studies have shown cFos activation in the PVN (Buwalda et al., 2012), BnST 
(Coolen et al., 1996) and amygdala (Coolen et al., 1996, Veening and Coolen, 1998) 
following sexual behavior. PVN CRF neurons have also been show to express cFos 
following other stimuli, including water deprivation (Benedetti et al., 2008) or 
lipopolysaccharide administration (Rorato et al., 2008). However, it should be noted that 
a lack of cFos activation does not indicate that sexual behavior does not cause activation 
of CRF neurons. The current study did identify an up-regulation of CRF mRNA in PVN, 
coinciding with the timepoint development of depression-like behavior is observed, 
suggesting that the PVN may be the source of CRF acting in NAc and mPFC to induce 
this negative affective state.   
An unexpected finding of the current study was a reduction in CRF mRNA and 
protein in the CeA, both immediately following sexual behavior and after prolonged 
period of sex reward abstinence. These results indicate that sexual behavior does indeed 
influence CeA CRF neurons, by causing down regulation of CRF gene and protein 
expression in these cells. It is not entirely clear how this decreased CRF in the CeA may 
mediate depression-like behavior. The amygdala is an important brain area for regulation 
of emotions, particularly related to fear, stress and aversive stimuli (Eibl-Eibesfeldt and 
Sutterlin, 1990). In human depression, amygdala volume is reduced (Sheline et al., 1998). 
In contrast, in the maternal separation model of depression, CRF mRNA in the CeA is 
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increased (Menzaghi et al., 1993) and glucocorticoids have been shown to be stimulatory 
to CeA CRF mRNA levels (Schulkin et al., 1994, Shepard et al., 2000). Hence, the 
current findings that CRF is decreased in CeA during abstinence from sexual behavior 
suggest that there is no chronic elevation of glucocorticoids during the abstinence period. 
This is supported by a lack of difference in baseline cort and ACTH levels in sexually 
experienced and naïve males following the prolonged period of mating abstinence. But, 
whether CeA CRF plays a role in the development of depression following loss of sexual 
reward remains unclear. 
A major finding of the current study, together with our previous findings, is that 
increased levels of CRF in the PVN and the development of depression-like behavior 
require a prolonged period of abstinence from sexual reward and are not induced 
immediately after sexual behavior. Development of depression-like behavior is 
completely prevented by twice weekly mating during the 28 days following daily sexual 
experience, demonstrating that abstinence from mating is critical. It is currently unknown 
what mechanisms underlie the effects of abstinence on subsequent alterations in behavior 
and neuropathology. One hypothesis for the pro-depressant effects of chronic stress is 
that stress reduces neurogenesis and numbers of spines in the hippocampus (Pham et al., 
2003, McEwen, 2005, 2010, Veena et al., 2011, Schoenfeld and Gould, 2012). In 
apparent contrast, sexual behavior, either once or daily during a 14 day period, promotes 
neurogenesis and spinogenesis in adult male rats (Leuner et al., 2010), despite the fact 
that mating causes increased cort and ACTH release (Buwalda et al., 2001, Bonilla-Jaime 
et al., 2006, Leuner et al., 2010). Likewise, running or exposure to an enriched 
environment, which cause activation of the HPA axis also increase hippocampal 
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neurogenesis (Schoenfeld and Gould, 2012). However, it is important to note that shortly 
following mating, and thus at the timepoint that increased neurogenesis has been 
demonstrated, sexual behavior causes a dampening of the stress responses and reductions 
in anxiety-like behavior (Fernandez-Guasti et al., 1989, Saldivar et al., 1991, Waldherr 
and Neumann, 2007, Waldherr et al., 2010). Therefore, it is critical to examine the effects 
of prolonged periods of abstinence from sexual reward on neurogenesis and spinogenesis 
in the hippocampus, as well as in the NAc and mPFC. Recent studies form our laboratory 
have shown that a short period of abstinence from sexual behavior (7 days) caused 
increased numbers of spines in the NAc (Pitchers et al, 2010), but this returned to 
baseline after the prolonged 28 day period of abstinence (Pitchers, 2012), suggesting that 
spinogenesis is a dynamic and time-dependent process.  
Another hypothesis for the effects of chronic stress on depression is that of stress 
sensitization: the view that previous exposures to stressors may cause an enhanced stress 
response upon re-exposure to a stressor and favor development of depression (Anisman 
and Merali, 2003, Anisman et al., 2003a). Anisman and colleagues showed that systemic 
infusions of the inflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha) caused 
activation of the HPA axis (Anisman et al., 2003b). Moreover, re-exposure to TNF-alpha 
elicited a sensitized stress response (Anisman et al., 2003b). Of particular interest was 
their finding that re-exposure to TNF-alpha triggered the most sensitized and robust stress 
effect after a re-expousre interval of 28, but not 7 days (Anisman et al., 2003b). Thus, 
inflammatory cytokines may also play a role in the development of depression following 
abstinence from sexual reward. It has been well documented that humans with depression 
have elevated inflammatory cytokines (Maes, 1994, Maes and Smith, 1998, Schiepers et 
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al., 2005, Kim et al., 2008, Dinan et al., 2009, Pace and Miller, 2009, Dowlati et al., 
2010). Moreover, it has been suggested that exercise is an effective treatment in 
depressed patients (Biddle, 1989, Beesley and Mutrie, 1997, Barbour et al., 2007, Greer 
and Trivedi, 2009, Carek et al., 2011, Rozanski, 2012) as it has anti-inflammatory actions 
(Das, 2004, Petersen and Pedersen, 2005, Gleeson et al., 2011, Rethorst et al., 2012). 
Recently it has been shown that TNF-alpha levels in serum of depressed patients may be 
a predictor for the antidepressant effects of exercise, with high TNF-alpha levels linked to 
better outcomes for exercise, but poor outcomes for antidepressant treatment (Rethorst et 
al., 2012). Thus, we hypothesize that sexual behavior and subsequent abstinence from 
sexual behavior may influence inflammatory and immune responses in the brain. Even 
though effects of sexual behavior on the brain immune system have not yet been 
reported, environmental enrichment has been shown to decrease inflammatory markers 
and cause a blunted pro-inflammatory response (Williamson et al., 2012). Moreover, 
exposure to females, without mating, has been shown to increase mast cells in the brains 
of male rats (Asarian et al., 2002). These mast cells have been implicated in the 
regulation of anxiety-related behaviors, suggesting that increased mast cells following 
exposure to female stimuli may mediate dampened anxiety responses (Nautiyal et al., 
2008). 
 In conclusion, results of these studies demonstrate that loss of sexual reward, 
which causes depression-like behavior, also leads to underlying neuropathology of 
depression including HPA axis activity and increased CRF in the PVN. Moreover, these 
studies provide insight into the mechanism by which CRF may modulate depression-like 
behavior following loss of sexual reward, via CRFR1 in the NAc and PFC. We suggest 
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that these studies of the effects of loss of sexual reward demonstrate homology to 
pathology seen in human depression following loss of social reward and may thus 
provide further insights into this particular form of depression. 
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6.1. Orexin and Sexual Reward 
Results from Chapter 2 demonstrated that the hypothalamic neuropeptide orexin 
plays a role in arousal and anxiety related to sexual behavior in sexually naive male rats, 
but is not critical for male sexual performance or motivation (Di Sebastiano et al., 2010, 
Di Sebastiano and Coolen, 2012). Results from Chapter 3 demonstrated that orexin is a 
critical mediator of sexual reward (Di Sebastiano et al., 2011, Di Sebastiano and Coolen, 
2012). Together, these studies formed a critical step in identifying the role of orexin in 
natural reward behavior (Di Sebastiano and Coolen, 2012) and specifically in sexual 
reward.  
 
6.1.1 Future Directions - Orexin 
 In our previous studies, we demonstrated the role of orexin using cell specific 
lesions of orexin neurons in the PFA-DMH and LHA (Di Sebastiano et al., 2010). 
However, as the lesioning technique permanently eliminated orexin neurons, it is 
currently unknown if orexin is involved in the acquisition of stimulus-reward learning or 
the expression of this learned association. We tested the role of orexin in sexual reward 
using the CPP paradigm, which includes both a phase of acquisition of the associative 
memory of reward-cue associations and a phase of expression of the seeking of the 
reward-associated cue (Tzschentke et al, 2007). Future studies may utilize 
pharmacological manipulations of orexin neurons in the PFA-DMH and LHA either 
during the CPP conditioning trials; to determine if orexin is involved in acquisition of 
sexual reward induced CPP, or during the post-test to determine if orexin is involved in 
the expression of mating induced CPP. Studies may also utilize newly developed 
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technologies such as optogenetics, which rely on activation or inhibition of specific 
neurons via expression of light activated proteins, channelrhodopsin or halorhodopsin, 
respectively (Fenno et al., 2011). This technique has a higher temporal resolution than 
pharmacological techniques (Fenno et al., 2011), and as such, would allow for more 
precise activation or inactivation of orexin neurons during the acquisition or expression 
phases of mating induced CPP. 
 In addition, it is unclear where in the brain orexin is acting to mediate sexual 
reward. Orexin is synthesized exclusively in the PFA-DMH and LHA (de Lecea et al., 
1998, Sakurai et al., 1998), but has broad projections, and orexin receptors are widely 
distributed throughout the brain and spinal cord (Trivedi et al., 1998, Marcus et al., 
2001). Orexin neurons project to both the NAc and VTA (Peyron et al., 1998, Fadel and 
Deutch, 2002, Baldo et al., 2003) and contact dopamine positive cells in the VTA (Fadel 
and Deutch, 2002). Furthermore, both orexin receptor 1 and orexin receptor 2 are located 
in the NAc and VTA, including on DA cells in the VTA (Korotkova et al., 2003, Narita 
et al., 2006). In the NAc orexin-A infusion stimulates feeding behavior (Thorpe and 
Kotz, 2005), suggesting a role for orexin in food reward, as the NAc plays an important 
role in hedonia related to feeding (Berridge, 1996, Pecina and Berridge, 2000). Orexin 
action in the VTA has also been shown to be important for food motivation and reward, 
as infusion of an orexin receptor 1 antagonist decreases seeking of high-fat, palatable 
food (Borgland et al., 2009). Much more is known about the role of orexin in the VTA in 
drug reward. Administration of an orexin receptor-1 antagonist into the VTA blocks 
morphine induced CPP (Harris et al., 2007) and intra-VTA administration of orexin-A 
has been shown to reinstate morphine CPP following extinction (Harris et al., 2005). 
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Thus, future experiments may use pharmacological or optogenetic manipulations of 
orexin receptors 1 or 2 in the VTA and NAc to determine if orexin action in these brain 
regions is critical for mediation of sexual performance, motivation or reward. As 
dopamine has been shown to play a role in reward-cue association learning (Robinson 
and Berridge, 1993, Berridge, 1996) and reward prediction (Schultz, 1997, 1999, 2006, 
2010); transgenic studies may utilize mice that have a conditional knockout (Friedel et 
al., 2011) of orexin receptors that are located on dopamine neurons to determine if orexin 
acts via dopamine to mediate sexual reward. 
 
6.2 Development of an animal model for depression following loss of sexual reward 
 Studies from Chapter 4 demonstrated that a 28 day period of abstinence from 
sexual behavior causes depression-like behavior including passive stress coping and 
anhedonia in male rats. Studies from Chapter 5 demonstrated that this prolonged loss of 
sexual reward induced depression-like behavior is also associated with underlying 
neuropathology of depression seen as increased corticotropin releasing factor (CRF) 
mRNA in the paraventricular nucleus of the hypothalamus (PVN) and increased 
corticosterone (cort) and ACTH responses to an acute stressor. Finally, it was shown that 
development of depression-like behavior following loss of sexual reward is mediated by 
CRF receptor 1 in mesolimbic brain regions, the NAc and PFC. 
 
6.2.1 Future Directions: Interactions with vulnerability to addiction 
In addition to causing depression-like behavior, abstinence from sexual reward 
also causes increased vulnerability for psychostimulant abuse in male rats (Pitchers et al., 
2010). Given that depression and substance abuse have a high comorbidity (Volkow, 
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2004); it will be interesting to determine which neural alterations caused by abstinence 
from sexual reward lead to this behavioral pathology. As CRF is activated by drugs of 
abuse (Sarnyai et al., 2001) as well as by withdrawal and abstinence from drug taking 
(Koob and Kreek, 2007, Koob, 2008), CRF may also be an important mediator of the 
enhanced drug reward (Pitchers et al., 2012) and locomotor sensitization to amphetamine 
(Pitchers et al., 2010) seen following a period of abstinence from mating. Thus, future 
studies may examine the effects of CRF antagonists in limbic brain regions that express 
CRF receptors and are also involved in depression and addiction, such as the PFC and 
NAc (Van Pett et al., 2000, Krishnan and Nestler, 2008) during the final week of mating 
abstinence on development of conditioned place preference for a subthreshold dose of 
amphetamine and sensitization of the locomotor response to psychostimulants (Pitchers et 
al., 2010).  
 
6.2.2 Glutamate 
 In the discussion of Chapter 5, I discussed the potential effects of prolonged 
sexual reward abstinence on neurogenesis, spinogenesis, and cytokines in the 
development of depression. However, many more transmitters and neural factors have 
been implicated in depression. Many studies have shown that glutamate, the main 
excitatory neurotransmitter in the central nervous system is altered in depressed patients, 
as they show increased plasma glutamate levels compared to healthy controls (Kim et al., 
1982, Altamura et al., 1993, Mitani et al., 2006). Glutamate receptor trafficking is also 
decreased in the striatum (Kristiansen and Meador-Woodruff, 2005) and thalamus 
(Clinton and Meador-Woodruff, 2004) of depressed patients and enhanced membrane 
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expression of ionotropic 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid 
(AMPA) receptors is observed in the hippocampus following treatment with 
antidepressants (Martinez-Turrillas et al., 2007), suggesting a role for glutamate receptor 
trafficking in mediation of depression. Glutamate receptor trafficking and function is also 
altered by exposure to drugs of abuse (Thomas et al., 2008, Wolf and Ferrario, 2010). 
Studies from our lab have shown that a one month period of abstinence from mating also 
induces alterations in glutamate receptors, including increased surface expression of the 
AMPA glutamate receptor subunits, GluA1 and GluA2 in the NAc (Pitchers et al., 2012), 
and decreased AMPA/NMDA ratio in the NAc (Pitchers et al., 2012). These sex 
abstinence-induced changes in glutamate receptor expression and trafficking are partially 
similar to changes induced by abstinence from drugs of abuse. Abstinence from repeated 
cocaine exposure causes increased cell surface AMPA and NMDA receptor subunit 
expression in the NAc and different receptor subunits have been shown to be 
differentially affected by drug withdrawal (Conrad et al., 2008, Wolf and Ferrario, 2010). 
These changes are thought to contribute to alterations in the locomotor response to 
psychostimulants and increased drug seeking (Vanderschuren and Kalivas, 2000, Conrad 
et al., 2008, Wolf and Ferrario, 2010, Ferrario et al., 2011). Thus, as glutamate and 
glutamate receptors appear to play a critical role in depression and drug withdrawal, and 
have also been shown to be altered by a periods of abstinence from sexual behavior, 
future studies may test the functional role of these alterations in development and 
expression of depression-like behavior following loss of sexual reward as well as 
alterations in stress responses.
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6.2.3 BDNF 
Brain derived neurotrophic factor (BDNF), is the most prevalent growth factor in 
the central nervous system (Autry and Monteggia, 2012). Depressed humans shown 
reduced plasma BDNF (Duman and Monteggia, 2006) as well as decreased BDNF levels 
in the hippocampus (Karege et al., 2005, Castren et al., 2007). Chronic stress in rodents 
has been shown to decrease BDNF signaling and this is reversed by chronic treatment 
with antidepressants (Nestler et al., 2002, Duman and Monteggia, 2006). Furthermore, in 
the social defeat model of depression, VTA specific deletions of BDNF blocked 
development of depression-like behavior (Berton et al., 2006). Moreover, BDNF is also 
critically involved in drug addiction as well as withdrawal. A single infusion of cocaine 
increases BDNF levels in the NAc (Russo et al., 2009), and infusion of BDNF into the 
NAc leads to increased drug taking and seeking, and enhances drug craving after 
withdrawal (Graham et al., 2007). Moreover, infusion of BDNF into the VTA during 
withdrawal enhances drug seeking behavior (Corominas et al., 2007). Much less is 
known about the role of BDNF in sexual behavior; however it has been shown that 
mating behavior leads to upregulation of BDNF mRNA in the PFC (Kakeyama et al., 
2003). Thus, as BDNF is involved in depression, and appears to facilitate drug seeking 
following drug withdrawal, BDNF may also be altered following abstinence from sexual 
reward, and mediate vulnerability for depression via the mesolimbic system. Future 
studies therefore may utilize pharmacological manipulations of BDNF during mating or 
the period of abstinence to test the functional role of BDNF on development of 
depression-like behavior and alterations in stress responses observed following loss of 
sexual reward. 
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6.3 Orexin interactions with CRF and the stress system 
 In addition to playing a critical role in mediation of reward, the hypothalamic 
neuropeptide orexin has also been shown to be involved in mediation of anxiety and 
depression-like behavior. Orexin-A infusion into the paraventricular nucleus of the 
thalamus of male rats causes decreased anxiety-like behavior on the elevated plus maze 
(Li et al., 2010). Orexin has also been shown to play a role in depression-like behavior, 
with activation of OxR1 having a pro-depressant effect and activation of OxR2 having an 
antidepressant effect (Scott et al., 2011), suggesting orexin differentially regulates 
depression-like behavior depending on which receptor is activated. Orexin has also been 
shown to interact with the stress system, as stimulation of orexin receptors increases CRF 
mRNA levels (Al-Barazanji et al., 2001, Singareddy et al., 2006), as well as ACTH (Ida 
et al., 1999, Ida et al., 2000a, Kuru et al., 2000) and corticosterone release (Ida et al., 
2000b, Kuru et al., 2000). Orexin mRNA is also increased in response to acute restraint 
stress (Ida et al., 2000a). Furthermore, orexin neurons in the hypothalamus also express 
CRF receptors, and CRF application to brain slices has been shown to increase orexin 
signaling (Winsky-Sommerer et al., 2004). Thus, it is clear that there are interactions 
between orexin and the CRF system, which may play a role in mediation of stress 
responses. 
The studies in this thesis demonstrated a critical role for orexin in mediation of 
sexual reward (Di Sebastiano et al., 2011), and for CRF in mediation of development of 
depression-like behavior following loss of sexual reward. Therefore, orexin and CRF 
may be acting together to mediate development of depression-like behavior following 
loss of sexual reward as well as alterations in stress responses. 
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6.4 Overall Conclusions 
Results of the studies in this thesis further elucidate the neural circuitry of sexual 
reward. Furthermore, results of these studies provide insight into the mechanism by 
which loss of natural rewards can influence disorders related to reward processing such 
as substance abuse and depression.  
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AUP Title: Neural regulation of rewarding behavior and substance abuse 
Approval Date: 03/22/2010 
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2010-211 has been approved. 
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the 
ACVS office. 
Health certificates will be required. 
REQUIREMENTS/COMMENTS 
Please ensure that individual(s) performing procedures on live animals, as described in 
this protocol, are familiar with the contents of this document. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with 
institutional safety standards and have received all necessary approvals. Please consult 
directly with your institutional safety officers. 
Submitted by: Kinchlea, Will D  
on behalf of the Animal Use Subcommittee  
 
 
 
 
 
 
 
 
199 
 
 
 
 
 
APPENDIX B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
200 
 
 
PI: Coolen, Lique 
Protocol Number: #10531 
Approval Period: 03/02/2011 - 03/02/2014 
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The University of Michigan Committee on Use and Care of Animals (UCUCA) has 
reviewed your application to use vertebrate animals (Application #10531). This project 
has been approved. The proposed animal use procedures are in compliance with 
University guidelines, State and Federal regulations, and the standards of the "Guide for 
the Care and Use of Laboratory Animals."  
 
When communicating with the UCUCA Office please refer to the Approval Number 
#10531. The approval number must accompany all requisitions for animals and 
pharmaceuticals.  
 
The approval date is 03/02/2011. The approval period is for three years from this date. 
However, the United States Department of Agriculture (USDA) requires an annual 
review of applications to use animals. Therefore, each year of this application prior to the 
anniversary of its approval date, you will be notified via email to submit a short annual 
review. Your continued animal use approval is contingent upon the completion and return 
of this annual review. You will also be notified 120 days prior to the expiration of the 
approval period so that your renewal application can be prepared, submitted and 
reviewed in a timely manner in the eSirius program and an interruption in the approval 
status of this project avoided.  
 
UCUCA approval must be obtained prior to changes from what is originally stated in the 
protocol. An amendment must be submitted to the UCUCA for review and approved 
prior to the implementation of the proposed change.  
 
The University's Animal Welfare Assurance Number on file with the NIH Office of 
Laboratory Animal Welfare (OLAW) is A3114-01, and most recent date of accreditation 
by the Association for the Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC, Intl.) is November 06, 2009.  
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Public Safety. 
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Richard Keep, Ph.D. 
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